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The incidence of disorders in human male reproductive health is increasing. It has been
proposed this change is a direct consequence of environmental effects on growth and sex
steroid induced alterations in programmed development. The aim of the experimental work
described in this thesis was to investigate the effects of an ubiquitous environmental
contaminant, the synthetic platiciser Di-butylphthalate (DBP) on the developing male
reproductive tract. Any changes were compared to those symptoms of the human male
clinical condition TDS (Testicular dysgenesis syndrome) which is increasing in incidence.
To investigate whether DBP treatment induced any TDS-like changes, pregnant rats were
gavaged daily with DBP at doses up to 500mg/kg/day from embryonic (e) day el3.5 up to
e21.5. Morphological and hormonal parameters (testosterone, inhibin-B) were assessed in
male rats aged e21.5 or adult ± in utero DBP exposure. Concurrently, untreated fetal rat and
fetal human testis explants were cultured in vitro ± MBP (Mono butylphthalate), the DBP
metabolite, at levels of up to 1 mM, to investigate whether the array of adverse effects seen
with the in utero exposure could be induced in vitro. Hormone production (testosterone,
inhibin-B) and explant morphology were compared ± MBP exposure. The in vitro
experiments were restricted to 48h exposure duration so an additional in vivo treatment
regime was established to compare the endpoints induced after just 48h exposure in utero.
Pregnant rats were dosed daily by gavage with 500mg DBP/kg/day on el9.5 and e20.5 only.
Morphological and hormonal parameters (testosterone, inhibin-B) were assessed in male rats
aged e21.5 ± 48h in utero DBP exposure. Findings were compared against those from the
original in utero studies ± 8 days DBP exposure.
The long-term in utero exposure regime induced an array of changes in the phenotype of the
male reproductive tract, evident in e21.5 and adult animals, including testis maldescent
(cryptorchidism) and reduced fertility. Changes in testis morphology such as alteration in the
distribution ofLeydig cells and abnormal nucleation of gonocytes at e21.5 were also seen.
The production of testosterone in testes at e21.5 was also significantly reduced following the
DBP treatment, including a significant reduction in the protein expression levels of the
steroidogenic enzyme P450scc. The in vitro experiments were unable to show a significant
decrease in testosterone production after 48h exposure to ImM MBP but when testosterone
production was stimulated by hCG, the level of stimulation was significantly reduced when
explants were co-incubated with hCG and ImM MBP. The adverse effect ofMBP on hCG
stimulated testosterone production was seen in media collected from both fetal rat and fetal
human testis explants after 48h co-incubation. The short-term in utero exposure regime
induced a generally less severe array of changes in the phenotype and testis architecture of
V
the e21.5 male reproductive tract than those seen after 8-day in utero DBP exposure.
However, a greater reduction in testis testosterone was seen than the long-term exposure
induced, despite less of a reduction in the protein expression ofP450scc.
The precise mechanism through which DBP induces its array of developmental
abnormalities is still unclear but these studies support the hypothesis that even short term in
utero exposure to DBP directly affects the developing testis, probably by acting on Leydig
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Chapter 1 Introduction L
1 Background
The incidence of human male reproductive health disorders appears to be increasing. The
increased incidence of reproductive health disorders is potentially a serious public health
concern, as reduced reproductive capability could significantly reduce the number of
offspring and may ultimately render a species unsustainable. This extrapolation of the recent
changes in human male reproductive health has catalysed an international push towards
understanding more about male health issues. One scenario highlighted by the burgeoning
research has been the observation that four clinical disorders, that encompass the majority of
the adverse changes in male reproductive health, are hypothesised to share a common fetal
origin (Skakkebaek et al., 2001). The disorders are collectively termed "testicular dysgenesis
syndrome" (TDS) and are believed to be consequences of disordered development of the
fetal testis. These manifest as:
• testis cancer
• low sperm count/ poor sperm quality
• cryptorchidism
• hypospadias
In order to explore whether environmental chemicals may be adversely influencing fetal
testis development, the physiology ofnormal testis development will be examined. This will
be compared against the phenotype described for TDS. Following review of reports on
disrupted reproductive health in man and in wildlife, in the UK and abroad, a specific class
of environmental chemicals was selected for further investigation as to whether or not such
compounds could induce TDS in laboratory animals and whether they might do in humans.
Comparisons will be made between data from novel studies presented here, involving acute
exposure to high doses of a single chemical under laboratory conditions, both in vivo and in
vitro, and published data regarding changes associated with continuous low-level
environmental exposure conditions. The outcomes of these studies will be discussed in the
context of contemporary findings. Together, this work should improve our understanding of
the risk that ubiquitous synthetic chemicals pose to fetal testis development.
1.1 Testis formation and development
The development of the gonads generally governs the phenotypic sex of a mammalian fetus.
As the gonadal anlage in the embryo can become male or female, sexual differentiation of
the initial bi-potential gonad is a tightly regulated process. Formation of the male gonad, the
testis, requires careful co-ordination of five processes: proliferation, migration and
differentiation of the testis cell types as well their physical organisation into seminiferous
cords alongside development of the testis specific vasculature. This section will review the
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scientific understanding of testis development, up to the time when this project started, with
occasional reference to the development of the female gonad, the ovary.
The gonads are unique in that they contain two distinct cell populations: somatic cells and
germ cells. Each cell type has a distinct developmental origin: the somatic cells arise from
the adjacent mesonephros and coelomic epithelium whereas the primordial germ cells
migrate into the genital ridge from the yolk sac via the hindgut and dorsal mesentery (Figure
1.1). The migration of each major cell type into or within the testis and their functions will
be reviewed.
Figure 1.1 Posterior view of a rodent embryo showing gonadal development. In both
sexes, the initial bi-potential gonad appears as a swelling of the mesonephros and coelomic
epithelium. This region is colonised by primordial germ cells, where they differentiate into
gonocytes. In the testis, the Sertoli cells surround the gonocytes forming basic seminiferous
cords, interspersed with steroidogenic Leydig cells. Taken from: Rouiller-Fabre et al. 2003.
1.1.1 Sry
Testis development is dependent on the sex of the somatic cells in the developing gonad
(Adams and McLaren, 2002). Sex is determined genetically by the presence of the Y
chromosome for the mammalian male. Male sexual differentiation is confirmed by the
hormonal secretions of the developing testis, as well as the development of the secondary
sexual characteristics.
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A pivotal revelation in reproductive biology emerged in the 1990's, with the identification of
the gene termed "Sry" for "Sex determining region on the Y chromosome". This gene was
identified as responsible for the commitment of an embryo to masculinisation, whether
expressed in the gonad or via an ectopic transgene (Gubbay et al., 1990; Koopman et al.,
1990). Prior to this point, it had long been assumed that the mammalian Y chromosome
either encoded for or controlled the production of a diffusible testis-determining molecule,
exposure to which was all that was required to divert the embryonic gonad along the
testicular pathway. The finding that Sertoli cells in XX—XY chimeric mouse testes were
exclusively XY led to a new model in which the Y chromosome acted cell-autonomously to
bring about Sertoli-cell differentiation, equating mammalian sex determination with Sertoli-
cell determination (Burgoyne, 1988).
So far, no equivalent ovary-determining gene has been clearly identified, but without normal
Sry expression, a fetus will develop as a phenotypic female, even though it may carry the
male Y chromosome (Adams and McLaren, 2002; Koopman et al., 1991). This is because
Sry is believed to act within cells of the supporting cell lineage of the indifferent gonad to
trigger a cascade of events resulting in the differentiation of these cells into male specific
Sertoli cells (Albrecht and Eicher, 2001; Hacker, 1995). The somatic cells in which Sry is
expressed differentiate into Sertoli cells, which in turn, trigger other cell lineages within the
gonad to follow the testicular pathway e.g. Leydig cells. Without Sry, the somatic cells
differentiate into female granulosa cells and the gonad follows the ovarian pathway with
theca cells developing instead of Leydig cells.
The Sry gene product encodes a protein with an HMG box DNA binding domain, believed to
regulate the transcription of downstream genes. The increase in cell proliferation in the male
coelomic epithelium is the earliest identified effect of Sry expression (Schmahl et al., 2000).
Expression of the Sry protein in the fetal mouse gonad 10.5 days after conception (em10.5)
precedes the formation of testis cords, the earliest overt evidence of testis differentiation
(observed by em12.5) and initiates male specific cell proliferation.
Comparisons of the predicted Sry protein sequences from different species have shown that
apart from the HMG domain, regions are highly divergent even amongst closely related
species. Comparison ofhuman and mouse sequences is especially difficult since there is no
region of extended homology apparent outside the HMG box (Hacker, 1995). This lack of
homology makes it difficult to identify common regulatory regions and contributes to why
no direct molecular target of Sry has yet been identified.
It should be noted that though Sry operates the "gender switch", and has provided a clear
molecular anchor point for the study of the divergence of the male gonad from the
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bipotential priraordium, many other genes are required to complete sexual differentiation
(Capel, 2000). The precise roles of some of the factors identified in mouse/rat sexual
differentiation have not been precisely identified for human sexual differentiation (Hughes,
2001).
It may be worth noting that among farm animals, the pig presents with an intersex condition
at a relatively high frequency i.e. XX sex-reversed individuals which are genetically female
but with a true hermaphrodite or male phenotype. It has been clearly demonstrated that Sry is
not involved in these phenotypes but genetic analyses suggest that instead, pig inter-
sexuality is controlled via many genes (Pailhoux et al., 2001). Studies ofXX sex reversal in
the insectivorous mole (Talpa occidentalis) indicate that the intersex animals are functional
fertile females and lack Sry but present with ovotestes. The trait is transmitted and
maintained in the population. These results suggest that XX intersex moles may have arisen
from a mutation of a gene located downstream from Sry in the testis determining pathway
(Jimenez et al., 1993).
While expression of Sry may appear in other regions of the embryo or at other ages, this
goes beyond the scope of this review (Capel, 2000; Hacker, 1995). A summary was
published by Koopman (2001) following a symposium on the Genetics and Biology of Sex
Determination listing the genes implicated in human and mouse sexual development,
revealed by mutation analysis. The meeting emphasised that while a great deal of progress
has been made in the years since Sry was first identified, most of the fundamental issues
surrounding how its protein works are still unresolved (Koopman, 2001).
1.1.2 The mesonephros and coelomic epithelium
The gonads emerge around el0-l 1.5 in the mouse, on the ventro-medial surface of the
mesonephros associated with a thickening of the coelomic epithelium in both sexes (Capel,
2000) (Figure 1.1). One of the first indications ofmasculinisation is the increase in the size
of the male gonad by em12.5 (Schmahl et al., 2000). Several mechanisms could account for
the size increase of the XY gonad following Sry expression but various studies show that
XY gonads recruit cells from the mesonephros and coelomic epithelium (Albrecht et al.,
2000; Karl and Capel, 1998; Merchant-Larios, 1998).
1.1.2.1 The mesonephros
Mesonephroi are derived from the embryonic mesoderm and are the precursor tissues for the
gonads for both sexes (Tilmann and Capel, 2002). These transient organs form a vital part of
the urogenital ridge, along with the pronephros (including the adrenal primordia) and the
metanephros (the embryonic kidney precursor) (Sainio, 1997). The two mesonephroi
evolveeither side of the gut mesentery and alongside the emerging gonad. Initially, both
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sexes have mesonephric tubules that extend into the developing gonad towards the coelomic
surface, in a process akin to branching morphogenesis in the developing kidney (Sainio,
1997).
As part of the reproductive tract, mesonephroi are subject to sex specific development. Both
sexes have two ductal primordia in each mesonephros, though only one of the two ductal
systems will normally develop, specific to the sex of the gonad and expression of supporting/
inhibiting factors. In the fetal female, the mesonephric duct regresses but the adjacent
paramesonephric (Miillerian) duct persists and matures into the oviducts, uterus and upper
part of the vagina of the adult female reproductive tract. In the fetal male, the Mullerian duct
regresses due to the action of Anti-Miillerian Hormone (AMH) released by Sertoli cells.
Additionally, in the fetal male the mesonephric (Wolffian) duct is actively maintained by the
production of testicular testosterone (Capel, 2000; Jost et al., 1981). It matures into the
epididymis, vas deferens and seminal vesicles of the adult male reproductive tract.
Consequences of inappropriate testosterone or AMH production are detailed in a later
section of this overview.
1.1.2.2 The coelomic epithelium
The coelomic epithelium is a single layer of cells derived from the mesoderm that lines the
inside of the coelomic cavity, the precursor cavity that will form the pericardial, pleural and
peritoneal cavities. The cavity is underlain by a basement membrane (coelomic
mesothelium) that proliferates into the adjacent loose connective tissue, enabling coelomic
epithelium cells to migrate towards the mesonephros, creating the gonadal anlage (Birk et
al., 2000).
Karl et al (1998) were able to dye individual coelomic epithelium (CE) cells and follow their
proliferation and migration into the interior of the gonad during early development, at tail
somite stages (ts) 15-30 (em10.5-l 1.5). Labelled CE cells were observed to proliferate, then
migrate into the parenchyma of the gonad and go on to become various somatic cell lineages.
These cell lines both expressed (i.e. Sertoli cells) or didn't express (e.g. Leydig cells) the
transcription factor Wt-1 protein. Those CE cells that did not arrive in the gonad until after
tsl8 always remained outside the seminiferous cords becoming part of the interstitial cell
population, whereas those that migrated during tsl5-17 went on to become Wt-1 expressing
intratubular cells, i.e. Sertoli cells (Karl and Capel, 1998). Different studies have shown that
mesonephric cells can differentiate into cells that have ultra-structural features akin to those
ofnormal steroidogenic Leydig cells (Merchant-Larios, 1998).
By ts30, the movement of CE cells ceased and the basement membrane beneath the
coelomic epithelium was no longer discontinuous but began to thicken and form the "tuniga
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albugninea", a tough capsule that covers the entire testis (Karl and Capel, 1998). These data
suggest that the coelomic epithelium is a dynamic cell population that is actively involved in
morphogenesis of the gonad, including contributing cells to the somatic cell population.
These findings corroborate previous observations that differentiation of Sertoli and Leydig
cells proceeds in the absence of the mesonephros (Merchant-Larios et al., 1993).
1.1.2.2.1 The coelomic vessel
By em12.5, a large blood vessel can be seen on the developing testis, just under the coelomic
epithelium. This arises from epitheliuml cells that migrate into the gonad from the
mesonephros and endothelial cells. Together with the unisex vasculature already present in
the eml 1.5 gonad, these endothelial cells form the coelomic vessel and a supporting vascular
system specific to the male gonad. This sexual dimorphism suggests that vascularisation
plays a role in defining the early architecture of the testis, including the rapid export of
testosterone after em13.5 (Tilmann and Capel, 2002). It is hypothesised that vascularisation
and seminiferous cord formation are simultaneous and mediated by the Sertoli cells but there
is no supporting data at this time.
1.1.2.3 Migration and cord formation
In order to become a testis, the indifferent gonad needs to acquire the various cell lines that
make up the male gonad and organise them into structured seminiferous cords. Germ cells
have an established extra-embryonic origin (detailed in a later section) whereas the major
somatic cell types arise from the embryonic urogenital tissues, i.e. the mesonephros and
coelomic epithelium as already outlined. Additional testis cell lines include the peritubular
myoid cells and various ill-defined interstitial cell types as well as as cells associated with
the testis vasculature. When labelled mesonephroi were grafted to unlabeled gonads,
endothelial and peritubular myoid-like cells migrated into the gonad. It has therefore been
proposed that these cells might be the mesonephric cells required for seminiferous cord
formation (Merchant-Larios et al., 1993).
Experiments have shown that mesonephric migration is Sry activated. Delayed Sry
expression postpones migration and thus cord formation, even resulting in aberrant ovotestis
formation (Albrecht et al., 2000; Capel et al., 1999). There is a critical timepoint after which
normal testis cord formation cannot be initiated i.e. if the movement ofprecursor cells into
the gonad has not started before em12.5 (rat el4.0), then cord formation is disrupted
(Tilmann and Capel, 1999) (Figure 1.2). Normal migration starts before tsl 8 (em11.5) and
has been suggested to last until em16.5 (rat el8.5), as evidenced with studies where gonads
explanted at eml 1.5, without a mesonephros, show normal development, supporting the idea
that migration must be initiated prior to this age. (Tilmann and Capel, 2002). Additionally,
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there is no migration of cells between an XX mesonephros and its adjacent gonad or between
an XY gonad with an adjacent XX mesonephros, but CE cells do contribute to the
complement of cells that make up the female gonad (Tilmann and Capel, 1999).
Pre-Sertoli cells, together with migrating mesenchymal cells, form the seminiferous cords
around the primordial germ cells that migrate in from the hindgut via the mesonephros.
Some mesenchymal cells flatten out and differentiate into peritubular myoid cells to form the
basal lamina with the Sertoli cells, enveloping the clustered germ cells into basic cords,
while others remain in the interstitial spaces between the cords (Figure 1.2). The co¬
ordination of all these cells into a testis, with defined seminiferous cords and interstitium, is
orchestrated by the only cell that expresses Sry, the Sertoli cell (Hacker, 1995). The Sertoli
cell is the logical candidate to induce mesonephric migration via a paracrine factor, yet
unidentified. Like Sry expression, cord formation starts in the central region of the gonad
and spreads to the poles of the testis (Albrecht and Eicher, 2001).
coelomic Leydig gonocytes Sertoli peritubular
Figure 1.2: Cartoon of seminiferous cord formation in fetal life. Panel A represents
the indifferent gonad with precursor somatic cells present. Panel B represents the formation
of the seminiferous cords showing how the Sertoli cells (pale green), Leydig cells (blue) and
peritubular myoid cells (red) organise themselves to form recognisable cords following
influx of the primordial germ cells (purple). Adapted from movie clip developed for RM
Sharpe, 2003.
Proliferation is also critical to gonad formation, as shown by the failure of gonad formation
in mouse models in which the Lhx-9 gene has been knocked out. This gene is normally
required for the growth of the gonads via the proliferation and invasion of the epithelium
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into the mesenchyme (Birk et al., 2000). The role of proliferation and the emerging male
gonad is returned to later in this review.
1.1.3 Sertoli cells
The cells of Sertoli are named after the Italian scientist Enrico Sertoli (1842-1910) who first
described this 'special cell' in a paper published in 1865, long before the discovery of Sry
(Skinner, 2005).
Sry is the principal initiator of the cascade of cellular and molecular events that enable the
development of the testis, yet is only detected in the male urogenital ridge for a short period,
just prior to when overt sexual differentiation is apparent. This transient pulse of Sry
expression is detected in the pre-Sertoli cells of the developing genital ridge, from em10.5 to
a peak around eml 1.5 after which it plummets until undetectable by em12.5 (Albrecht and
Eicher, 2001; Hacker, 1995). Due to the expression of Sry exclusively in the Sertoli cells,
these cells are thought to orchestrate male development by influencing the differentiation of
other cell types in the XY gonad.
The sole source of pre-Sertoli cells is believed to be the CE, though the mesonephros cannot
be conclusively eliminated as a source of pre-Sertoli cells. It has even been proposed that the
two sources may provide functionally distinct types of Sertoli cells though this has not been
well investigated in mammals (Karl and Capel, 1998). If this is the case, it is suggested that
the non-CE Sertoli cells must either migrate prior to eml 1.5 or arise in situ as they were not
reported in organ culture experiments where mesonephroi and gonads were re-assembled at
this stage (Capel, 2000).
Fetal Sertoli cells can be identified in the developing testis as they lie alongside the basement
membrane of the testis cords and appear cuboidal with almost spherical nuclei, each with a
distinct nucleolus (Figure 1.3). Germ cells are the only other cell type in the cords but they
appear distinctly larger, rounder and more centrally located (Figure 1.3). The Sertoli cell
cytoplasm envelops the fetal germ cells. The presence of Sertoli cells can be confirmed by
the detection of specific biomarkers, typically either the cytoplasmic glycoprotein AMH
(Anti-Miillerian Hormone) or the transcription factor Wt-1 (Hacker, 1995; Sainio, 1997).
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Figure 1.3 H&E stained section of el5.5 fetal rat genital ridge. The left panel shows
a longitudinal section of a developing testis (—) surrounded by the coelomic epithelium (C)
with the mesonephros (M) attached (xlO magnification). An area (rectangle) enlarged in the
right panel, shows cord formation: Sertoli cells (S) surround gonocytes (G), including
mitotic gonocytes (MG), bounded by the basal lamina ("') of the seminiferous cords, which
is in turn surrounded by peritubular myoid cells (P). Between the cords are the interstitial
cells including probable Leydig cells (L), some probable mitotic Leydig cells (ML) and
occasional un-defined interstitial cells (pink).
Many genes expressed in the fetal Sertoli cells are associated with testis development. Sry,
the "testis determining gene" has already been mentioned. Some of the other genes encode
for transcription factors such as Wt-1 or Sox-9 while others encode for secreted proteins
such as AMH and inhibin-B. These four gene products are described in more detail below
but this is definitely not an exhaustive list of genes critical to testis development. Others
include Dmrtl, Wnt-4, Lhx-1, Emx-2, Lhx-9, Sf-1 and Dax-1 but to expand on the
contribution made by all of these is beyond the scope of this review. An thorough reference
book that details the functions of these genes and many more associated with the Sertoli cell,
was just published (Skinner, 2005).
1.1.3.1 AMH
Following the determination phase of sex differentiation, re-enforcement and regulation of
further testis development is influenced by hormone production and expression of the
cognate receptors in target tissues (Hughes, 2001). One such hormone is Anti-Miillerian
Hormone (AMH), strongly expressed in the immature Sertoli cell cytoplasm of the perinatal
testis. It is also weakly expressed in ovarian granulosa cells from birth to the end of ovarian
activity, menopause (Josso et al., 2001). In normal testes, the switch-offofAMH expression
is associated with the appearance ofprimary spermatocytes, suggesting that their presence
had an inhibitory effect on AMH, though AMH expression was also down-regulated in testes
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lacking germ cells (because of anti-cancer treatment) or testes with a complete lack of
spermatogenesis (idiopathic germ cell aplasia) (Rajpert-De Meyts et al., 1999). The decrease
in AMH expression thus reflects the terminal differentiation of Sertoli cells and is probably
only partially dependent upon a regulatory factor associated with the onset ofmeiosis in the
adjacent germ cells (Sharpe et al., 2003).
Amh gene expression is an early marker of Sertoli cells. Amh expression begins 20 hours
after the onset of Sry expression in the mouse testis, at a time when Sry transcripts are at
their peak, around ern11.5. While this result does not prove a direct interaction between the
two genes, it defines the critical period during which SRY must act to initiate Sertoli cell
differentiation (Hacker, 1995). Additionally, AMH was detected in culture media following
incubation of eml 1.5 gonads without a mesonephros, indicating that some Sertoli cells must
be present in the gonad by then (Merchant-Larios et al., 1993).
AMH is a member of the TGF-P superfamily of growth factors which includes another
Sertoli cell product, inhibin. AMH is a homodimeric disulfide-linked glycoprotein with a
molecular weight of 140kDa (Josso et al., 2001). The main role ofAMH is to cause
regression of the female Mullerian ducts, hence its alternative name - Miillerian Inhibiting
Substance (MIS). This sex-specific event is carried out via binding to AMH type II receptors
(AMHR-II) on mesenchymal cells which are proposed to induce apoptosis of the Mullerian
epithelium via a poorly defined paracrine mechanism (Hughes, 2001). The identity of a type
I receptor is controversial.
AMHR-II is also expressed on Leydig cells (Racine et al., 1998; Teixeira et al., 1999).
AMHR-II-deficient mice exhibit Leydig cell hyperplasia suggesting AMH could be a
negative modulator ofLeydig cell differentiation and function, as aside from regression of
the Mullerian ducts, AMH inhibits the postnatal differentiation ofLeydig cell precursors into
mature steroidogenic cells (Racine et al., 1998). In Leydig cell lines, AMH has been shown
to reduce in vitro testosterone production to 10% of the basal level, due to the repression by
AMH of the transcription of the gene for the steroidogenic enzyme P450Cn (Teixeira et al.,
1999).
Given that the expression level ofAMH varies between fetal, neonatal, pubertal and adult
testes as well the ovary, it is reasonable to assume that different mechanisms regulate AMH
during development in males and females (Watanabe et al., 2000). In the fetal male, AMH
expression is tightly regulated to ensure that it is expressed during the critical period of
Mullerian duct regression. The absence of the hormones AMH and testosterone, produced by
the developing male gonad, creates a permissive environment for the differentiation of the
Mullerian ducts and female reproductive organs (Habert et al., 2001).
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To facilitate this regulation, the AMH gene has several response elements within its
promoter. Response elements have been identified for: the orphan nuclear receptor Sf-1; the
high mobility group protein Sox-9 and the transcription factor GATA-4, all of which are
integral to normal testis development (Josso et al., 2001). In the testis, AMH expression is
initiated by Sox-9 and up-regulated by Sf-1 with interaction from GATA-4, Sox-9 and Wt-1
(Watanabe et al., 2000). Germ cells can also influence AMH expression. Germ cells that
have initiated meiosis effect a repression of Sertoli cell AMH expression in the same
seminiferous tubule. However, the precise molecular pathways through which regulation by
these factors is imposed, or the factors influencing AMH expression in ovarian granulosa
cells, remain unclear (Josso et al., 2001). Outside the testis, AMH might be associated with
delayed airway branching, specifically within the developing male lungs (Catlin et al., 1997).
1.1.3.1.1 Sox-9
The human AMH proximal promoter can bind the transcription factor Sox-9 (Sry-related
HMG box-9), a Sertoli cell factor closely associated with Sertoli cell differentiation and the
initiation and regulation ofAMH expression. Sox-9 can cooperate with Sf-1 in this
activation process (De Santa Barbara et al., 1998; Wilhelm and Englert, 2002). Sox-9 is an
High Mobility Group (HMG) protein transcription factor i.e. works by binding to the minor
groove ofDNA causing it to unwind and widen (Migeon, 2000). Sry is also an HMG
protein. Possibly regulated by Sry, the Sox-9 gene is associated with the differentiation of
Sertoli cells and the suppression of ovarian differentiation (Migeon, 2000). It is expressed at
low levels in the genital ridge prior to Sry but is dramatically up-regulated following
initiation of testis development. Sox-9 expression decreases in the fetal rat until postnatal d2
then at dl5 Sox-9 protein strongly reappears in the testicular cords. In the adult rat, Sertoli
cells are positive for Sox-9, whereas ovaries are negative for Sox-9, confirming its sex-
specific nature. The prominent presence of Sox-9 in the developing testis and at puberty
suggests that this protein is needed at important phases of aggregation and reorganization of
the Sertoli cells. The age- and stage-specific presence of Sox-9 in the testicular cords and in
the seminiferous tubules of the adult suggests that Sox-9 also may have a pivotal role in
germ cell differentiation (Frojdman et al., 2000). Sox-9 is sufficient to induce testis
formation in mice, indicating that it can substitute for the sex-determining gene Sry, but
unlike Sry, Sox-9 expression is not transient (Vidal et al., 2001). Mutations in Sox-9 are
associated with male-to-female sex reversal in humans and a severe dwarfism syndrome,
campomelic dysplasia (Morais da Silva et al., 1996).
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1.1.3.2 Wt-1
The Wilms' tumour gene (Wt-1) codes for a zinc finger transcription factor. Mutations of the
gene result in embryonic tumours of the kidney, sometimes associated with gonadal
dysgenesis such as in Denys-Drash syndrome (decreased Wt-1 binding to DNA) or Frasier
syndrome (abnormal intron 9 splice variant). The 50bp Wt-1 gene has 10 exons and encodes
a protein with four zinc finger DNA binding domains. Alternative splicing creates four
isoforms with roles in transcription regulation as well as RNA processing, with 96%
conservation between the human and mouse amino acid sequences (Moore, 1999). Splice
variant II has an insertion between zinc fingers 3 and 4, the KTS sequence (+KTS isoform),
and accounts for the majority ofWt-1 in a cell. The different splice variants have different
roles in sexual development (Wilhelm and Englert, 2002). The +KTS variants are important
regulators of Sry in the sex determination pathway compared to the -KTS forms, which are
associated with the survival of the gonadal primordium (Hammes et al., 2001).
Cells that express Wt-1 protein are found in the urogenital ridge prior to the expression of
Sry and sexual differentiation, indicating it is involved in the differentiation ofmany
genitourinary tissues, all potential sites ofWilms' tumour as well as proliferation/
tumourogenesis (Hirose, 1999). Wt-1 can also activate target genes such as Dax-1. Though
the role ofDax-1 in gonad formation is not firmly established, it is known that if it is
duplicated, it induces XY sex reversal in humans whereas Dax-1 inactivation leads to
reduced testis size and impaired spermatogenesis, (Wilhelm and Englert, 2002).
Inactivation ofboth Wt-1 alleles results in the failure of the kidneys and gonads to develop
and the mice to die in utero around em12-14. These embryos also have fatally malformed
hearts because of disrupted migration ofWt-1 expressing epicardal cells from the
proepicardial organ to the myocardium surface. When these embryos were "rescued" and
survived beyond mid-gestation, they were found to have impaired adrenal gland
development. Wt-1 is not found in the developing adrenal cortex but is expressed earlier in
development when the adrenal and gonad share a common primordium. This steroidogenic
anlage also expresses steroidogenic factor -1 (Sf-1), found in the Leydig and Sertoli cells of
the testis. Wt-1 (-KTS splice variant only) and Sf-1 interact to regulate the expression of
AMH (Moore, 1999). Sf-1 is activated by Wt-1: the -KTS splice variant binds to and
transactivates the Sf-1 promoter (Wilhelm and Englert, 2002). Wt-1 regulates many genes
during urogenital development, though characterisation of this pivotal transcription factor
and its associated co-factors is ongoing, as it is still not known precisely how this protein
contributes to early gonad development. Wt-1 is continuously expressed in Sertoli cells in
the fetal and the adult testis.
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1.1.3.3 Inhibin
Inhibin is a member of the transforming growth factor (TGF)-p superfamily, members of
which share structural similarities but are diverse in their biological activities. Inhibin is a
heterodimeric glycoprotein made up from an a-subunit plus either of several P-type subunits
(A, B or C in the human, plus E in the mouse, plus D in Xenopus), joined by disulphide
bonds (Ying, 1988). Homodimers of the p-subunit are known to activate FSH secretion and
are called "Activin". The inhibin specific a-subunit dimerises with any of the P-subunits,
though in mammals, only the pB (inhibin B) subunit is associated with male reproductive
health (Illingworth et al., 1996).
Inhibin B is produced by the Sertoli cells as precursor a and p subunits which are believed to
dimerise intra-cellularly into a 120kDa precursor protein, which undergoes maturational
processing into a 60kDa intermediate form and finally a 30kDa mature form. The
mechanism of inhibin signalling is still unclear but two receptors have recently been
characterised in the rat testis: p-glycan (localised to the Leydig cells) and Pi2o (found on
Leydig and Sertoli cells). In the human fetal testis, P-glycan was localised in the peritubular
myoid cells and interstitium (fetal Leydig cells) but it is not assumed that these are the only
targets for Sertoli cell derived inhibins (Anderson et ah, 2002).
The expression pattern for the inhibin a-subunit depends on developmental age. First
detected in rat testes at el4.5, immunostaining has revealed inhibin-a protein expression in
Sertoli cells and interstitial cells. As pregnancy progresses the interstitial cell staining
intensifies (Majdic et ah, 1997a). By the day ofbirth, low levels are still expressed in the
cytoplasm of Sertoli cells but interstitial staining intensity has lessened and by postnatal d5
all interstitial staining has vanished, leaving low-level Sertoli cell expression. The bioactive
form i.e. the dimeric form of testicular inhibin, is not detected until after birth (Noguchi et
ah, 1997). The role of the bio-inactive inhibin-a expressed in the fetal Leydig cells is
unclear.
Inhibins are hormones involved in the regulation of a number of diverse physiological
functions e.g. regulation of FSH production (Majdic et ah, 1997a). The only bioactive
inhibin form in fetal and adult male rat and human circulation has the pB subunit,
abbreviated to inhibin-B, and is predominantly secreted by the Sertoli cells (Anderson et ah,
2002). However, the mechanism by which inhibin-B exerts its biological effect is still under
investigation (Meachem et ah, 2001). Inhibin is most likely not bioactive during fetal testis
development but vital to postnatal testis function. In the postnatal testis, the level of secreted
inhibin-B is proportional to the number of Sertoli cells in a testis, as shown by the increase in
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levels concurrent with normal and disrupted Sertoli cell proliferation in the postnatal rat
testis (Sharpe et al., 1999). The final number of Sertoli cells in a testis has an important
effect on the circulating levels of inhibin-B but not exclusive control, though the relative
contribution of these factors requires further investigation. Inhibin levels can be affected by
various factors, e.g. Sertoli cell maturation, route of excretion, change in germ cell
complement or changes in the feedback sensitivity with FSH (Sharpe et al., 1999). During
adult spermatogenesis, it is the germ cell population rather than FSH that has the greater
influence on inhibin-B levels, though the inverse correlation between inhibin-B and FSH is
still evident in healthy males (Meachem et al., 2001). At puberty, when Sertoli cell
proliferation is complete and spermatogenesis commences, the basal adult inhibin-B
production level is fixed and therefore is considered an index of Sertoli cell density
(Meachem et al., 2001).The role ofFSH is covered in more detail in a later section.
1.1.3.4 Proliferation
Following the formation of the seminiferous cords, the testis undergoes a dramatic sex
specific growth spurt. Sertoli cell proliferation is vital, as their finite number will limit the
number of germ cells that can be supported through spermatogenesis in the adult testis.
Germ cells are completely dependent on the physical and metabolic support of the Sertoli
cells to complete their development into spermatozoa (Orth, 1982; Sharpe et al., 1999).
Sertoli cell mitosis essentially occurs in sexually immature testes in mammals (Jegou, 1992;
Sharpe et al., 2003). In mammals there are probably three distinct phases of Sertoli cell
proliferation: fetal, perinatal and prepubertal, all of which are potentially vulnerable to
disruption, thus affecting the final Sertoli cell number (Sharpe et al., 2003). In the rat, Sertoli
cells proliferate throughout fetal development until around 15 days after birth, producing the
adult population of Sertoli cells prior to the completion ofpuberty (Orth 1982; 1984).
Experiments with administration of recombinant FSH to neonatal rats saw an increase in
final Sertoli cell number of 149% (Meachem et al., 1996). Conversely the suppression of
FSH by the administration of a GnRH antagonist or Diethylstilboestrol, saw around a 50%
decrease in the final number of Sertoli cells (Atanassova et al., 1999). Fetal rat Sertoli cells
do not appear to respond to FSH but do express the FSH receptor after el8.5 (Rouiller-Fabre
et al., 2003). Any reduction in Sertoli cell numbers such as decreased proliferation during the
fetal/ neonatal period can result in a decrease in the maximum spermatid numbers produced
by the mature adult, presenting as reduced sperm counts and possibly reduced fertility.
Differentiation
Around puberty, the Sertoli cell undergoes a dramatic change from an immature proliferative
state to a terminally differentiated and non-proliferative, mature state. Tight junctions form
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between adjacent Sertoli cells creating the blood: testis barrier. This provides a unique
environmental niche for the germ cells and removes them from direct access to any non-
Sertoli cell secreted products (Jegou, 1992; Sharpe et al., 2003).
The mature Sertoli cell extends its cytoplasm from the basement membrane of the
seminiferous tubule to the lumen. Mature Sertoli cells carry out a wide range of functions
including: structural support of the seminiferous epithelium, displacement of germ cells and
release of sperm; formation of the Sertoli cell blood-testis barrier; secretion of tubule fluid (=
lumen formation); nutrition of germ cells; phagocytosis of degenerating germ cells/ germ
cell materials (Jegou 1992). Each Sertoli cell hosts a number of germ cells across a range of
stages of differentiation into mature spermatozoa.
1.1.3.5 Endocrine influences on the Sertoli cell
The postnatal and adult testes are largely dependent on endocrine regulation via hormones
such as the gonodotrophins (FSH and LH) to maintain testicular functions, but this system is
not established until late in fetal life (Rouiller-Fabre et ah, 2003; Sharpe et ah, 1999). The
regulation of the fetal testis, by contrast, is largely endocrine independent, implying that it is
regulated via testis produced paracrine factors, such as AMH and testosterone. Testosterone
is utilised by the fetal Sertoli cell to convert into oestrogen, via the P450 aromatase enzyme.
Oestrogen is thought to suppress androgen production by immature Leydig cells, though its
specific paracrine action is unclear. However, fetal Sertoli cells do not express the androgen
receptor protein (AR). In the rat, AR expression is seen in the Sertoli cells from around
postnatal d6, but not in the human until late puberty (Sharpe et ah, 2003). This implies that
any androgen influence on fetal Sertoli cells must be indirect. The roles ofLH and FSH are
discussed in more detail in section 1.2.
This review of the Sertoli cell is focused on the fetal phase of testis development so only
skims over the role of the mature Sertoli cell and spermatogenesis. It should be noted that a
fetal testis and its cells are not a mini version of the adult testis but has a unique pattern of
protein expression (Rouiller-Fabre et ah, 2003). However, it should not be underestimated
how much influence the development of the immature Sertoli cell has on the successful
function of the adult Sertoli cell and testis (Sharpe et ah, 2003).
1.1.4 Peritubular myoid cells
These cells are poorly represented in the literature, despite their contribution to the
architecture of the testis. They arise from the mesonephros and form the perimeter of the
seminiferous cords in the testis, enveloping the immature Sertoli cells and gonocytes
(Schmahl et ah, 2000; Yao and Capel, 2002). It is proposed that a minimum number of
myoid cells is required to establish and maintain initial testis cord formation following Sry
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expression in Sertoli cells. Studies in which the mesonephros was separated from the gonad
prior to the completion of mesonephric cell migration resulted in a reduced myoid cell
population. This was proposed to reduce the production ofmatrix proteins that contribute to
the formation of the basal lamina, between the Sertoli cells and the myoid cells, that
separates the Sertoli cells from the stromal compartment of the testis, which in turn limited
testis cord formation (Buehr, 1993; Merchant-Larios, 1998). Different studies showed that
disruption of the signalling between the Sertoli cells and the myoid precursors (by
Cyclopamine) or ofmesonephric cell migration (by Forskolin) also resulted in disrupted
testis cord formation (Yao and Capel, 2002).
Peritubular myoid cells proliferate during fetal life but this ceases shortly after birth,
suggesting that peritubular myoid cell proliferation is not a major contributor to postnatal
testis growth. At puberty, these cells change shape to become flatter and longer, increasing
in volume rather than number (Palombi et al., 1992). Peritubular myoid cells also have a role
in testicular development that is likely to be androgen regulated as they express androgen
receptor protein, though this role requires to be clarified (Anderson et al., 2002). There is no
ovarian cell type that is analogous to this testis cell type, though connective tissues may fulfil
a similar role (Adams and McLaren, 2002).
1.1.5 Germ cells
The germline is responsible for the passing on of genetic information between generations.
Primordial germ cells (PGC's) arise from the proximal epiblast of the embryo and their
migration into the developing gonad, from the yolk sac via the gut mesentery, is one of the
first events of gonad formation (Adams and McLaren, 2002). The germline is first detectable
at em7.25 as a small population in the extraembryonic mesoderm near the base of the
allantois (a membranous sac that grows from the lower gut in mammalian embryos). These
migrate towards the urogenital ridge so that by em12, they are located in the gonadal anlage.
During this migration, the PGC's are stimulated to initiate proliferation, completed by
em13.5 (Richards, 1999). In the mouse embryo PGC numbers increase from less than one
hundred to approximately four thousand during the period of their migration (Godin and
Wylie, 1991). The regulation of this proliferative phase is thought be autonomously
programmed into the PGC's, dependent on time rather than the number of cell doublings, as
rare ectopic PGC's in the adrenal cortex stop mitotic proliferation in near synchrony with
those in the ovary (Richards, 1999).
PGC's migrate in association with each other via intercellular cytoplasmic processes
(filopodia). Following migration into the gonad, the PGC's round up and collaborate with
somatic cells to form the primary sex cords (Bendel-Stenzel et al., 2000). Cadherins are a
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family of intercellular adhesion molecules that are involved with the sorting of cells during
morphogenesis, ofwhich E-cadherin has been proposed to maintain the inter-PGC contacts
in both sexes. Removal of E-cadherin disrupts the condensation of the germ cells in the
genital ridge, resulting in an increase in the number of ectopic (extragonadal) PGC's
(Bendel-Stenzel et al., 2000). Normally ectopic germ cells do not survive but the majority of
paediatric germ cell tumours arise outside the gonads (Bendel-Stenzel et al., 2000).
Having migrated and proliferated, the male germ cells still need to differentiate into sperm.
Already they have matured from PGC's into fetal germ cells (gonocytes) as seen by the
declining expression ofGCNA1 protein (Germ cell nuclear antigen-1). As this
differentiation can also occur in vitro, it must be independent of the process ofmigration or
exposure to the genital ridge. For clarity in this document, the post-migratory germ cells will
be referred to as gonocytes.
Once in the gonad, the gonocytes have the potential to develop into ooctyes or pre-
spermatogonia. This differentiation process is completely dependent on the somatic cells of
their gonad host, rather than their own chromosomal sex (Richards, 1999). Little is known
about the interactions between the somatic cells and gonocytes in the early testis but it has
been shown that without the presence of male somatic cells, PGC's develop as if female
(Adams and McLaren, 2002). Male gonocytes, enveloped by Sertoli cells, are mitotically
quiescent until after birth whereas in female embryos, the pre-oogonia enter meiosis such
that by birth they have reached the diplotene stage (Richards, 1999).
Gonocytes are not required by the male gonad to enable cord formation or differentiation of
the Sertoli cell, but somatic cells are required by the male gonocytes to prevent them from
becoming meiotic and direct them towards spermatogenesis. Ifmale gonocytes are recovered
from the mouse genital ridge prior to eml 1.5, they can revert to developing as oocytes. By
em12.5 male gonocytes can synthesise prostaglandin D2 and are committed to
spermatogenesis, coincident with the onset ofAMH expression by the adjacent Sertoli cells
(Hacker, 1995). By em13.5 female gonocytes are committed to oogenesis, so if the gonocytes
have not been exposed to a male environment prior to em13.5, they assume an oocytic fate.
Regardless of their genetic sex, germ cells within a gonad will enter meiosis by em13.5 and
follow normal ovarian differentiation unless there are signalled not to (Adams and McLaren,
2002).
It is proposed that the synthesis ofprostaglandin D2 by the recently differentiated male
gonocytes promotes the differentiation of Sertoli cells in the gonad. As Sertoli cells direct
testis formation, this paracrine factor will consolidate rather than regulate male sex
determination (Adams and McLaren, 2002). The effect of the absence of prostaglandin D2 on
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testis development has been difficult to ascertain due to the multiple prostaglandin D2
synthase enzymes and receptors. Mice generated with mutations in genes vital for
prostaglandin biosynthesis (e.g. Coxl or Cox2 "'"), die perinatally due to failure of the pups
to successfully commit to pulmonary respiration as the lack ofprostaglandins prevents the
closure of the ductus arteriosus between the pulmonary artery and the aorta (Loftin et al.,
2001). No defect in the testes of these animals was reported, is consistent with the rationale
that paracrine induction of Sertoli cell differentiation might have only a small role in testis
development (Adams and McLaren, 2002).
In the rat the male gonocytes remain mitotically quiescent until just after birth, when they
start to migrate from the cord centre to the basement membrane and begin differentiation
into pre-spermatogonia (Boulogne et al., 1999).
The proliferation of PGC's is independent of their somatic environment but the survival and
differentiation of gonocytes is completely regulated by their somatic neighbours. Although
regulation of male germ cell development is not fully understood, it is presumably controlled
by an interaction ofmultiple gene expression and the regulation of signal molecules in the
local testis environment, such as: c-kit receptor/ steel factor (SF), Dazla and retinoic acid
(Olaso and Habert, 2000).
• Mutations on the loci that encode the tyrosine kinase receptor c-kit and its ligand SF,
show adult sterility, with reduced germ cells evident in em9-10 gonads, implicating
effects on PCG migration (SF= possible mitogenic factor) and proliferation or loss
through increased apoptosis (SF = anti-apoptotic around eml 1) (de Miguel, 2002;
Loveland and Schlatt, 1997)
• Dazl mutants are infertile, with reduced germ cells evident by em19.5 but not at
em15. The Dazl gene encodes for an RNA binding protein associated with the
survival of gonocytes during the period of quiescence in fetal life (Ruggiu et al.,
2000)
• Retinoic acid (RA), the bioactive form of vitamin A, increases the rate of apoptosis
in em14.5 but not em18.5 gonocytes in vitro yet decreases apoptosis of d3 germ cells
(Livera et al., 2000)
Gonocyte proliferation resumes postnatally between dl-d4, but their actual number falls
during this time from around 100 000 per testis to almost 50 000. This decrease is not
accounted for by the start of gonocyte differentiation into spermatogonia but by apoptosis.
The demise of gonocytes by apoptosis is characteristic of germ cell development in the
testis. Its physiological significance is not clear but is considered to be the result ofmistakes
in DNA replication being removed, to protect the integrity of the germline (Boulogne et al.,
1999). The incidence of gonocyte apoptosis is affected by age, with peak rates over el4-15.5
decreasing to 0% by el 8.5 and resuming on d2 - a similar pattern to gonocyte proliferation
(Table 1.1). This balance of proliferation and apoptosis is responsible for the final population
of differentiated pre-spermatogonia available to undergo spermatogenesis and ultimately
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become mature spermatozoa. It is suggested that the control of germ cell mitosis is directed
by Sertoli cells, based on in vitro studies of gonocytes ± Sertoli cells. Purified gonocytes
only resumed proliferation when co-cultured with Sertoli cells otherwise they perished
within 48h (Li et al., 1997). Postnatal germ cell survival is regulated by FSH, LH and
androgens, but this is not evident in the fetal testis (Boulogne et ah, 1999; Tapanainen et ah,
1993).
Species
























21-28 35-42 42-45 70-140 (unclear) puberty 0-5 years
Mouse (19) 7.5 11.5 12.5 13.5-16.5 16.5 dl 13.5-17.5, d7
Rat
(21)
8 13.5 13.5 13-18 18 d3-4 14.5-17.5, d3
Table 1.1 Outline of the stages of germ cell differentiation during fetal and neonatal
life in the rat, the mouse and the human (Olaso and Habert, 2000).
1.1.6 Leydig cells
The interstitial glands of Leydig in the testis are named after the German scientist Franz
Leydig (1821-1908) who first described this cell in a manuscript published in 1850. These
cells are not to be confused with the Leydig cells of the amphibian epidermis that are also
named after him. Though Leydig's paper described the consistent appearance of cellular
clusters between the seminiferous tubules in many species, the role of these cells did not
become apparent until after he retired in 1887. In 1896, another German scientist, Friederich
Reinke (1862-1919) proposed that
"...these interstitial cells, produce an unknown product, which is transported through the
lymph to the blood, ... and [has] something to do with spermatogenesis and probably with
sex drive."
However, the endocrine role of the Leydig cells was not highlighted until a publication in
1903 by Bouin and Ancel. Pol Bouin (1870-1962) also developed an original chemical
mixture to successfully preserve testes for histological analysis (reported in 1897, still used
today and known as Bouin's fixative). During his employment at the University ofNancy,
France, Bouin met Paul Ancel (1873-1961). Together they furthered the evidence that
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Leydig cells produced a product that controlled male sexual characteristics. Subsequent
investigators extended their work, such that during the 1930's this product was identified as
a steroid and became known as testosterone, and during the 1950-60's it was demonstrated
that Leydig cells were the main source of testicular androgens in many mammals, including
man and rodents (Payne, 1996; Saez, 1994).
Today, it is well established that a major role of Leydig cells is the production of
testosterone and other endocrine hormones. This part of this review will focus on the
biosynthesis of testicular testosterone, as it is critical for male sexual differentiation and the
development of secondary male characteristics in addition to the initiation and maintenance
of spermatogenesis, as well as the origin, proliferation and differentiation of the Leydig cell.
1.1.6.1 Steroidogenic cell origin
There are two types of testicular Leydig cells, fetal and adult, which develop as distinct cell
lineages (Mendis-Handagama and Ariyaratne, 2001). It has been suggested that due to the
simultaneous occurrence of the fetal Leydig cells and the adult population of Leydig cells,
and their distinct formation, that these cells lines are distinct and developmentally unrelated
(Kerr and Knell, 1988). The first population develops during fetal life, downstream of Sry,
but regresses following masculinisation of the male urogenital system, although a few fetal
type Leydig cells do persist into adulthood (Kerr and Knell, 1988). The second population
appears postnatally (Habert et al., 2001). Though the details of the origin and differentiation
of these two lineages has not been clearly determined, they share a common function - the
production of testosterone, for the support ofmasculinisation and spermatogenesis
respectively.
Adult Leydig cells are proposed to derive from adult peritubular mesenchymal cells whereas
fetal Leydig cell origin is less clear. They are known to migrate into the gonadal anlage from
the mesonephros, though this may not be their exclusive origin (see 1.1.6.1.1) (Habert et al.,
2001; Siril Ariyaratne et al., 2000; Yao et al., 2002). In the rat, adult Leydig cells begin their
differentiation during postnatal week two, via proliferation of non-steroidogenic precursor
cells that differentiate and mature into steroidogenic adult Leydig cells through a series of
morphological and functional changes. This process is dependent on the co-ordination of
various cytokines (Meinhardt et al., 1996; Mendis-Handagama and Ariyaratne, 2001). The
differentiation of adult Leydig cells occurs postnatally so the details of this process and the
gene expression behind it extend beyond this review of fetal testis development. Some of the
gene products associated with the origin of fetal Leydig cells, their development and
function, are described in more detail below but this is not a complete or exhaustive list. A
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reference book that outlines the functions of various genes, including those associated with
the adult Leydig cell, is available (Payne, 1996).
1.1.6.1.1 Fetal Leydig cells
The initial embryonic origin of Leydig stem cells is still unclear but by observing
development patterns using mesonephros/ gonad cocultures, it has been demonstrated that
fetal Leydig cells are derived from the population of cells that migrate from the embryonic
mesonephros (Capel, 2000; Habert et al., 2001; Merchant-Larios, 1998). Proliferation studies
and Dil lineage tracing studies have revealed that cells from the coelomic epithelium also
contribute to the population of interstitial cells of the developing testis though the fate of
these is not clearly defined (Yao et al., 2002). Another proposed source of fetal Leydig cells
is the embryonic neural crest due to their expression of neural proteins such as NCAM
(neural cell adhesion molecule), suggesting a role for these molecules in the development
and function of these steroidogenic cells (Mayerhofer et al., 1996). By eml 1.5, the interstitial
cell precursors are already in the testis and by em12.5 (el5.5 in the rat) testosterone is being
produced (Buehr, 1993; Merchant-Larios et al., 1993; Merchant-Larios, 1998; Yao et al.,
2002).
It is uncertain what the key factors are, that regulate fetal androgen production, given that the
initial differentiation of Leydig cells and androgen production is gonadotrophin independent
as serum LH is not detected until later in gestation, around el7.5 in the rat (El-Gehani et al.,
1998b; O'Shaughnessy et al., 1998). This observation is supported by studies in hypogonadal
(hpg) mice in which almost no GnRH is present to stimulate LH production/ release by the
fetal pituitary, yet normal fetal development of the male reproductive tract still occurs
(O'Shaughnessy et al., 1998). During the perinatal period, endogenous gonadotrophins (e.g.
LH) become essential for normal Leydig cell function. This suggests that in late gestation,
both gonadotrophin support and gonadotrophin-independent support of Leydig cell function
may exist. Perhaps these two systems synchronise to maximise androgen production during
the androgen dependent virilisation of the male urogenital tract. What induces the late
gestational conversion of steroidogenesis to gonadotrophin dependence is not clear, but may
be related to birth itself, to changes in Leydig cell function as the fetal population starts to be
replaced by the adult population, or to changes in Sertoli cell function as the germ cells start
to differentiate (O'Shaughnessy et al., 1998).
Following their differentiation, the fetal Leydig precursor cells proliferate such that there are
approximately 25xl03 cells by el7.5, reaching 90 xlO3 cells by e21.5. Afterbirth, fetal
Leydig cell numbers regress but are variable with a mean of45-60 xlO3 per testis up to
postnatal dlOO (Kerr and Knell, 1988). As Sertoli cells differentiate ahead of the Leydig cells
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(prior to el2.5 and after el2.5, respectively), it has been considered that Sry expression in
the Sertoli cells induces a paracrine signal to a population of undifferentiated mesonephric
cells to follow the Leydig cell lineage, though what this signal might be is also unclear
(Habert et al., 2001). The Sertoli cell product AMH has been implicated in the inhibition of
adult Leydig cell development and steroidogenesis (via P450cn) but this is still being
investigated, and there is evidence that AMH effects fetal Leydig cell development (Fynn-
Thompson et al., 2003).
In the human, the first fetal Leydig precursors are identifiable during week 8 of gestation,
following differentiation of the gonad during week 6, though testicular testosterone has been
reported at week 6-7. This initial androgen production precedes gonadotrophin detection
(during week 10) including any stimulation by placental chorionic gonadotrophin (hCG).
This analogue ofpituitary LH is produced maternally and is utilised later in gestation to
stimulate androgen production coincident with virilisation of the male reproductive tract.
Following birth, a second wave of Leydig cells develops, peaking around postnatal month 3,
but overall the postnatal Leydig cell population decreases steadily until a nadir around 1 year
afterbirth. Numbers are then steady until the pubertal wave of Leydig cell development. As
for the rat, differentiation of the Leydig cells is recognised by their increase in cytoplasmic
volume, appearance of the smooth endoplasmic reticulum and increased numbers of steroid-
type mitochondria (reviewed in Habert et al, 2001).
1.1.6.1.2 Sf-1
The mesonephros and coelomic epithelium of the embryonic rat both include a population of
cells that can be immunostained for Steroidogenic factor-1 (Sf-1, also known as Ad4BP or
FTZF1 or NR5A1), a member of the nuclear hormone receptor family of transcription
factors (Achermann et al., 2002; Birk et al., 2000). These cells can be tracked during
embryogenesis and while some end up in the testis, others inhabit the developing adrenal
gland, hence they are termed the "adreno-genital primordium" (Hatano et al., 1996). Sf-1 is
expressed in a wide range of steroidogenic and non-steroidogenic tissues where it
orchestrates the development of the reproductive axis (e.g. via the pituitary and
hypothalamus) and adrenal glands (Hatano et al., 1994). More than 20 genes have been
identified as influenced by Sf-1 via Sf-1 binding sites that regulate the transcription of the
genes e.g. P450 steroidogenic enzymes, such as testicular P450scc and P450 Cn and the a-
subunit ofglycoprotein hormones (Achermann et al., 2002; Majdic et al., 1997b). The role
these steroidogenic enzymes play in the synthesis of testosterone is detailed later in this
review.
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Immunoexpression studies have shown that Sf-1 is expressed in both the pre-Sertoli and the
interstitial cells, especially the pre-Leydig cells of the presumptive testis. Examination of
mice lacking Sf-1 revealed abnormalities of the genital ridge prior to the appearance of overt
gonads. As testis cord formation progresses, Sf-1 levels fall in the Sertoli cells but rise in the
fetal Leydig cells (Hatano et al., 1994).
The role of Sf-1 in the fetal Sertoli cell extends beyond the regulation of P450 steroidogenic
genes (e.g. P450arOmatase) to other genes such as for the glycoprotein AMH. Sertoli cell
specific Wt-1 binds to and transactivates the Sf-1 promoter, increasing Sf-1 expression, and
together they up-regulate AMH expression, with interaction from GATA-4 and Sox9
(Watanabe et al., 2000; Wilhelm and Englert, 2002). This synergistic increase in AMH
levels can be disrupted by the transcription factor Daxl via direct interaction with the DNA
bound Sf-1 protein (Tremblay and Viger, 2001). The expression profile ofAMH is similar to
that of Sf-1, even in ovarian granluosa cells (Hatano et al., 1994). Of the many genes whose
products are known to be associated with the development of gonads post differentiation,
both Wt-1 and Sf-1 are essential to gonadogenesis prior to differentiation, though the details
of their hierarchy is still unclear (Birk et al., 2000; Wilhelm and Englert, 2002).
Targeted disruption of the Sf-1 gene was examined in mice. All Sf-1 null animals lacked
adrenal glands and gonads because of apoptosis of the primordial organs just as both adrenal
and gonad differentiation takes place. This supports adrenocortical insufficiency as the
probable cause of death by postnatal d8. Male and female Sf-1 knockout mice had female
internal genitalia, despite complete gonadal agenesis (Luo et al., 1994).
Sf-1 expression levels in the adrenal glands during fetal and postnatal development is not
sex-specific, unlike for the testis. Sf-1 mRNA expression was first detected in the adrenal
and the gonadal ridge of both sexes of fetal rats from el3.5, but after el4.5, the testis had a
much greater level of Sf-1 expression than an ovary of the same age (Majdic et al., 1997b).
This change in the Sf-1 expression levels in the gonads after sexual differentiation, indicates
that maintenance ofhigh level Sf-1 expression is sexually dimorphic, possibly a downstream
target of Sry in the male. This is supported by the observation that both Sry and Sf-1 are
expressed in the identical lineage of the somatic cells in the genital ridge (Hatano et al.,
1994). The level of Sf-1 in the fetal testis peaks at el6.5 and is maintained until a dramatic
decrease from postnatal d21 until only low levels are detected during adulthood. Conversely,
fetal ovarian expression levels of Sf-1 increase postnatally from d7 until d21 then decrease to
adult levels. For both sexes, Sf-1 levels fluctuate in the gonads during the first 3 weeks of
postnatal life but not in the adrenals, confirming tissue specific and sex specific differential
regulation of Sf-1 expression (Hatano et al., 1994).
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An example of the tissue specific differential regulation of Sf-1 expression is the effect of
mutations of Lhx9, a transcription factor and member of the LIM homeobox domain family.
When Lhx9"/+ mice were paired, the Lhx9 progeny were infertile at 3 months old and had
female internal genitalia, despite complete gonadal agenesis, including those that were
genetically male, as for the Sf-1 null mice described above (Birk et al., 2000; Luo et ah,
1994). At eml 1.5, the mutated Lhx9 gene inhibited normal proliferation of the gonadal ridge,
particularly of the Sf-1 stained cells. Markedly reduced levels of Sf-1 expression were
observed in the Lhx9 ''' gonadal ridge but not in the adrenal bud, indicating that Lhx9 might
lie upstream of Sf-1 in the development cascade. By em13, the Lhx9 gonads had regressed
completely but the absence of the adrenals was not noted. The specific effect of the Lhx9
null mutation on gonad development, despite its normal widespread expression, was
proposed to be a consequence of either redundancy of this gene in other Sf-1 expressing
tissues (e.g. adrenal gland) or compensation by similar genes e.g. Lhx2 (Birk et ah, 2000).
1.1.6.1.3 Dhh
Desert Hedgehog (Dhh) is a signalling protein essential for the early differentiation and
proliferation of the Leydig cell lineage. Sertoli cells express the Dhh protein, whereas its
receptor (Patched 1, Ptchl), is expressed by interstitial cells. Dhh is expressed downstream
of Sry, and is proposed to be a positive regulator of the differentiation of steroid producing
cells as it up-regulates the expression of Sf-1 in Ptchl expressing cells outside the testis
cords, specifying the Leydig cell lineage (Yao et ah, 2002). It is likely that additional factors
combine with Dhh to confirm the fate of the Leydig cell lineage from the precursor cells that
contribute to the interstitium in the fetal testis.
1.1.6.1.4 PDGF-a
The platelet-derived growth factor (PDGF) family of ligands and receptors has a diverse
range of roles across various physiological processes including migration, proliferation and
differentiation, including early testis development(Brennan et ah, 2003). There are two
receptors (a and (3) and four ligands (A, B, C and D) that dimerise and activate various
intracellular pathways. Examination ofPdgf-ff1' mice showed no overt changes in XX or XY
gonads but Pdgf-aand Pdgf-A null mice showed a sexually dimorphic expression pattern
that was followed up in Pdgf-a'1' mice (Brennan et ah, 2003). The role ofPDGF signalling in
the embryonic testis has not been thoroughly investigated but initial studies with Pdgf-a'1'
XY gonads, revealed impaired cord formation, proliferation and endothelial cell migration.
Additionally, Pdgf-a is associated with the differentiation of the fetal Leydig cell lineage as
fetal Leydig cells are reduced or even absent as in Dhhf'" mutants (Brennan et ah, 2003).
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1.1.6.2 Cholesterol transport
Testosterone, a C21 four-ringed steroid, is produced following the enzymatic conversion of
cholesterol (Figure 1.4). However, this is dependent on there being a source of cholesterol,
i.e. dependent on the translocation of cholesterol, into the Leydig cell cytoplasm and then
into mitochondria to start steroid biosynthesis. Cholesterol is a lipid molecule with 27 carbon
atoms (C27), a hydroxyl head region and a hydrocarbon tail region, separated by a rigid four-
ringed steroid structure. It is found nestling among the phospholipid molecules that make up
the lipid bi-layers of eukaryotic cell membranes (Alberts, 1994). This transport of cholesterol
to the first enzyme complex in the steroid biosynthesis cascade is considered the rate-











Figure 1.4: Simplified illustration of testosterone biosynthesis in a rat Leydig cell.
Extracellular cholesterol is recruited into the cell cytoplasm (turquoise) via SRB1 (pink).
Trophic stimulation of the LH receptor (dark blue) induces an increase in cAMP levels,
which in turn mediates a multitude of intracellular activities, such as an increase in the
mobilisation of intracellular cholesterol through the mitochondria membranes by StAR
(yellow) where P450scc (red) converts it to pregnenolone. P450scc is found on the matrix
(white) side of the inner mitochondrial membrane (purple) where it is associated with two
proteins: adrenodoxin (pale green) and adrenodoxin reductase (darker green). Pregnenolone
is transported to the smooth endoplasmic reticulum (ER) (blue) where it is converted to
progesterone (via 3J3-HSD, brown), to androstenedione (via P450Ci7, orange) then to
testosterone (via 17P-HSD, gold), which is mostly secreted out of the Leydig cell.
1.1.6.2.1 SRB1
Leydig cells differ from other cells in that they do not depend on exogenous lipoprotein-
cholesterol sources during periods of normal steroid hormone production but utilise
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endogenous cholesterol sources, such as plasma lipoproteins in the form of cholesteryl esters
or oil droplets (Rao et al., 2003). They can be regulated by different factors than the similar
steroidogenic cells of the adrenal glands (Payne and Youngblood, 1995).
Scavenger receptor class B, type 1 (SRB1) is an isoform of a high-density lipoprotein (HDL)
receptor protein. SRB1 binds various lipoproteins, particularly HDL, then internalises only
the cholesteryl ester particles it may carry, leaving the HDL carrier outside the cell (Figure
1.4). This way it mediated intracellular delivery of cholesterol from the HDL. There is a
variant, type II, and though it exists in high levels in rodent testes, it appears to have no role
in mediating intracellular cholesterol levels (Reaven et al., 2000). This mechanism is seen in
small amounts through experiments with 3H-labelled HDL-cholesteryl-esters and rat Leydig
cells (Reaven et al., 2000). Once internalised, the cholesteryl esters may be stored as lipid
droplets until needed, such as to be hydrolysed to produce free cholesterol for
steroidogenesis (Rao et al., 2003).
SRB 1 expression levels are possibly regulated by physiological conditions that reflect the
cell's need for cholesterol. Unexpectedly high levels of SRB1 expression were observed by
electron microscopy near the exterior of the cell membrane of hCG treated adult rat Leydig
cells, compared to low level expression in control Leydig cells. This prompted investigation
into whether Leydig cells acquired at least some of the cholesterol used in steroid hormone
synthesis from exogenous sources. This work revealed that significant levels of exogenous
lipoprotein cholesterol were not used routinely by Leydig cells as a steroidogenic precursor,
but this process could be induced following chronic trophic stimulation (Reaven et al.,
2000).
1.1.6.2.2 StAR
The transcription of the gene encoding the steroidogenic acute regulatory (StAR) protein is
acutely regulated by trophic hormones via a cAMP second messenger pathway. In turn,
StAR regulates the rate-limiting step of steroidogenesis in the adrenal cortex and the gonads
i.e. the translocation of cholesterol from the cytoplasm of Leydig cells to the P450scc enzyme
on the inner mitochondrial membrane (Figure 1.4). Without StAR to facilitate the journey,
such low levels of hydrophobic cholesterol would cross the aqueous space between the two
mitochondrial membranes that the observed physiological levels of steroidogenesis could not
be supported (Stocco, 2001).
The gene encoding StAR is carefully regulated to ensure its proper temporal and spatial
expression in steroidogenic tissues during development, and it is rapidly inducible in
response to acute cAMP stimulation (Reinhart et al., 1999b). The molecular mechanisms
underlying this regulation remain unclear. Functional analysis has demonstrated that
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transactivation of the StAR promoter is Sf-1 dependent and immunostaining has shown that
the expression of StAR correlates both temporally and spatially with Sf-1 expression
(Pollack et al., 1997; Reinhart et al., 1999a). As StAR is not detected in the urogenital ridge
of Sf-1 null mice, Sf-1 is proposed to developmentally regulate StAR expression. Daxl is a
negative regulator of StAR. Its exact mechanism is unclear but it works either by interacting
with the StAR promoter sequence directly or via direct binding to and inhibiting Sf-1
regulated steroidogenesis (Stocco, 2001).
The StAR gene product is a precursor protein that undergoes two modifications from the
37kDa precursor to a 32kDa intermediate followed by cleavage into a mature 30kDa protein.
This processing occurs during import of the precursor StAR protein from the Leydig cell
cytosol into the outer then the inner mitochondrial membrane. This has been proposed to
create contact points between the two membranes thus enabling cholesterol to be presented
to P450scc for conversion to pregnenolone. On reaching the inner membrane, StAR is
processed to its 30kDa form and the contact point is lost, making further cholesterol transfer
dependent on de novo synthesis of the 37kDa protein. The levels of 30kDa StAR build up
and do not display the anticipated turnover kinetics consistent with the loss of steroidogenic
capacity (Stocco and Sodeman, 1991). It is not yet clear whether StAR can act as a
cholesterol shuttling protein or affects cholesterol transfer less directly. The peripheral
benzodiazepine receptor (PBR) is also located in the outer mitochondrial membrane and is
associated with cholesterol transfer in mitochondria of steroidogenic cells, but it is not clear
whether these proteins act together to promote cholesterol transfer (Papadopoulos et al.,
1991; Stocco, 2001). The means by which the StAR gene is regulated and the exact
mechanism of its action are still under investigation (Stocco, 2001). Studies have shown that
StAR mRNA levels can be regulated by non-cAMP dependent factors such as upregulation
via retinoic acid and thyroid hormone but down regulation by lipopolysaccharides, TGF-(3,
interferon-y and TNF-a (reviewed in Habert et al 2001).
In the human, StAR protein has been immunolocated in fetal and adult gonads and adrenal
glands, with intense staining in the Leydig cells of the fetal testis between 14-19w/40w,
during peak fetal testosterone production (Pollack et al., 1997). Additional staining was
noted in cell types that did not express the steroidogenic enzyme P450scc (e.g. Sertoli cells),
suggesting that StAR has roles in metabolic processes other than pregnenolone biosynthesis.
It was not detected in placenta suggesting existence of a StAR independent pregnenolone
biosynthesis mechanism (Pollack et al., 1997). Mutations in the StAR gene result in the
human condition "lipoid congenital adrenal hyperplasia" (lipoid CAH). Patients with this
potentially fatal syndrome are unable to synthesise steroids as required from birth, despite
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excessive levels of cholesterol and cholesteryl esters in their adrenal and testicular
steroidogenic cells. This phenotype has also been noted in StAR null mice, confirming that
the StAR protein has an indispensable role in normal steroidogenesis (Stocco, 2002).
1.1.6.3 Steroidogenesis
The main function of Leydig cells is the biosynthesis of the androgen testosterone.
Androgens are vital during perinatal development to ensure completion of testicular descent,
regulation of Sertoli cell number and initiation of spermatogenesis (Siril Ariyaratne et al.,
2000). Testosterone is produced in response to acute and/or chronic stimulation, initiated by
the pituitary hormone, luteinising hormone (LH), binding to specific high affinity LH-
receptors on the surface of Leydig cells (Payne and Youngblood, 1995). The cellular protein
kinase A (PKA) -dependent steroidogenic response is primarily mediated by phosphorylation
of cyclic AMP (cAMP) -dependent transcriptional activators (e.g. Sf-1), resulting in the
upregulation ofStAR and other steroidogenic genes (Rao et al., 2003). More information on
the role ofpituitary hormones is detailed in section 1.1.8.
The conversion of cholesterol to testosterone in the testis requires the transcription of the
genes that encode four catalytic proteins:
• cholesterol side-chain-cleavage (P450scc)
• 3 p-hydroxysteroid dehydrogenase (3 P-HSD)
• 17 a-hydroxylase/ C17-20 lyase (p45ocn)
• 17 P-hydroxysteroid dehydrogenase (17p-HSD)
These enzymes form an organised sequence, creating a steroidogenic cascade (Figure 1.5),
yet are physically separated into different compartments within the Leydig cell (Figure 1.4)
and subject to different mechanisms of regulation. Further details are outlined in the
following sections. The steroidogenic enzymes fall into two major classes: the P450 heme-
containing proteins and the hydroxysteroid dehydrogenases (Table 1.3).
Perturbations in any of the steps in the steroidogenic cascade (Figure 1.4), from the levels of
binding of LH to its receptor, expression levels of the catalytic proteins, alterations in the
mitochondrial or smooth ER membranes, could result in disrupted steroidogenesis and levels
of testosterone production (Zirkin and Chen, 2000). Testosterone is the substrate for at least
two enzymes: P450aromatase catalyses the aromatisation of testosterone into oestradiol (E2) and
5a-reductase catalyses production of dihydrotestosterone (DHT), a more potent androgen
than its precursor and vital for masculinisation of external genitalia (Habert et al., 2001).









P450scc CYP11A1 (15) Cypllal (9) cholesterol to pregnenolone 56
P450Ci7 CYP17 (10) Cypl7 (19) progesterone to androstenedione 57
P450arom CYP19 (15) Cypl9 (3) testosterone to oestradiol 58
Hydroxysteroid dehydrogenases
3P-HSD HSD3P3 (1) Hsd3pi (3) pregnenolone to progesterone 42-44
17P-HSD HSD17P3 (9) Hsdl7p3 (13) androstenedione to testosterone 34
Table 1.3 Summary of the major enzymes involved in testicular testosterone
biogenesis expressed in human and mouse Leydig cells. Adapted from Hanukoglu (1992).
Figure 1.5: Simplified testosterone biosynthesis in a mammalian Leydig cell. One
enzyme can catalyse more than one reaction and the most favourable route can vary between
species, according to reaction kinetics. Each enzyme involved is represented by a different
coloured arrow: red = P450scc, brown = 3P-HSD, orange = P450 cl7, gold = 17p-HSD,
blue = P450 aromatase, black = 5-reductase.
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1.1.6.3.1 P450scc
Cytochrome P450 cholesterol side-chain-cleavage enzyme (P450scc also known as 20, 22-
desmolase) is a member of the membrane bound cytochrome P450 superfamily. P450scc is
bound to the mitochondrial inner-membrane of steroidogenic cells, where it catalyses the
conversion of the steroid precursor cholesterol to the metabolic intermediate pregnenolone
(Pelletier, 2001). This is the rate-limiting enzymatic step in the biosynthetic cascade of all
steroid hormones (Figure 1.5). The conversion of the C27 steroid cholesterol to the C2i
steroid pregnenolone has three steps: first hydroxylation (therefore requires oxygen) at C22,
generating the intermediate 22-R-hydroxycholesterol and second, hydroxylation at C2o
generating the intermediate 20,22-R-dihydroxycholesterol (Burstein, 1976; Burstein, 1975).
These intermediates bind very tightly to P450scc without significant dissociation, unlike the
final product pregnenolone which dissociates up to 600x more easily (Hanukoglu, 1992).
Finally, P450scc cleaves the molecule between C20-22 to produce pregnenolone (transported to
the smooth ER) and isocaproaldehyde (oxidised to isocaproic acid). For every mole of
pregnenolone produced, three moles of oxygen and three moles ofNADPH are also needed
(Simpson, 1979).
This single enzyme complex catalyses all three reactions at a single active site, facilitated by
two associated electron transport proteins: adrenodoxin reductase and adrenodoxin.
Adrenodoxin reductase (also described as testodoxin reductase or ferrodoxin reductase) is a
FAD-containing flavoprotein i.e. it accepts electrons from the electron donor NADPH
(nicotinamide adenine dinucleotide phosphate), transferring them to adrenodoxin (also
described as testodoxin or ferrodoxin), a non-heme iron-sulphur protein that in turn mediates
the electron transfer to P450scc as the terminal oxidase of this reaction (Simpson, 1979).
The various members of the P450 superfamily share a diverse range of regulatory
mechanisms, including tissue-specific patterns of isoform expression, though the most
common means of regulation is via transcription control. P450scc exhibits a high level of
constitutive expression suggesting its synthesis is not dependent on, but can be increased by,
stimulation by LH or its second messenger cAMP. Thus P450scc is regulated by both cAMP
dependent and independent mechanisms (Oonk, 1990). It has been suggested that each P450
gene has its own cAMP response element (CRE) and even its own set of CRE binding
proteins (Porter, 1991). Sf-1 has been shown to be necessary for the expression of P450scc as
it binds to a consensus element in its promoter sequence.
Quantification of P450scc expression in human fetal testis samples (13-26/40weeks of
gestation) showed that P450scc mRNA was most abundant in the adrenal gland, followed by
the testis, placenta, and ovary and that none was detected in kidney, liver, spleen, intestine,
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or muscle samples. The P450scc mRNA reached its peak between 14-16 /40w and showed
significantly lower levels by 26/40w (Voutilainen and Miller, 1986). In the rodent, P450scc
mRNA is detected in the mouse urogenital ridge from em10.5 and in the differentiated testis
from em12.5 throughout gestation with little if any expression in the fetal ovary (Payne and
Youngblood, 1995).
1.1.6.3.2 3p-HSD
Three beta-hydroxysteroid dehydrogenase/A5-A4-isomerase (3p-HSD) is found in the smooth
endoplasmic reticulum/ mitochondria of the Leydig cell, where it catalyses multiple steps in
the steroidogenic cascade (Pelletier, 2001). Overall, 3|3-HSD converts 3|3-hydroxy-5-ene
steroids into 3-keto-4-ene steroids (Hanukoglu, 1992). In the Leydig cell, it converts
pregnenolone to progesterone but it can also convert 17-OH hydroxypregnenolone to 17-OH
hydroxyprogesterone or dehydroepiandrosterone (DHEA) to androsterone (Figure 1.5). The
first reaction is the conversion of the 3 (3-equatorial hydroxysteroid (e.g. pregnenolone) via
the coenzyme NAD+ to produce a A5 -3-keto intermediate (e.g. pregn-5-ene-3, 20-dione) and
reduced NADH which activates the isomerisation of the A5 -3-ketosteroid to a A4-3-
ketosteroid (e.g. progesterone). All this happens without release of the intermediate or the
NAD(H) cofactor (Payne, 1997).
In the rat, mouse and the human multiple isoforms of this protein have been identified, each
with different tissue specific expression and catalytic kinetics for the same substrates. At
least six isoforms have been described for the mouse, ofwhich types I and VI are expressed
in the testis (Abbaszade, 1997). In the human testis, only 3J3-HSD type II is expressed but in
the rat both types I and II are seen (Hanukoglu, 1992; Mason et al., 1993).
3|3-HSD type I and 3(3-HSD type VI are expressed in the mouse testis. When each isoform
was measured individually, it was clear that the type I isoform was expressed at all ages
from em13 to adulthood. In contrast, the type VI isoform was only expressed at significant
levels during fetal life on em13 and then not again until after dlO postnatally (Baker et ah,
1999). This finding is consistent with the observation in man that neonatally 3(3-HSD is non-
detectable until puberty (Mack et ah, 2000).
The distribution of 3(3-HSD among fetal tissues is widespread and not restricted to the male
or the reproductive tract. In the rodent, 3|3-HSD expression parallels that of P450scc and its
mRNA is detected in the mouse differentiated testis from em12.5 then throughout gestation
with little if any expression in the ovary until after birth (Payne and Youngblood, 1995). 3(3-
HSD exhibits a high level of constitutive expression in Leydig cells, however, in vitro
studies demonstrated that LH and cAMP treatments increased the level of 3|3-HSD
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transcription after 24h, perhaps suggesting that like P450scc, 3|3-HSD is regulated by both
cAMP dependent and independent mechanisms (Keeney and Mason, 1992). However,
endogenously produced testosterone, but not oestradiol, represses cAMP-induced 30-HSD
mRNA synthesis (Majdic et ah, 1997b). Meanwhile, levels of testicular mRNA encoding 3p-
HSD type I were similar in normal and hpg mice (i.e. gonadotrophin deficient model),
suggesting that the expression of this protein was independent of trophic stimulation
(O'Shaughnessy et al., 1998).
The expression of 3|3-HSD could be dependent on the expression of Sf-1 as for the P450
enzymes, though this is possibly exclusive to adrenal 3(3-HSD expression (Payne and
Youngblood, 1995).
1.1.6.3.3 P450C17
Cytochrome P450 17 alpha hydroxylase/ Ci7_20 lyase (P450Cn also known as P450i7a) is a
member of the membrane bound cytochrome P450 superfamily. P450Cn is found in the
smooth endoplasmic reticulum of the Leydig cell where it catalyses the conversion of
progesterone into androstenedione (Pelletier, 2001). The conversion of the C2i steroids to Ci9
steroids has two steps: first 17a-hydroxylation, also required for Cortisol synthesis, then
cleavage of a two-carbon side chain at Cn - C20 producing a Ci9 steroid and acetaldehyde
(Hanukoglu, 1992). Human P450Ci7 can also perform 16a-hydroxylation, perhaps depending
on the orientation of the steroid at the time ofhydroxylation (Swart et al., 1993). The
absence ofP450cn from the rat adrenal means that corticosterone (derived via progesterone)
rather than Cortisol (derived via 17a-hydroxyprogesterone) is the major glucocorticoid
product. Additionally, the absence ofP450c2i in Leydig cells channels the steroid
biosynthetic pathway towards androgen production (P450c2i catalysis determines the
biosynthesis of adrenal steroid hormones from A4 steroids) (Hanukoglu, 1992).
P450Ci7 catalyses both reactions at a single active site, without the 17a-substrate leaving the
enzyme and is facilitated by an electron transfer system with oxygen and NADPH, similar to
that described for P450scc (Hanukoglu, 1992). There are two possible substrates for this
sequence: pregnenolone (a A5 steroid) producing dehydroepiandrosterone (DHEA), or
progesterone (a A4 steroid) producing androstenedione, the precursor to testosterone. The use
of the A5 or A4 substrate is dependent on the Ci7 - C20 lyase species e.g. the human enzyme
has extremely low C]7, C20 -lyase activity toward A4 progesterone, compared to A5
pregnenolone so favours the A5 steroidogenic pathway. The opposite is true in the rat (Fluck
et al., 2003; Swart et al., 1993).
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P450Ci7 expression is induced following stimulated increases in cAMP levels, implying
different regulatory mechanisms are in place than for P450sccand 3(3-HSD (Payne and
Youngblood, 1995). For example, P450Cn protein expression was reduced but 3(3-HSD
levels were unaffected in testes from fetuses exposed in utero to oestrogenic compounds
(Majdic et al., 1997b). Additionally, in vitro studies with the protein synthesis inhibitor
cyclohexamide demonstrated that P450Cn transcription is mediated via cAMP and requires
the synthesis of de novo proteins (i.e. cAMP responsive region (CRR) binding proteins) to a
greater extent than for P450scc transcription, suggesting different regulatory mechanisms
exist for the transcription of the two proteins (Payne and Youngblood, 1995). Activation of
AMH-receptor type II (a Sf-1 dependent protein) has recently been shown to inhibit postnatal
PKA mediated expression ofP450cn via a cAMP regulatory element-binding (CREB)
protein independent mechanism, leading to inhibition of steroidogenesis (Fynn-Thompson et
al., 2003).
Quantification of the P450Cn expression in human fetal testis samples (13-26/40weeks of
gestation) showed that P450 C\i mRNA was most abundant in the adrenal, followed by testis
and ovary, but was undetectable in the placenta, kidney, liver, spleen, intestine, or muscle.
The P450cn mRNA reached its peak between 14-16 /40w and showed diminished levels by
26/40w (Voutilainen and Miller, 1986). In the rodent, P450ci7mRNA is detected in the
mouse urogenital ridge from em10.5 and in the differentiated testis from em12.5 throughout
gestation as for P450scc (Payne and Youngblood, 1995).
1.1.6.3.4 17(3-HSD
Seventeen beta-hydroxysteroid dehydrogenase (17(3-HSD, also known as 17-ketosteroid
reductase, 17KSR) is found in the smooth endoplasmic reticulum of the Leydig cell. In the
Leydig cell, it catalyses the reduction of androstenedione to testosterone, the final step in
testosterone biosynthesis (Payne and Youngblood, 1995). This is a reversible reaction,
dependent on the levels of substrate and co-factors, namely androstenedione and NADPH for
testosterone synthesis (Hanukoglu, 1992).
There are multiple isoforms of 17(3-HSD. Studies in mice have shown changes in the
localization of isoform expression and consequent testosterone secretion occur during
development. For example, the type 3 isoform (the main reductive isoform in the testis) was
expressed only in the seminiferous tubules in fetal testes but in the interstitial tissue in adult
testes. Expression of the type 3 isoform declines in the seminiferous tubules before puberty
but then reappears in the developing adult Leydig cell population. Production of testosterone
up until puberty is dependent upon 17f3-HSD activity in the seminiferous tubules: a "two
cell" requirement for fetal testosterone synthesis (O'Shaughnessy et al., 2000). It is
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increasingly clear that in the mouse, Leydig cells in the fetal/neonatal testis lack significant
levels of any isoforms of the enzyme capable of reducing androstenedione to testosterone
and appearance of this enzyme in the interstitial tissue is due to development of the adult
Leydig cell population. Androstenedione is a weak androgen and data show that formation of
the bioactive 17|3-hydroxy-Ci9 steroids in the fetal/neonatal testis is dependent on 17(3HSD
localized in the seminiferous tubules, probably within the Sertoli cells (O'Shaughnessy et ah,
2000).
To examine regulation of 17(3-HSD type 3 mRNA expression in the testis, mRNA levels
were measured during development in normal mice and in mice lacking circulating
gonadotrophins (hpg) or functional androgen receptors (Tfm). During neonatal development
expression of 17P-HSD type 3 is independent of gonadotrophin action, while the increase in
expression at puberty is primarily dependent upon androgen action although testicular
descent and gonadotrophins are also required (Baker et al., 1997).
Overall, fetal Leydig cells appear in the interstitium of the developing testis just as the
seminiferous cords form, characterised by the appearance of large mitochondria and lipid
droplets and copious amounts of smooth ER. Fetal rat testosterone production is evident in
vivo from el5.5, though from el3.5 the testes can convert progesterone to testosterone in
vitro. The ability of the Leydig cell to bind LH starts after el5.5, though the coupling of
cAMP with steroidogenic responsiveness is functional before that (Saez, 1994). The role of
the LH and cAMP signalling is detailed in section 1.2.
Mutation of any of the genes for the four steroidogenic enzymes discussed above, leads to
compromised testosterone synthesis, such as lipoid CAH as with StAR mutations, and
psuedohermaphroditism because of failure of normal masculinisation during development
(Hanukoglu, 1992; O'Shaughnessy et al., 2000; Payne, 1997; Stocco, 2002).
As Sertoli cells differentiate prior to the Leydig cells, and probably perform the last step of
fetal testosterone biosynthesis in the mouse, it appears that the Sertoli cells really are the
orchestrators of testis formation and development.
1.1.7 Embryological events in male sex differentiation
This review has described the development of the testis mostly in the mouse but also in the
rat and with occasional reference to the human. At birth, the human and rat testes have
already achieved an organised structure with defined cell types and vasculature, ready to
grow and differentiate further into a mature hormone- and gamete-producing organ. The
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most fundamental difference in the development of this organ between these three species is
the timescale over which it occurs. For clarity, the major events of development are tabulated
per species below (Table 1.2), above a simplified time-line for development, using the
human as an example (Figure 1.6).
Species
Stage of testis development




(week of gestation/ 40w)
5 6 7 7-8
Mouse
(embryonic day (em))
9-10 10-11.5 10.5 11.5-12.5
Rat
(embryonic day (e))
10-11 11.5-12.5 12 13.5-14.0
Table 1.2 Gestational age at each stage of testis development in humans, mice and
rats. Taken from "Sertoli cell biology" (Edited by M.K.Skinner and M.D.Griswold, 2005).

















Figure 1.6 Temporal events in testis development in the fetal human over the 40
weeks of gestation. The dashed lines represent: (—) AMH and (...) testosterone production
levels, following differentiation of Leydig cells from 8 weeks, which peaks at around 12-16
weeks. Based on (Hughes, 2001) and (Voutilainen, 1992).
1.2 Endocrine regulation of testis development
Testis development requires the correct spatial and temporal expression ofmany genes. In
part, the regulation of this highly complex sequence is under the control of hormones. In
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turn, the sexual differentiation of the developing gonad is confirmed by its own hormonal
secretions (Capel, 1998). The release of a hormone from one cell, to act on another cell
located remotely from the origin, is performed by endocrine cells, naking the testis an
endocrine organ.
1.2.1 The HPG axis
Many endocrine organs influence the reproductive tract, including the thryoid and the
adrenals, but three tissues are vital to the regulation of the endocrine health of the
reproductive system: the hypothalamus, the anterior pituitary and the gonads. Together, they
form the Hypothalamic-Pituitary-Gonadal (HPG) axis (Figurel.7).
For the male, the stimulation ofproduction of hormones from the testes is initiated in the
hypothalamus of the brain. The hypothalamus synthesises a peptide hormone, gonadotrophin
releasing hormone (GnRH), that travels via the portal blood system to the anterior pituitary.
GnRH is released in a pulsatile manner, stimulating rhythmic release of the gonadotrophic
hormones from the pituitary. The male pituitary releases two hormones into the blood:
luteinising hormone (LH) and follicle stimulating hormone (FSH). These are named after






















Figure 1.7: Outline of the HPG axis in the male. Certain hormones stimulate (red)
production of other hormones; others inhibit (blue) production when their circulating level
reaches a critical concentration. The balance of stimulation and inhibition is the regulatory
mechanism that underlies this axis.
1.2.1.1 Gonadotrophin release
Regulation of gonadotrophin secretion involves complex interplay between GnRH and
feedback regulation by gonadal sex steroids (e.g. testosterone) and peptides (e.g. inhibin-B)
as well as pituitary factors (e.g. activin) (Figure 1.7) (Blumenfeld and Ritter, 2001).
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GnRH stimulates the secretion of LH and FSH from pituitary gonadotroph cells, therefore it
is considered the central regulator of gonadotrophin dependent regulation of the reproductive
system. At least two forms ofGnRH exist, each capable of regulating different pituitary
endocrine cells, enabling the differential stimulation of LH or FSH secretion. The
gonadotrophins are released from the anterior pituitary following GnRH stimulation. This
triggers secretory granules, formed from the trans-Golgi network and containing the
regulatory proteins, to fuse with the cell membrane, dispersing their contents in the
extracellular space (Tooze, 2001).
The hpg mouse is a model for hypogonadotrophic hypogonadism due to a deletion in the
GnRH gene, preventing formation of a functional GnRH protein. These animals show that
pre-natal GnRH expression is vital to enable the necessary development of the neural
connections needed for normal hypothalamic-pituitary interactions (Markkula, 1996).
Pituitary LH synthesis can start in the absence ofGnRH but is dependent on GnRH for a
normal level of synthesis and secretion. The undetectable level of LH in the circulation of
the hpg mouse despite the development of LH synthesis in the pituitary shows that GnRH is
essential for LH release from the pituitary. It should, however, be noted that although
circulating LH is undetectable in the hpg mouse, there might be low basal secretion from the
pituitary. FSH data was not reported (O'Shaughnessy et al., 1998).
1.2.1.2 Hormone stimulation
LH and FSH belong to the same glycoprotein family as thyroid stimulating hormone (TSH)
and chorionic gonadotrophin (hCG). Their actions are executed following their binding to
specific receptor proteins on the target cells surface. Many cell surface receptors respond to
stimulation by activating heterotrimeric guanine nucleotide binding proteins (G-Proteins).
Activation of an expressed G-protein coupled receptor by its ligand results in a
conformational change in the cytoplasmic domain of the receptor and the dissociation of the
a subunit from the (3y dimer of the coupled G-protein. Both subunits are then free to
modulate intracellular targets. Several ligands modulate multiple effectors as single receptors
can interact with multiple G-proteins via differential coupling preferences. Usually it is the a
subunit that determines the typical consequence of the receptor binding and the classification
of the G-protein e.g. Gs- coupled receptors stimulate adenylyl cyclase via GTP hydrolysis,
Gj- coupled receptors inhibit adenylyl cyclase and Gq- coupled receptors stimulate
phopholipase C (PLC) (Zhu, 1996).
Co-ordination of the stimulation / inhibition of adenyl cyclase regulates the concentration of
small intracellular signalling molecules, such as cyclic adenine mono-phosphate (cAMP).
Adenyl cyclase is a membrane bound enzyme responsible for the formation of cAMP from
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its precursor molecule adenine tri-phosphate (ATP). The de novo synthesised cAMP is
rapidly destroyed by competing enzymes, cAMP-phosphodiesterases, which hydrolyse it to
inert 5'AMP, hence its effectiveness as a transient signal. cAMP goes on to activate the
enzyme cAMP-dependent protein kinase A (PKA), which catalyses the phosphorylation of
selected proteins, regulating their activity. Specific phosphatase enzymes de-phosphorylate
the effects ofPKA. The substrates ofPKA are cell specific, hence the potential for a diverse
range of acute responses via the same second messenger molecule (reviewed in Alberts,
1994 and Saez, 1994). The rise in cAMP induces three responses: lipid synthesis, protein
synthesis and/or phosphorylation of specific proteins to modify their function (Lacapere and
Papadopoulos, 2003).
1.2.1.3 Luteinising Hormone
LH action is exerted on cells expressing the LH receptor. In the testis LH is the main
hormone that controls Leydig cell function. LH binding to the Leydig cell activates
adenylate cyclase (and phospholipase C to a lesser extent) to increase cAMP production
within the cell, that stimulates steroidogenesis and leads to an increase in testosterone
production and secretion (Habert et al., 2001). hCG exerts 'superagonist" properties on the
LH receptor, inducing a greater level of testosterone production than equivalent amounts of
LH (Zhou and Hutson, 1995). Quite how this superantagonism effect works is unclear.
The adult rat Leydig cell can have either an acute or a chronic response to LH stimulation.
The short-term reaction sees a sharp increase in the levels of steroidogenesis by the Leydig
cell, associated with altered StAR expression, whereas longer-term effects are induced on
Leydig cell structure and function. At low doses, LH stimulates the expression of the
steroidogenic proteins but long-term high doses induce desensitisation of the steroidogenic
response to the trophic hormones, perhaps due to the androgen repressed P450Ci7 expression
(Payne and Youngblood, 1995; Sharpe and Cooper, 1987).
The fetal Leydig cell responds to LH with an increase in cAMP and testosterone production,
via a G-protein coupled receptor, as early as 15.5 days of gestation in vitro. Although Gs
protein is functional in the fetal Leydig cell as early as 14.5 days of gestation, there is no
measurable LH receptor in the fetal rat testis at this age, preventing stimulation via this
transmembrane signaling system in the fetal Leydig cell (O'Shaughnessy et al., 1998;
Warren, 1989). Testosterone produced prior to the establishment of the LH responsive
signalling mechanism is therefore gonadotrophin independent, suggesting either that the
Leydig cells are constitutively
active during early development or that an unknown factor maintains and stimulates Leydig
cell function during at least part of fetal life (O'Shaughnessy et al., 1998). Possible factors
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are being investigated, with potential candidates including vasoactive intestinal peptide
(VIP) and pituitary adenylate cylclase-activating polypeptide (PACAP-27), both of which
stimulate fetal but not adult Leydig cells (El-Gehani et al., 1998a; El-Gehani et ah, 1998b).
Study of fetal pituitary LH levels and Leydig cell function in hypogonadal (hpg) mice that
lack GnRH and, thus, circulating gonadotrophins revealed that LH receptor mRNA was
detected in fetal testes from el6 in both normal and hpg mice. In hpg mice, intratesticular
testosterone levels were normal throughout fetal development until the day ofbirth, but were
barely detectable by postnatal d5. Together these data confirm that fetal Leydig cell function
in the mouse is normal in the absence of LH but they become dependent on LH shortly after
birth (O'Shaughnessy et ah, 1998). These observations have been complemented by studies
with decapitated rat fetuses that also showed fetal Leydig cells produced testosterone without
LH stimulation (Migrenne et ah, 2001).
In the human, testosterone is detected in the testis by 7w/40w of gestation, following the
initiation of sexual differentiation at the start of week six, peaking between 15-18w/40w.
However, pituitary gonadotrophins are not detected until 1 l-12w/40w (Saez, 1994).
Placental hCG may regulate testosterone synthesis intermediately, during 15- 22w/40w, in
parallel with the surge in testosterone production known to occur during the same period of
development (Molsberry et ah, 1982). LH and FSH are proposed to have regulatory effects
on fetal gonads during the last third of gestation. (Molsberry et ah, 1982; Voutilainen, 1992).
Mutation of the LH-receptor in humans results in a range ofphenotypes from complete sex-
reversal to micro-penis (Hughes, 2001).
1.2.1.4 Follicle stimulating hormone
FSH action is exerted on cells expressing the FSH receptor, exclusive in the testis to the
Sertoli cell. FSH binding to adult Sertoli cells activates adenylate cyclase to increase cAMP
production within the cell. In turn, this results in the phophorylation of the transcriptional
activator CREB protein (cAMP response element binding protein). Fetal rat Sertoli cells do
not appear to respond to FSH but do express the FSH receptor after el8.5 (Rouiller-Fabre et
ah, 2003). The presence of FSH receptors in fetal human testes, from 8w/40w has been
shown (Plant and Marshall, 2001). In the rat, during perinatal development, FSH
concentrations influence the rate at which the immature Sertoli cell proliferates and possibly
stimulates release of a paracrine factor from the Sertoli cells to stimulate Leydig cell
function (Markkula, 1996; Migrenne et ah, 2003). In the adult testis this is balanced via a
feedback loop with the Sertoli cell product inhibin-B, which suppresses FSH gene
expression, and in turn might be regulated by germ cells, according to their number and
differentiation stage (Plant and Marshall, 2001).
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1.2.2 Secondary sexual characteristics
Premature activation of the HPG axis presents as central precocious puberty in children, due
to a premature stimulation of pubertal gonadotrophin release by GnRH. This results in
pubertal serum levels of sex steroids and development of secondary sexual characteristics,
such as the growth of external genitalia (Sehested et al., 2000). The loss of normal endocrine
communication along the HPG axis can result in an altered correlation between the
phenotype and the genotype of an individual, described as hermaphroditism.
Normal development of male external genitalia is dependent on endocrine activity as the
presence of androgens converts the bipotential genital primordium into the penis shaft, glans
penis and scrotum and facilitates the descent of the testes from their initial high abdominal
position through the inguinal canal to the scrotum. Normal development of female genitalia
is sex-steroid independent, to the point that even if the ovaries are removed, the external
genitalia develop normally (Olaso and Habert, 2000).
1.2.2.1 Testis descent
Relocation of the testis from its origin, by the base of the kidney high in the abdominal
cavity, to the scrotum is a two phase process: transabdominal then inguino-scrotal descent
(Hutson et al., 1997). Transabdominal migration is influenced by various factors but is
primarily mediated by the enlargement of the gubernaculum via a combination of insulin-
like-factor-3 (Insl-3) and testosterone/ DHT and the regression of the cranial suspensory
ligament (CSL) via an androgen dependent process (Hughes, 2001). The ultimate positioning
of testes and ovaries is the result of the sexually dimorphic development of the CSL and the
gubernaculum as well as hormone production levels. In the male, the gubernaculum, a
mesenchymal tissue, thickens and contracts becoming bulbar and so tethers the testis at the
caudal end of the abdominal cavity during elongation of the fetus, from el 5.5 to birth (Shono
et al., 1994). In the female, development of the CSL and absence of gubernacular growth
maintains the ovary beside the kidney.
Gubernacular enlargement is also seen in female mice that over-express Insl-3, where
normally it would remain a thin cord in the female (Adham et al., 2002). Insl-3 males
present with maldescended testes, cryptorchidism, as a direct consequence of defective
gubernacular growth (Boockfor et al., 2001) (Figure 1.8). Insl-3 is produced by the fetal
Leydig cell and its receptor (LGR-8) is located in the gubernaculum (Kubota et al., 2002).
Following birth and under androgen regulation, the mesenchymal cells of the gubernaculum
disappear while the muscular layer invaginates towards the developed scrotum, creating the
processus vaginalis, also called the cremasteric sac. Contraction of the inverted cremaster
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muscle and the intra-abdominal forces the testes into their mature location: the scrotum.
Unlike in the human, the rat processus vaginalis does not narrow, enabling descended testes
to be retracted, if required. Complications of undescended testes include infertility and
increased risk of testicular malignancy (Adham et al., 2002).
Figure 1.8 Illustration of testis descent, from normal fetal positioning in the
abdominal region to adult scrotal position. Examples of ectopic testis positions,
cryptorchidisms are also shown. Image found on-line via www.google.com.
1.2.2.2 Penis formation
In mammals, fertilisation requires specially formed external genitalia. These develop from
the genital tubercle, a ventrocaudal structure composed ofbilateral shelves of mesenchyme
bisected by a central epitheliuml plate. The transformation of this primordium into a
functioning penis is mostly androgen dependent (Morgan et al., 2003). Disturbances in the
signalling associated with normal penis development can result in the incomplete fusion of
the urethral folds during perinatal development, resulting in the malpositioning of the
urethral opening along the penile shaft or on the scrotum, hypospadias (Bianca et al., 2003).
Hypospadias can affect any of several different regions of the developing glans penis,
ranging from slight changes (coronal hypospadias) to proximal defects (perineal
hypospadias) (Figure 1.9). The mechanisms behind normal and maldevelopment of the
genital tubercle are still being investigated. These include androgen dependence as well as
other, less defined, factors as highlighted by recent studies with Hoxal3 mutant mice
(Morgan et al., 2003).





Figure 1.9 Illustration of urethral malclosure on the penile shaft, hypospadias. Note
mid-shaft hypospadias also described as penile. Image found on-line via www.google.com.
1.2.2.3 Male accessory glands
The male reproductive tract includes the testes and the penis but also the epididymis, the
prostate and the seminal vesicles. The epididymis extends from the efferent ductules to the
vas deferens and plays a vital role in regulating the development of sperm motility and
fertilising capacity as well as being a storage area, in some species, for mature spermatozoa
pending ejaculation (Rodriguez, 2001). Along with the other Wolffian structures, the seminal
vesicles and vas deferens, the epididymis derives from embryonic mesoderm. The prostate
envelops the urethra by the bladder and has a secretory role. It is derived from the embryonic
endoderm. Androgens are required for prostatic growth and development as well as to
initiate and maintain its secretory activity in adulthood (Thomson, 2001).
1.3 Testicular dysgenesis syndrome
Fetal development has a crucial influence on postnatal development and life-long related
disease risk. For example, perturbed fetal growth is associated with increased risk of
coronary heart disease and type II diabetes (Davies and Norman, 2002). Increasing reports in
the literature extend this observation to indicate that external influences i.e. environmental
exposures, can also affect fetal growth (e.g. cigarette smoking) as well as mis-programme
specific stages of development, resulting in permanent changes in structure, physiology and
metabolism of the target organ. The physiological mechanisms through which environmental
influences are transmitted to the target organs are many and diverse. Any external influence
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that insults the establishment of these inter-related systems can result in mal-development,
contributing to an increased risk of disease in later life (Davies and Norman, 2002).
Regarding the development of the testis, this is a complex process associated with hormonal
regulation via many endocrine organs including the thyroid, pituitary, hypothalamus, the
adrenals and the testes themselves. In 2001, an article was published that applied a
comprehensive analysis of the increase in the incidence of disorders of male reproductive
tract development, traditionally managed across several different medical disciplines. It
hypothesised that though the disorders were typically analysed separately following clinical
presentation, they shared a common theme: they were all the result of disrupted
programming and gonadal development during fetal life. Together, the four disorders
(testicular cancer, low/ declining sperm quality, cryptorchidism and hypospadias) were
symptoms of a testicular dysgenesis syndrome (TDS) (Skakkebaek et al., 2001).
Some of the evidence contributing to Skakkebaek's hypothesis, of the shared fetal origin for
the four disorders of the human male reproductive system, is reviewed here.
1.3.1 Testicular cancer
In 1994, Adami et al reported their analysis of the incidence of testicular cancer among 10
European cancer registries. During the entire period of registration (maximally between
1943-1989), incidence increased rapidly in all countries, by 2.3-3.4 % annually in the Nordic
countries and by about 5% in Poland and Germany. The rising trend was most pronounced in
men below 30 years old. The age-specific incidence peaked in all countries at ages 25 to 34,
but the geographical variation was considerable (Adami, 1994). These data indicated that
environmental influences on testicular cancer are strong and demanded new aetiological
hypotheses, such as set out in Skakkebaek's 2001 paper. Danish data on testicular cancer
collected between 1943-1996, along with prostate cancer data, showed an annual increase in
testis cancer of 2.6% compared to 1.6% for prostate cancer. This data also revealed that the
epidemiological pattern seen with prostate cancer could be explained by changes in
diagnosis and disease registration but this could not account for the change in testis cancer
incidence which was associated with causal factors (Moller, 2001).
Testicular germ cell tumours are the most common cancer in men aged between 20-45years.
They arise from precursor premalignant cells, carcinoma-in-situ (CIS) cells, which are
believed to derive from primordial germ cells that failed to undergo normal differentiation
during fetal testis development (Rajpert-De Meyts et al., 1998). Ultrastructural studies
suggest that the pathogenesis of germ cell neoplasia involves excessive proliferation of
precursor germ cells associated with loss of intercellular communication (Gondos, 1993). It
is hypothesised that if the development of the testis is disturbed or delayed, primordial germ
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cells or gonocytes undergo maturation delay or differentiation arrest, which may render them
susceptible to neoplastic transformation. Furthermore, the phenotypical heterogeneity of CIS
cells may be associated with their potential to give rise to different tumour types and may be
related to the developmental stage of the early germ cell which has undergone malignant
transformation (Rajpert-De Meyts et al., 1998).
There are no reliable imaging techniques or serological parameters that can diagnose CIS
leaving the only means of accurate diagnosis as surgical biopsy of the testis. A biopsy
sample is fixed and subjected to immunhistochemical staining for placental alkaline
phosphatase (P1AP), not usually detectable in normal adult germ cells (Dieckmann and
Skakkebaek, 1999). Early detection ofCIS enables their eradication by low-dose irradiation
but established germ cell tumours can only be cured by removal (i.e. orchidectomy) or
irraditation (Mosselman et al., 1996).
CIS cells are associated with other clinical conditions, including male infertility,
cryptorchidism and low sperm counts. Background levels of CIS are less than 1% among
infertile men but increase to 4% when associated with cryptorchidism. Where ambiguous
genitalia are presented, up to 25% of patients also have CIS in their testes, consistent with
the high risk of testicular cancer associated with this clinical condition (Dieckmann and
Skakkebaek, 1999). A recent study prompted by the Skakkebaek hypothesis investigated
whether testicular germ cell cancer may be aetiologically linked to other male reproductive
abnormalities as a part of the TDS. CIS was detected in 8.7% ofbiopsies from contralateral
testes in patients with a testicular germ cell tumour. The cumulative incidence of one or
more signs of microscopic testicular dysgenesis was 25.2%, supporting the hypothesis that
this cancer is part of a testicular dysgenesis syndrome (Hoei-Hansen et al., 2003). Increased
risk ofCIS being present was seen in a separate study following ultrasonic detection of
micro-calcifications in the contralateral testis (Holm et al., 2003).
1.3.2 Semen quality
Most commonly and most mildly, TDS presents as impaired spermatogenesis and only rarely
with the full range of disorders in a single patient (Skakkebaek et al., 2003). Reports of a
decrease in semen quality ofmen in four European countries has suggested regional
differences. A study was undertaken of semen samples from fertile men from four European
cities (Copenhagen, Denmark; Paris, France; Edinburgh, Scotland; and Turku, Finland).
Finnish men had the highest sperm counts but men from Edinburgh had the highest
proportion ofmotile spermatozoa (Jorgensen et al., 2001). The Danish population was
generally the worst affected and further reports state that >30% ofyoung Danish men have
sperm counts in the sub-fertile range, a change that is not accounted for entirely by social
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factors (Jensen et al., 2002). In Denmark, 5% of children are born after assisted reproduction
(Skakkebaek, 2002). Even if a secular trend cannot be demonstrated to be biologically
significant, the data regarding regional differences are more convincing (Jensen et al., 2002).
These differences in semen quality may indicate different environmental exposures or
lifestyle changes in the various populations (Jorgensen et al., 2001).
1.3.3 Cryptorchidism
The maldescent of the testes, cryptorchidism, is the most common congenital anomaly in
humans, affecting up to 5% of male infants (Adham et al., 2002). In Western countries, 1-2%
ofmales at the age of 3 months are diagnosed with this condition but its aetiology is still
unclear. Potential causes might include physical obstruction of the descent, endocrine
abnormalities or genetic mutations associated with the gubemaculum (Raivio et al., 2003;
Roh et al., 2003). Cryptorchidism can resolve spontaneously in boys up to around 3 months
old and of those left, up to 40% recover following hormonal stimulation by hCG
(Giannopoulos et al., 2001).
According to two comparable English studies, the incidence of cryptorchidism in full-term
boys approximately doubled between the 1950s and the 1980s (-2.7 and -3.84% at birth and
-0.9 and -1.4% at 3 months, respectively). Regionally there are large differences: e.g. in
Finland the incidence of cryptorchidism (<1%) is clearly lower than in Denmark (-2% at 3
months). Regional and temporal trends may help to identify environmental factors that might
be associated with these disorders (Toppari et al., 2001).
Recently, a prospective study of cryptorchidism was reported, that compared the
contemporary prevalence of cryptorchidism in Denmark (1997-2001) and Finland (1997-99).
9% ofDanish and 2.4% of Finnish boys were found to exhibit cryptorchidism at birth,
falling to 1.9 and 1% respectively, by 3 months of age. The conclusion of the paper
suggested that while genetic variation might account for this geographical difference, it was
considered more likely to be a consequence of different environmental factors exposure (e.g.
endocrine disruptors) and lifestyle between the two countries (Boisen et al., 2004).
Additionally, these data showed an increase in cryptorchidism in Denmark over the past 40
years (1.8% in the 1950's), consistent with Skakkebaek's hypothesis (Boisen et al., 2004).
1.3.4 Hypospadias
The malpositioning of the urethral opening, hypospadias, is another common congenital
anomaly in humans, affecting up to 0.4% of male infants (Vrijheid et al., 2003). Increasing
trends in the incidence of hypospadias were found in Sweden during the 1960s, and in
Norway, Denmark, England and Elungary during the 1970s. In Norway and Denmark, the
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increase continued in the 1980s, while in the USA it has continued from the 1970s to the
1990s. Finland has shown a lower reported rate of hypospadias than other Nordic countries.
However, it is difficult to make comparisons between countries because of variable inclusion
criteria, but as with the related reports of cryptorchidism, regional and temporal trends may
help to identify environmental factors associated with these disorders (Toppari et al., 2001).
A study of the contemporary prevalence of hypospadias in Danish newborn boys (1997-
2004) was recently reported (Boisen et ah, 2005). The boys were examined 4 times: shortly
after birth then at 3, 18 and 36 months and data compared to a concomitant Finnish study. At
birth, 1.03% of Danish and 0.27% of Finnish boys were found to exhibit hypospadias. This
increased to 4.64 and 1% respectively by 36 months of age. This increase was due to the
detection ofmilder cases that only became evident as normal development progressed and
the prepuce could be retracted. The conclusion of the paper suggested that while the
aetiology ofmost hypospadias remains obscure, genetic variation might account for some of
the cases seen but it was hypothesised that other cases may be due to intra-uterine exposure
to unspecified environmental factors. This approach could partly explain this geographical
difference, consistent with Skakkebaek's 2001 hypothesis (Boisen et al., 2005).
Given that historical data for cryptorchidism and hypospadias from international registries
may not be totally reliable due to different calling levels, and that sperm count data is still
emerging, only the data regarding testicular cancer shows a definite progression towards a
significant increase in the symptoms of TDS (Sharpe, 2001). Perhaps with these data in
mind, Skakkebaek added to his hypothesis that the increased risk of TDS in recent times may
be related to adverse environmental influences during fetal development, accentuating any
genetic predisposition of the male reproductive tract to disease. This posed a question: what
effects may be expected in humans if those endocrine disrupters, ubiquitous in small
amounts in food and water, have an impact on the male reproductive system (Skakkebaek et
al., 2001)?
1.4 Endocrine disruption
Experimental and epidemiological studies suggest that TDS is the result of disruption of he
hormonal contribution to embryonal programming and gonadal development during fetal life
(Skakkebaek, 2003). Endocrine disrupters (ED's) are environmental substances that mimic/
antagonize/ or alter normal endocrine signalling. Changes in endocrine programming
inflicted during early development, can permanently affect the physiology of the fetus,
perhaps predisposing it to adult onset disease (Davies and Norman, 2002).
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The physiological mechanisms through which environmental influences are transmitted to
the target organs are varied and complex. Environmental agents can act as weak oestrogens
or anti-androgens and are believed to contribute to the increase in impaired sex
determination, reduced sperm counts and reduced fertility reported in many wildlife species
(Skakkebaek et al., 2001). Though the testis itself undergoes fetal development without
hormonal stimulation, the hormones it produces (e.g. testosterone, AMH, Insl-3) are vital for
normal development of all other aspects ofmasculinisation. Any chemical with the ability to
interfere with the production of these factors, and others, has the potential to mis-programme
the masculinisation of the fetus (Sharpe, 2001).
1.4.1 Examples in wildlife
Accidental exposure of wildlife to unusually high levels of endocrine disrupters following
environmental disasters has highlighted the effect these chemicals can have. For example, a
study in the early 1990s reported a number of abnormalities in the hatchling and juvenile
alligators of Lake Apopka, Florida, USA. This lake had been contaminated following a spill
ofDDT which added to existing contamination by local agricultural activities and nearby
sewerage treatment facilities. Lake Apopka juveniles had significantly elevated serum
concentrations ofmany synthetic compounds including p,p'-DDE, DDT and PCBs compared
to juveniles from the other lakes (Guillette et al., 1999). Juvenile male alligators living in/
around the contaminated lake were found to have reduced levels of plasma testosterone
compared to control males from a nearby but uncontaminated lake (Lake Woodruff), as well
as poorly organized testes and abnormally small phalli (Guillette et al., 1994). These
observations were followed up with in vitro experiments examining the steroidogenic
activity of gonads removed from juvenile alligators obtained from contaminated or control
lakes in central Florida. Testes from males obtained from the contaminated lake synthesized
significantly higher concentrations of oestradiol when compared to testes obtained from
control males (Guillette et al., 1995). The effects seen in these studies were hypothesised to
be due to chemical exposures during embryonic development rather than a consequence of
levels of contaminants in the juvenile serum (Guillette et al., 1999).
Studies with captive reptiles, whiptail lizards (Cnemidophorus inornatus) investigated the
source of individual variation in intensity of sexual behaviours in captive males. The data
suggested that individual variation in the sexual behaviours exhibited was not due to low
circulating concentrations of androgens or different profiles of testicular steroidogenesis but
considered either an inability to respond to androgens or an inability to exhibit sexual
behaviour (Lindzey and Crews, 1992). These lizards were not bred in captivity, implying
that any purtubations in their sexual behaviour must have occurred prior to capture. This
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may reflect the level ofED contamination present in the environment from where they
originated, as even following castration and androgen replacement, low intensity courters
continued to exhibit weak and infrequent sexual behaviour. Chemicals that affect breeding
performance alone (polychlorinated biphenyls (PCBs), fenarimol, or losulazine), without
altering sperm and testicular measures have been reported (Gray et al., 1989).
Portelli et al (1999) tested whether the pesticide l,l,l-trichloro-2, 2-bis(p-chlorophenyl)
ethane (DDT) and its metabolite dichlorodiphenyltrichloroethane (p,p'-DDE), as well as
oestradiol-17p, were able to induce feminization of the common snapping turtle (Chelydra s.
serpentina). Normally this species of turtle relies on incubation temperature to regulate the
sexual differentiation of its eggs. When eggs were incubated at a male-producing
temperature (26°C), oestradiol induced female development at this temperature, but p,p'-
DDE did not affect sex determination, even at exposure levels comparable to those found in
moderately contaminated sites in the Great Lakes (Portelli et al., 1999).
Sewage is considered a major source of environmental pollution and contains a complex
mixture of organic and inorganic chemicals (Jobling et al., 1995). Discharge effluents from
sewage treatment plants have been highlighted as responsible for the feminization of fish as
many EDs occur in effluents, including natural and synthetic oestrogen hormones,
degradation products of alkylphenol ethoxylate surfactants, and plasticisers. For example,
surface and sediment water samples were collected from the Tyne and Tees estuaries (UK)
and analysed for their oestrogenic content. The Tyne and Tees estuaries represent estuaries
that have been historically contaminated by industrial activities, and continue to receive
treated domestic sewage and industrial effluent. In 1998, Dabholm Gut on the Tees received
a mixture of treated and untreated effluent, while Howdon sewage treatment works on the
Tyne discharged primary treated effluents. An oestrogenically active water sample collected
from Howdon was shown to contain 17P-oestradiol, androsterone, and unknown oestrogenic
compound(s). Most of the activity contained in a sample collected from the Dabholm Gut
was due to 17P-oestradiol with additional activity from nonylphenol and (tentatively) di(2-
ethylhexyl)phthalate (DEHP) (Thomas et al., 2001). Metcalfe (2001) reported that
oestrogenic hormones induced intersex (i.e. testis-ova) when fish were exposed to ng/1
concentrations of oestrogenic test compounds for 100 days from hatching. Bisphenol A
induced testis-ova at a concentration of 10 micrograms/L, but diethylhexyl phthalate (DEHP)
did not induce a response. Results were consistent with oestrogenic responses in the yeast
oestrogen screening assay (Metcalfe et al., 2001). Jobling et al (1995) randomly screened 20
chemicals present in liquid effluents. Half the compounds tested appeared able to interact
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with the oestradiol receptor, demonstrated by their ability to inhibit binding of 17p-oestradiol
to the fish oestrogen receptor (Jobling et ah, 1995).
These studies showed that aquatic species are susceptible to adverse effects of endocrine
disrupting chemicals. However, as this is not directly applicable to the human situation as we
are not aquatic (postnatally), further studies have been carried out using mammalian species
under laboratory conditions.
1.4.2 Examples in laboratory experiments
Androgens are important for the structural and functional integrity of the testis and the
prostate and this may in part be mediated by the aromatisation of testosterone to the
oestrogen, oestradiol (Turner et ah, 2001). It has been proposed that reduced androgen action
sensitizes the reproductive tract to oestrogens, demonstrating that the balance in action
between androgens and oestrogens, rather than their absolute levels, may be of fundamental
importance in determining normal or abnormal development of some regions of the male
reproductive tract (Rivas et ah, 2002). The effects of neonatal exposure to the potent
reference oestrogen diethylstilboestrol (DES) or the environmental oestrogen bisphenol A
(BPA) on reproductive tract development in male rats were compared against untreated rats
during the neonatal period before onset ofpuberty. Adverse changes to the testis and
reproductive tract were induced by exposure to DES, but not BPA. The changes mainly
resulted from a combination of high oestrogen and low androgen action as either situation on
its own was unable to induce the same changes (Williams et ah, 2001). Reproductive tract
abnormalities induced in the neonatal male rat by a high dose ofDES are associated with
reduced androgen receptor expression and Leydig cell volume compared to treatments that
interfere with androgen production (GnRHa) or action (flutamide) alone which fail to induce
reproductive tract abnormalities or alter AR expression akin to that induced by DES
(McKinnell et ah, 2001).
The above data demonstrate that neonatal development is highly dependent on hormonal
regulation, but though fetal testis development is considered to be largely independent of
gonadotrophin regulation, studies looking at fetal exposure to anti-androgens or oestrogens
have reported treatment related changes (Rouiller-Fabre et ah, 2003). Acute exposure to high
levels of DES or 4-octylphenol (OP) or vehicle (oil, control) to pregnant rats on el 1.5 and
el5.5 produced no difference between fetuses from control and treated mothers at el7.5,
except for a reduction in the amount of immunostaining for P450Cn and SF-1 detected in
Leydig cells from both treatment groups. Oestrogen receptors (ERa) were present in the
fetal Leydig cells of all animals (Saunders et ah, 1997). The follow-up studies again showed
that in both DES- and OP-exposed fetuses, immunoexpression of SF-1 was reduced in
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Sertoli and interstitial cells when compared with controls but not in fetal ovaries. These
results suggested that Sertoli cell-derived oestradiol may be important in the physiological
regulation of SF-1 in the fetal testis, providing a possible mechanism by which inappropriate
exposure to oestrogens might alter the genetic cascade that ensures normal development of
the testis is via altered expression of SF-1 (Majdic et al., 1997b).
Another study investigated the effect of oestradiol (E2) and diethylstilbestrol (DES) on the
testis from 14.5-day-old rat fetuses in culture. Exposure to DES and E2 decreased gonocyte
number, due to a decrease in the gonocyte mitotic index and a dramatic increase in
apoptosis. The effects ofDES were more drastic than E2but in the presence of the anti-
estrogen ICI 182.780 (ICI), the effect ofDES was abolished. Sertoli cell number decreased
due to a decrease in Sertoli cell proliferation, which was not antagonized by ICI. DES had no
effect on FSH-stimulated cAMP production after adjustment for Sertoli cell number. Both
oestrogens reduced the levels of basal and LH-stimulated testosterone production in vitro,
resulting in the disruption of the balance between androgens and oestrogens (Lassurguere et
ah, 2003).
The anti-androgenic properties of chemicals with endocrine disruptor potential has become
the subject ofwider research (Skakkebaek et ah, 2001). Anti-androgenic chemicals can be
clustered into separate groups, based on the resulting profiles of reproductive effects, due to
their altering ofmasculinisation via different mechanisms (Gray et ah, 1999). The profile of
changes induced by some potentially antiandrogenic compounds on the rodent reproductive
system in vivo was described by Gray et al (1999). These were a mixture of environmental
agents and research/ therapeutic agents and included: linuron, a urea-based herbicide that
induces prolonged LH hyperstimualtion of Leydig cells resulting in adenoma formation;
p,p'-DDE, a metabolite of the pesticide DDT, that binds to the AR in vitro and may be
associated with the high level of cryptorchidism seen in the Florida panther via dietary
exposure (see Facemire et al 1995, 1997) ; procymidone, iprodione and chlozolinate
(dicarboxymide fungicides like vinclozolin); ethane dimethane sulphonate (EDS) and
ketoconazole (inhibitors of testosterone synthesis: EDS kills Leydig cells, ketoconazole
inhibits cytochrome P450 enzymes); di-n-butyl phthalate (DBP) and diethylhexyl phthalate
(DEHP) (phthalates induce malformations in androgen-dependent tissues following in utero
exposure but not via an AR associated mechanism) and PCB congener number 169, an aryl
hydrocarbon (Ah) receptor agonist like the known endocrine disruptor 2,3,7, 8-
tetrachlorodibenzo-p-dioxin (TCDD) (Gray et al., 1999).
In utero treatment with the AR antagonist, flutamide, produces ventral prostate agenesis and
cryptorchidism, while finasteride, an inhibitor ofDHT (a potent androgen and testosterone
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derivative) synthesis, rarely, if ever, induces such malformations. Di-n-butyl phthalate
(DBP) alters reproductive development by a different mechanism of action than the AR
antagonists, evidenced by the display of an unusually high incidence of testicular and
epididymal alterations in the male offspring of exposed dams - effects rarely seen after in
utero flutamide treatment (Gray et al., 1999). Exposure to low concentrations ofDBP during
a short, but critical window of development (i.e., sexual differentiation), impaired
development of the male reproductive tract and induced a variety of testicular lesions in
Xenopus laevis frogs. Most notably, these lesions persisted into adulthood, long after
cessation of treatment with DBP (Dawson et al., 1989).
It should be noted that these effects are only usually observed after administration under
laboratory conditions and in high doses. This should mean that similar effects are unlikely to
be found in humans except perhaps within small at risk populations with unusually high
levels of exposure (Sharpe, 2001).The impact of environmental chemicals on reproductive
health has gained much attention over the last decade or so, both from scientists and the
media. (Norgil Damgaard et al., 2002). Concern about possible adverse effects caused by the
inadvertent exposure of humans and wildlife to EDs has led to the development of screening
programmes for endocrine effects. New laws in the USA mean that the Environment
Protection Agency (EPA) is required to test pesticides etc for endocrine effects (Gray et al.,
1999). The laboratory methods needed to identify these compounds are being developed
(O'Connor et al., 2002).
1.4.3 Effects on man
Disturbances of hormonal regulation during fetal or postnatal development in humans may
induce adverse effects on the male reproductive system, but these adverse effects of
endocrine disruptors on humans are subtle, and difficult to research and detect. Based on
current knowledge, the impact of endocrine disruptors on male reproductive function
remains to be quantified. Monitoring of environmental chemicals in Japan, for example, has
already revealed that several endocrine active chemicals are in river water, sediments, and
wildlife as well as in the human umbilical cord (Iguchi et al., 2002). While animal studies
provide us with valuable insights into the range of effects that can be attributed to EDs
following in utero exposure, the concentration of EDs representative of fetal exposure levels
is uncertain. Confounding factors include: the ability of chemicals to bioaccumulate in body
lipid, the metabolism of body lipid during pregnancy/lactation releasing the mothers lifetime
legacy of potential EDs into circulation and the poorly understood kinetics ofED transfer
across the placenta (Murray et al., 2001). Assessment ofprenatal polychlorinated biphenyl
(PCB) exposure, by measuring levels in umbilical cord ofwomen who consumed fish caught
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in the Great Lakes, USA, revealed that consumption of fish from Lake Ontario increased the
risk ofprenatal exposure to the most heavily chlorinated PCB homologues. PCBs are
recognised as an environmental pollutant though they were banned in the 1970s from
industrial use, but are highly resistant to environmental degradation. They bioaccumulate in
fat tissue, especially in marine life including fish at the top of the food chain, and cross the
placenta providing in utero exposure as well as becoming concentrated in breast milk fats
providing neonatal exposure (Stewart, 1999).
Puerto Rico has the highest known incidence of premature breast development (thelarche)
ever reported in girls younger than 8 years of age without other manifestations of puberty.
Organic pollutants, including pesticides and some plasticizers, have been widely used in
Puerto Rico. Significantly high levels of various diester phthalates and the metabolite MEHP
were identified in 68% of the samples from thelarche patients, compared to only one control
sample. This study suggests a possible association between phthalates and premature breast
development in a human female population, though no mechanism is yet known via which
phthalates could affect breast development in this way (Colon et al., 2000).
Extrapolation of effects from rodents to humans will be enhanced if future studies
incorporate determination of tissue concentrations of the active metabolites. Knowledge of
the tissue concentrations of the active toxicants also would provide an important link to in
vitro studies, which can provide more useful mechanistic information when they are
executed at relevant concentrations (Gray et al., 2001). The relevance of animal study
findings to observations in man await a greater understanding of the physiological roles of
androgens and oestrogens in normal males and a thorough evaluation of the sources, routes
of exposure, concentrations in vivo and bioavailability of chemicals that are potential
endocrine disruptors (Saunders et al., 1997).
Epidemiological human studies are necessary to fill in these gaps in our knowledge of the
mechanisms that underlie ED action in fetal development, in order to elucidate how they
exert their effects (Mori, 2001). But until that data is available, the next best thing is to use
alternative models to investigate the mechanisms that underlie the chemicals associated with
ED changes known so far and explore the effects of exposure to combinations of such
compounds (Sharpe, 2001).
Phthalates are used as plasticisers in PVC products and as solvents in some personal care
products, and are among the most common and widely used industrial chemicals (Foster et
al., 2001). Their ubiquity in the environment is well known (Jobling et al., 1995). Much of
1.5 Phthalates
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this review ofphthalates will be biased towards Di-n-butyl phthalate because it is the focus
of the studies presented in this thesis.
1.5.1 Biochemistry
1.5.1.1 Structure and properties
A phthalate is a synthetic chemical, commercially produced by the condensation of alcohols
with phthalic anhydride (1,2-benzenedicarboxylic acid), resulting in paired ester groups on a
cyclohexatriene ring (Figure 1.10). Hydrolysis of the phthalate reproduces the phthalic acid.
The products of the condensation produce at least three isoforms of the phthalate esters
(ortho, meta and para) but the generic term of phthalate ester refers to the ortho
configuration. Adipate esters are related chemicals, also used as plasticisers, but their
structure a four carbon (C4) chain separates the ester groups rather that the carbon ring.
Depending on the "parent" alcohol, respective alkyl groups are formed on the arms of the
phthalic ester (Kluwe, 1982). Those with shorter chains are more water soluble, though the
class is generally insoluble in aqueous media (Table 1.4).
0_ R
0_ R'
Figure 1.10: A schematic of the condensation reaction between phthalic anhydride and
alcohol (+HO-R/R') that creates the common chemical backbone of phthalate structure. The
'R' groups are the alkyl groups from the "parent" alcohol, making the respective di-ester.
DBP is formed from n-butanol with phthalic anhydride (Kavlock et al., 2002).
Di-n-butyl phthalate (DBP) has the molecular formula Ci6H2204, giving a molecular weight
of 278.34. At room temperature DBP appears as pale yellow oil, with a boiling temperature
of 340°C and a melting point of -35°C. Its specific gravity is 1.0465, similar to water. It is
partially soluble in water but easily soluble in organic solvents. It is also known by its CAS
number 84-74-2 and many synonyms: 1,2-Benzenedicarboxylic acid dibutyl ester; benzene-
o-dicarboxylic acid di-n-butyl ester; o-benzenedicarboxylic acid dibutyl ester; butyl
phthalate; n-butyl phthalate; DBP; dibutyl 1,2-benzene dicarboxylate; dibutylphthalate; di-n-
butylphthalate; di(n-butyl) phthalate; dibutyl-o-phthalate; phthalic acid dibutyl ester. Trade
Names: Celluflex DBP; Elaol; Ergoplast FDB; Ersoplast FDA; Genoplast B; Hexaplas M/B;
+ HO-R
+ HO-R'
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Palatinol C; Polycizer DBP; PX 104; RC Plasticizer DBP; Staflex DBP; Uniflex DBP;
Unimoll DB; Witcizer 300; Witicizer 300 (Marsman, 1995).
It has been investigated whether dialkyl phthalates can imitate steroid structure in vitro. Data
suggested that the phthalate benzene moiety recognizes the core of the estrogen receptor
(ER) binding site, and the hydrophobic interaction of the dialkyl moiety substantiates the
binding characteristics of the phthalates. The data indicated that chemicals with slight
structural analogy and weak receptor affinity could perturb the endocrine system when
administered in high concentrations (Asai et al., 2000).
R/R'
structure
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- 2-ethylhexyl -CH2CH(C2H5)CH2(CH2)2CH3Di-2- ethylhexyl phthalate
DEHP MEHP
- n-octyl -CH2(CH2)6CH3Di- n-octyl phthalate
DOP MOP
- iso-nonyl -CH2CH2CH(CH3)CH2C(CH3)3Di- iso-nonyl phthalate
DNP MNP
- iso-decyl -CH2CH2CH(CH3)CH2(CH2)2CH(CH3)3Di- iso-decyl phthalate
DDP MDP
Table 1.4 A summary of the most common chemical formulae of the R and R' arms
and the names of the resulting phthalates. Adapted from Blount et al, 2000.
1.5.1.2 Absorption and distribution
Their lipophilic nature makes phthalates easily absorbed thorough the skin, though the most
common route of adult human exposure is thought to be dietary ingestion. They are
generally well absorbed from the gastrointestinal (GI) tract following oral administration.
Sub-populations are also prone to high levels of exposure via direct intravenous contact
through medical equipment such as DEHP associated with PVC in medical equipment such
as blood bags, cannulae or syringes (Blount et al., 2000a). The distributions ofDEHP and its
metabolite among the protein constituents ofhuman plasma resulting from the leaching of
phthalates from blood bags were studied. More than 80 % of the diester was associated with
lipoproteins, the remaining diester adsorbed weakly to other proteins, including albumin.
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MEHP was in equilibrium between free in solution and adsorbed to albumin; none was
bound to lipoproteins (Albro and Corbett, 1978). Because phthalate esters associate with
plasma proteins, they are widely distributed in the body. Fat absorptive organs (e.g. GI tract)
and excretory organs (e.g. kidney) are considered the main repositories for phthalate di-
esters, whereas the monoesters are not accumulated (Kluwe, 1982).
1.5.1.3 Metabolism and excretion
Phthalates can undergo hydrolysis of either or both of their ester groups. Hydrolysis ofjust
one group occurs more readily in vivo, producing a monoester phthalate (Figure 1.11). This
is catalysed by esterase enzymes present in many tissues including intestinal mucosal cells.
Short-chain esters can be metabolised by extracellular enzymes found in the intestinal
contents, e.g. pancreatic enzymes. For the longer-chain molecules such as DEHP, hydrolysis
to the corresponding monoester metabolite largely occurs prior to intestinal absorption, then
it undergoes oxidative metabolism prior to excretion. Short-chain dialkyl phthalates, such as
DBP, can be excreted in an unchanged form or following complete hydrolysis to phthalic
acid. It is generally well accepted that orally administered diester phthalates are hydrolysed
by lipases in the wall of the small intestine and absorbed almost entirely as the
corresponding monoester (Kavlock et al., 2002).
Metabolites ofDBP include monobutyl phthalate (MBP), monobutyl phthalate glucuronide,
o-phthalic acid and oxidised monobutyl phthalate glucuronide metabolites. MBP-
glucuronide is the primary metabolite identified in urine, with -45% excreted into the bile
and -5% in the faeces (implying efficient enterohepatic recirculation occurs) (Kavlock et ah,
2002). Glucuronidation (by (3-glucuronidase) has been hypothesised to reduce mono-ester
toxicity (Foster et ah, 1983; Saillenfait et ah, 2001).





Figure 1.11: Schematic representation of the chemical structure of DBP and the
metabolite MBP after conversion of DBP by liver esterase enzymes. Phthalates undergo
further metabolism e.g. -COOH group replaced by -glucouronide via ^-glucuronidase.
The major route ofphthalate ester elimination from the body is urinary excretion (Kluwe,
1982). Clearance from the body is rapid. It has been determined that >90% of up to
23 lOmg/kg ofDBP can be excreted within 48h of administration, via the urine, with
undetectable levels after 5 days (Kluwe, 1982). MBP and the other metabolites are excreted
in the urine mainly as glucuronide conjugates e.g. MBP-glucuronide (Foster et al., 1983;
Tanaka et al., 1978). Additional metabolic products include phthalic acid (only the liver can
hydrolyse phthalates to phthalic esters to phthalic acid) but the monoester (e.g. MBP) is
believed to be the agent responsible for the toxic effects seen following oral DBP exposure
in vivo (Blount et al., 2000b). The route of administration does not obviously affect their
metabolism. DEHP is extensively metabolized by mammals, but different species show
dramatic differences in their metabolite distributions. Studies in rats led to the suggestion
that the enzymatic processes normally associated with oxidation of fatty acids could account
for the known metabolites ofDEHP found in the urine (Albro et al., 1983). In a study in
which 14C labelled DEHP was intravenously administered to African green monkeys, -80%
of the urinary metabolites were excreted in the form of glucuronide conjugates. This is
analogous to what has been reported for the urinary metabolites ofDEHP from humans, but
in clear contrast to the metabolites found in rat urine. Rat urinary metabolites of DEHP are
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excreted unconjugated, and consist primarily of derivatives more highly oxidized than the
major metabolites produced by monkey or human (Albro et al., 1981). Additionally, traces
of the treatment were still evident in the monkeys livers several months after cessation of
treatment but in contrast in the rat, radioactivity was below the level of detection after three
weeks recovery.
Species differences are postulated to involve kinetics of several biochemical and
physiological events acting in concert or competition (Albro, 1986). However, it has been
demonstrated that humans and rats share similar gut lipase activity, such that it could be
reasonably expected that human intestinal metabolism ofDBP would be similar to that by
rats (Lake et al., 1977) . It is undetermined which metabolite plays the causal role in which
biological effects, and what factors (e.g. endocrine balance) can modify the metabolism of
phthalate esters and in what way.
1.5.2 Toxic effects
The human health effects of phthalates are not well understood but evidence from animal
studies has raised concerns that they may affect reproduction and early fetal development,
particularly in males. There are many different phthalates with slightly different chemical
properties, hence their varied industrial uses and potential toxicity. The biologic activity of
phthalates on hepatic peroxisome proliferation will not be covered in this review, which will
focus on the effects of phthalate exposure on the male reproductive tract, especially the
testis. For example, DEHP is a well-known Sertoli cell toxicant (Dalgaard et al., 2000; David
et al., 2000a; David et al., 2000b; Mann et al., 1985; Oishi, 1986).
Industrial chemicals are subjected to routine regulatory toxicity testing prior to their use but
the protocols are not designed to investigate the endocrine disrupting potential of synthetic
compounds. Plasticizers are among the highest-volume chemicals produced, with an
estimated 2-8 million tons per annum (WHO, 1992). Environmental contamination or
exposure occurs indirectly as the result of the manufacture, use, or disposal by leaching out
of plastic products or directly through one of the numerous consumer products (cosmetics,
pharmaceuticals, etc.). DBP has extensive use in industry in such products as plastic (PVC)
piping, various varnishes and lacquers, safety glass, nail polishes, paper coatings, dental
materials, pharmaceuticals, and plastic food wrap. Associated with this extensive worldwide
use is the high potential for human exposure to DBP in the workplace and the home
environment through direct sources as well as indirectly, through contamination ofwater,
air, and foodstuffs (Marsman, 1995).
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1.5.2.1 Routine toxicological assessment
Due to concern over the potential for pervasive exposure of humans to DBP, various studies
examined rats and mice after exposure to phthalates via different dose routes, at different
ages, different doses and different durations. Additional studies examined the effects on rats
of combining perinatal and adult subchronic exposure. Reproductive assessment by
continuous breeding (including crossover mating trials and offspring assessment) and genetic
toxicity studies were also conducted (Marsman, 1995).
Routine regulatory developmental toxicity tests did not induce any reproductive
malformations when animals were exposed to the phthalate DEHP (Narotsky and Kavlock,
1995; Tyl et al., 1988). Toxic effects were limited to decreases in maternal food and water
consumption with consequent decrease in bodyweight of dams and fetuses seen in rats. No
external, visceral, and skeletal malformations or variations were noted in the DEHP exposed
rat fetuses compared to the controls (Tyl et ah, 1988). Then Kavlock et al (2002) published
an expert panel report on the reproductive and developmental toxicity ofDBP. In it, the
general toxicology and biological parameters ofDBP were summarised. The oral LD50 in
rats was reported as >8000mgDBP/kg bodyweight but the majority of repeat dose studies
tested relatively high doses of DBP (500 mg/kg/day) still at concentrations not normally
found in the environment (maximum estimate = <5 pg DBP/kg/day) (Kavlock et ah, 2002).
Pregnant rats exposed to 500 mg DBP/kg/day from el2 to e21 induced a high incidence of
testicular maldescent and impaired differentiation of the Wolffian duct and the prostate and
external genitalia in their male offspring (Mylchreest and Foster, 2000; Mylchreest et al.,
1999). The weights of the androgen-dependent organs (testes, epididymides, seminal
vesicles, and prostate) were also reduced at d100 postnatal, long after cessation of treatment.
Phthalate-mediated male reproductive toxicity in the developing testis is thought to occur by
a complex interaction between Sertoli, Leydig, and germ cells associated with decreased
fetal androgen production (Mylchreest et al., 2002). Further information regarding the
toxicity related to DBP is incorporated into Chapter 3.
1.5.2.2 Human exposure
For decades, phthalates have built up to become ubiquitous pollutants and are only now
being recognised as a contributor to an enormous ecological problem that is poorly
understood. It was estimated that >600 000 workers in the United States are exposed to
DEHP and that over 100 000 are exposed to phthalic anhydride, yet few data were available
on levels of phthalates in biological fluids of these workers. One study of urine samples
obtained from 48 workers in jobs with high exposure to phthalates and from 47 workers in
jobs with low exposure, showed a two-fold increase in urinary phthalate concentration over
Chapter 1 Introduction 59
their shift, with post-shift phthalate levels of >10 nmol/ml observed in 25% of the exposed
operators (Liss et al., 1985).
DBP has been found in the sediment, water, air, biota, and even in stored foods (Aurela et
ah, 1999; Giam et ah, 1978). Biomonitoring ofphthalate levels in the urine of Americans
revealed DBP to be the most common phthalate ester with reprotoxic potential, that was
measured in the urine of American women of child bearing age (Blount et ah, 2000b). The
source of the DBP peak in this sub-population was hypothesised to be associated with
increased DBP exposure through their environment, given that DBP is found in cosmetics
and personal care products.
Epidemiological studies have attempted to correlate exposure to phthalate-containing
materials with decline in semen quality and increased risk of testicular cancer (Murature et
ah, 1987). A weak negative correlation between sperm density and phthalate concentration
was found in a random population of college students (Murature et ah, 1987), while an
increase in risk for developing testicular seminomas was determined in workers
occupationally exposed to phthalate-containing materials (Hardell et ah, 1997). However,
another study using a larger population found no increased risk for testicular cancer in these
workers (Hansen, 1999).
Amann (1982) observed that in utero, adolescent, or postpubertal exposure of rats to DBP
decreased the percentage ofmorphologically normal sperm in the ejaculate and increased
seminiferous epithelial loss, and that exposure to DBP in utero or during adolescence
decreased the number of sperm in the ejaculate by 23 and 20%. Human males have low
reproductive efficiency; therefore, the human testis would be more vulnerable to
toxicological insult, assuming similar responses occur (Amman, 1982).
The 2002 report by the American National Toxicology Programme Centre for the Evaluation
ofRisks to Human Reproduction (NTP CERHR) summarised various sources' data on DBP
exposure (Kavlock et ah, 2002). Estimated doses (pg/kg/bodyweight/day) depended on the
exposure route: ambient air = 0.00026-0.0009, drinking water = 0.005-0.02, food = 0.007-7.
Data was included from Canada that estimated that 0.5-11 year old children had the highest
levels of estimated DBP exposure (4.3-5.0 pg/kg/bodyweight/day) ofpeople under 19 years
old, compared to exposure ofpeople aged between 20-70 years (1.9 pg/kg/bodyweight/day),
mostly via food for all ages. UK data estimated mean DBP exposure levels to be <0.48
pg/kg/bodyweight/day (1993, based on fatty food intake).
Furthermore, phthalates with similar toxicological effects may have a cumulative effect that
would be expected to be additive. This body burden may be highest in certain populations,
such as infants that mouth PVC- toys/ teethers, teenagers with increased food intake/kg
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bodyweight and women of child bearing potential that use cosmetics and personal care
products (Koch et al. 2003). For the curious, there is even a website dedicated to phthalates,
albeit run by the relevant industrialists (i.e. the Phthalate Esters Panel of the American
Chemistry Council): www.phthalates.org.
There is growing evidence that male reproductive function is declining in human and some
wildlife populations. This is coincident with the increasing use and prevalence of man-made
chemicals in the environment over the last fifty years. One chemical, DBP, is a known
endocrine disruptor that does not extensively bioaccumulate in most environmental strata,
but it is continuously being released into the environment where it may act synergistically or
additively with many other contaminants via an unknown toxic mechanism. In order to
elucidate how DBP exerts its adverse effects, further studies of its mechanism of action and
the consequences of exposure to phthalates in fetal development were necessary. This can
best be achieved using a combined approach whereby animal models are used in
combination with in vitro human studies (Murray et al., 2001). The primary aim of the
experimental work described in this thesis was to investigate the effects ofDBP on the
developing testis. Pregnant rats were treated with DBP and/or MBP to assess their potential
to induce a syndrome of changes in testis development in the male fetuses that parallel the
human testicular dysgenesis syndrome (TDS) (Chapters 3 and 6). If successful, this model
could assist in the elucidation of the causes/pathways of TDS. Human fetal testes were also
exposed to DBP and/or MBP, in vitro via a novel organotypic culture system (Chapter 5).
This was a unique opportunity to investigate whether changes in the development of human
fetal testes could be adversely affected by exposure to these chemicals under controlled
conditions i.e. through in vitro experiments. These studies were performed in parallel with
experiments exposing fetal rat testes to DBP and/or MBP in vitro (Chapter 4). An overall
discussion of the role of these experiments in contributing to the elucidation of the
mechanism of toxicity induced by DBP and current understanding ofhow this environmental
contaminant might be behind the increasing levels of TDS, are described at the end of this
thesis in Chapter 7.
1.6 Aims of this thesis
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2 General Methods and Materials
The aim of this project was to investigate the changes induced by exposure to certain
phthalate esters to the fetal rat and human testis during embryonic development. This
involved the use of rats for in vivo experiments and for the provision of fetal testes for in
vitro experiments. Additional in vitro studies were performed using fetal testes obtained
from aborted human fetuses. Details on the sourcing of the biological tissues, their handling
and their experimental processing are provided in this chapter. Where specific procedures
were used, further information is provided in the relevant experimental chapter.
2.1 Animal Work
All studies involving rats were carried out in accordance with the Animal (Scientific
Procedures) Act 1986. Experienced and licensed handlers working under the relevant Home
Office project and personal licenses performed the necessary procedures. The animals were
housed in specific facilities provided by the University of Edinburgh. The physical location
and management of these facilities changed midway through this project but this had no
impact on the present studies.
The day-to-day husbandry of these animals and the majority of the licensed procedures were
carried out by Mark Fisken and Denis Doogan of the MRC and Keith Chalmers of the
University of Edinburgh. Huge thanks are due to them for their expert assistance. As a
personal license holder, I was able to perform some procedures myself (PIL 60/8817).
All procedures were carried out according to the UK Home Office regulations, under project
license 60-2442 until 2003 when it was transferred to project license 60-3045.
The background work to this project and the animal studies presented in this thesis were all
carried out using the Wistar strain of rats. The colony was bred in-house (University of
Edinburgh, UK) but was initially sourced from Charles River UK, a Home Office designated
breeder. Latterly the colony was re-derived and re-housed in the BRF, University of
Edinburgh.
2.1.1 Welfare conditions
Animals were accommodated in specially built facilities in which food (Type 3, soy free, rat,
SDS diets, UK) and fresh mains tap water were available ad libitum. Light was provided for
12h every day from 7am until 7pm. Humidity was generally kept at 55% and the temperature
generally ranged between 20 -25°C.
Rats lived in cages with clear sides and solid bottoms, except during mating when grid
bottomed cages were used to enable copulatory plugs to be detected on trays placed beneath
the cage. Normally female rats were group housed with up to six adult females per cage with
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a bedding mixture of corn cob and wood shavings. Each cage usually contained a cardboard
igloo or a cardboard tunnel for environmental enrichment. All bedding etc was supplied by
BS&S, Scotland.
For experiments that extended beyond fetal development, dams were individually housed
from late gestation throughout parturition until weaning of the pups after 21 days old. Stud
male rats were kept singly housed except during mating.
2.1.2 Time-mating
Female rats were time-mated so that an accurate calculation of their stage of gestation could
be determined. One male and one female rat were paired in a grid-bottomed cage towards the
end of the working day (~ 4pm). The next morning, the tray beneath the cage was examined
for copulatory plugs. Positive detection of these plugs implied the animals had mated. The
date was noted and designated embryonic day 0.5 (e0.5). Daily tray checks were continued
until plugs were detected for each female. This usually took up to 5 days, reflecting the 4-5
day menstrual cycle of the female rat, ofwhich only one day sees the dam in the oestrus
phase and receptive to mating. Once a positive mating sign was detected, the female was
removed from the male rat.
Stud males were derived from the in-house colony and were between 6-12 months of age at
the time ofmating. Dams were at least 10 weeks old at mating. Where possible, proven sires
and dams were used. The standardisation of husbandry practises helped to maximise the
reproducibility of the experimental work.
2.2 In vivo treatments and test compounds
Pregnant adult female rats were dosed once daily by oral gavage using a 10-12cm long 15-
16G commercial blunt ended steel gavage cannula (Medicut, Sherwood Medical Industries
Ltd., UK). This procedure caused minimal discomfort and was a Home Office recognised
dosing route and placed an accurate volume of the test substance directly into the rats'
stomach. The measured volume was transferred via attached disposable plastic 1ml insulin
syringes (B-D Plastipak). Individual animals were weighed immediately prior to dosing to
enable accurate individual bodyweight related volumes to be administered. The clinical signs
of treated rats were checked frequently following administration to ensure that any treatment
related changes in their welfare were addressed, such as accidental gavage misdosing into
the lungs.
Only two different chemicals were used for treatments in vivo: Di-rc-butyl phthalate (DBP)
and its metabolite Monobutyl phthalate (MBP), with their respective vehicle controls.
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2.2.1 Di-n-butyl phthalate (DBP)
CAS No.: 84-74-2, a viscous pale yellow oil, stored at rtp (Sigma D-2270, >99% pure).
For most of the studies described in this thesis, the dose of DBP administered to pregnant
rats was 500mg/kg bodyweight. At this level, it has been demonstrated that there are no
adverse toxicological effects on the dam but there was high reproducibility of reproductive
tract maldevelopment in the male fetus without an increase in embryonic lethality (Ema et
al., 1997; Ema et al., 1998). This dose level was required to induce the full syndrome of
effects seen in the background work to this project.
In order to generate the dose level used, pure DBP was diluted in pure corn oil (supermarket
bought), as it was lipid soluble. The use of corn oil as a vehicle is consistent with previous
studies of in vivo dosing ofDBP by this and other laboratories. The preparation assumed
both corn oil and the DBP had similar density: lg/ml. For example: to dose at 500mg/kg
bodyweight, 5ml of DBP was made up to 10ml with corn oil, and administered at a volume
of 1ml/kg bodyweight.
Treatments were freshly prepared for each experiment and were stored at room temperature
between administrations, with any excess disposed of appropriately at the end of the
treatment phase. The treatment regimes used are summarised in the table below.
Dose Level
(ml DBP/kg bodyweight)




(ml corn oil/ kg bodyweight)
Treatment age range Kill Age
1 e13.5-20.5 e21.5
1 e19.5-20.5 e21.5
Table 2.1: DBP or corn oil was administered by oral gavage, once daily, according to
the tabulated regimes. All doses were given at 1ml/kg bodyweight. Necropsy was undertaken
24h after the final dose, e = the timed day of embryonic development (gestation) the
treatments were given.
Separate corn oil only treated animals received pure corn oil at 1ml/kg bodyweight according
to the same dosing regime as the DBP treated animals. The only anticipated vehicle effect
was on bodyweight due to the calorific value of the oil.
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2.2.2 Monobutyl Phthalate (MBP)
CAS No.: 131-70-4, a white powder, stored at 4-8°C (TCI Europe: PI 132).
MBP is the major metabolite ofDBP and generally thought to be the active agent that
induces the toxicological effects on the testis following DBP exposure in utero (Imajima et
al., 2001; Saillenfait et al., 2001; Shono and Suita, 2000).
An equivalent dose to that used in the DBP studies was used (500mg/kg bodyweight). MBP
powder was slightly more water soluble, but less lipid soluble than DBP so would not
dissolve in corn oil but dissolved in the organic solvent dimethylsulfoxide (DMSO, Sigma,
D-2650) at a ratio of 1:0.6 w/v. DMSO is a low molecular weight compound that is liquid at
room temperature and is often used as a solvent for hydrophobic compounds (Akingbemi et
al., 2000). DMSO has been shown to be non-toxic at dietary concentrations as high as 1.0%
(Dresser et al., 1992). The preparation assumed both corn oil and the MBP/DMSO solution
had comparable densities. For example: to dose at 500mg/kg bodyweight, 5.00g MBP
required 3ml DMSO to go into solution, made up to 10ml with pure corn oil, administered at
a volume of 1ml/kg bodyweight. Treatments were freshly prepared for each experiment and
were stored at room temperature between administrations, with any excess disposed of
appropriately at the end of the treatment phase. The treatment regimes used are summarised
in the table below.
Dose Level
(mg MBP/kg bodyweight)




(ml vehicle/ kg bodyweight)
Treatment age range Kill Age
1 e19.5-20.5 e21.5
Table 2.2: MBP was administered by oral gavage, once daily, according to the
tabulated regimes. All doses were given at lml/kg bodyweight. Necropsy was undertaken
24h after the final dose, e = the timed day of embryonic development (gestation) the
treatments were given.
The dosing levels were chosen to investigate the potency of the effects ofMBP in the fetus
compared to DBP and compared to in vitro MBP exposure. The separate DMSO control
animals received a DMSO/com oil mix according to the same dosing regime as the MBP
treated animals. The maximum DMSO exposure level was 0.3ml/kg bodyweight. As with the
DBP-treated animals, the only anticipated vehicle effect was on bodyweight due to the
calorific value of the oil, equally affecting treated and control animals.
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2.2.3 5-Bromo-2'deoxyuridine-5'-monophosphate
(Brdll)
CAS No.: 59-14-3, a white powder, stored at -20°C(Sigma B-9285).
BrdU is a synthetic chemical used as a marker of cell proliferation. It infiltrates proliferating
cells where it replaces the thymidine nucleotide during mitosis with an analogue base for
uridine. This uridine containing DNA (U-DNA) is not corrected by the DNA polymerase
quality control mechanisms in the cell, so can later be detected in the nucleus of a recently
divided cell by a specific anti-BrdU antibody. Cells undergoing DNA repair also incorporate
BrdU, but such cells were considered infrequent. The number of labeled/unlabelled nuclei
can be counted and the Proliferation Index (PI%) per cell type then calculated.
BrdU was administered by intraperitoneal injection at lOOmg/kg bodyweight in saline (0.9%
NaCl, w/v) at a dose volume of 2ml/kg bodyweight. To aid solubilisation of the BrdU, the
saline was heated (by submersing a sealed aliquot under running water from the hot tap) to
around 40°C before the BrdU powder was added. Solubility ofBrdU appeared to be
temperature sensitive, though care was taken to ensure the animals did not receive a
substance warmer than body temperature. Animals were injected 1,5h prior to their
scheduled kill if pregnant or lh if non-pregnant (adult males). BrdU was administered
equally to vehicle-dosed control animals and treated animals.
2.3 Necropsy Procedure
Adult animals were routinely killed by C02 asphyxiation followed by cervical dislocation,
under Schedule 1 of the Animal (Scientific Procedures) Act 1986. In the occasional absence
ofC02, animals were killed by cervical dislocation by an experienced technician, followed
by exsanguination. Following removal from the freshly killed dam, fetuses were immersed in
refrigerated buffer (0.01M PBS, Sigma); late gestation fetuses (from el9.5) were decapitated
prior to immersion
2.3.1 Gross Dissection
Rat fetuses were removed using an established gross dissection technique.
The abdomen of the supine dam was opened and the intact gravid uterus removed.
The umbilical cord was severed for each fetus prior to its removal from the amniotic sac and
the body immersed in refrigerated 0.01M PBS. The carcasses were transported in PBS, on
ice. This minimised the onset of any degenerative changes prior to fine dissection and tissue
recovery.
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2.3.2 Fine Dissection
Once immersed, the fetuses were relocated into the designated dissection area of the research
laboratory. The fetal testes were removed under a binocular microscope with a
transilluminated stage, according to the technique described below, and placed in fresh
chilled PBS until processed.
The supine fetus was cradled between pieces of PBS soaked tissue for stability.
A careful horizontal incision was made beneath the liver, in line with the umbilical cord.
Abdominal tissues such as intestines were gently removed to reveal the gonads and
urogenital tract beneath. The gonads were located in the abdominal cavity between the
kidneys and the bladder, depending on gestational age and treatment.
2.3.3 Microdissection
Retrieved testes were further trimmed of the attached reproductive duct e.g. fetal
epididymides/ mesonephros. The trimming was carried out using 27G needles (Monoject,
sterile needles, 0.4mm x 12mm) attached to disposable plastic 1ml insulin syringes, for
improved dexterity. This was undertaken using a binocular dissecting microscope (Leica,
MZ6) at up to 4x magnification. The stage had in-built underlighting but additional external
cold lights (Leica CLS 150x) were also used for maximum visibility and minimal heat
damage.
2.4 Tissue preservation
Retrieved tissue was preserved either by snap freezing or by fixing in Bouin's. Whole fetal
testes froze instantly on dry ice in 1.5ml Nunc cryovials, were carefully labeled and archived
at -80°C, until used. When weights were required, tissue was weighed just prior to use.
Alternatively, testes were fixed by immersion in Bouin's solution, a formaldehyde based
fixative containing picric acid. It is the preferred fixative for testis tissue. Fetal tissue was
immersed in at least lOx its own volume of Bouin's for lh at room temperature in an airtight
container and was weighed after fixation. Adult testes were weighed prior to immersion
fixation in an air-tight container for 3h, cut transversely with a razor blade and the halves re-
immersed for a further 3h, cut transversely again and the quarters immersion fixed for a final
2h. Following fixation in Bouin's, tissue was transferred to 70% ethanol and stored in an
airtight container at room temperature until processed for paraffin embedding.
2.4.1 Fixed Tissue Processing
After the ethanol transfer, tissue was processed through a series of graded alcohols using the
18h automated cycle on a Leica TP-1050 (Leica UK Limited, UK) tissue processor and
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finally embedded in molten paraffin wax by hand. The cooled wax block was stored at room
temperature until needed. Efforts were made to deliberately orient the processed testes prior
to embedding to try to standardise the plane of sectioning generated (see section 2.6.1.1).
2.5 In vitro experiments
Fetal testes from untreated rats and aborted human fetuses were recovered then further
dissected to produce explants suitable for in vitro culture experiments. A culture method was
developed by adjusting/ combining two in-house methods: one based on the experiments of
Robinson et al (2003) for the fetal human ovary and testis and the other established by
Thomson et al (1997) for the fetal rat prostate (Robinson et al., 2003; Thomson, 1997). The
final method was achieved after much fine-tuning and is detailed in Chapter 4, but the
principles are outlined below.
2.5.1 Explant preparation from the rat fetal testis
One of the key aspects ofmaintaining viability of tissue in culture, was ensuring sufficient
oxygen and nutrient supply to the whole of the explant. The process of dissection disrupted
the normal distribution system by disturbing the blood supply to and through the tissue. In
order for nutrients to reach the tissue, the explants needed to be surrounded in a bath of
nutrient rich media so that the vital components could reach their target by diffusion.
Diffusion is a passive process; consequently its effects are not far reaching. To minimise the
possibility of tissue dying through oxygen or nutrient depletion, the testes were carefully
sliced into thin sections.
However, as the fetal testis is an actively and rapidly developing tissue, it was necessary to
minimise the level of developmental disruption the explant preparation caused. It was known
that some of the cells in the fetal testis arrive by migration from the adjacent mesonephros
and coelomic epithelia tissues (see Chapter 1). Though the majority ofmigration was
considered complete by the sampling ages used (generally el9.5), there may have been
residual migratory cells in the organ periphery, particularly with younger samples as normal
migration has been proposed to continue until el8.5 in the rat (Tilmann and Capel, 2002). It
was considered critical to ensure that every explant included a portion of the surrounding
tissues, by using a specific plane of dissection to generate the explants (Figure 2.1). The
effect of fetal age on the number of explants generated is described in Chapter 4.
To achieve these fine slices, a scalpel blade (Product no. 0201, Swann Morton, UK) was
used to make neat incisions through the testis along the target plane. A single incision was
made to reduce shearing injuries to the tissue. The tissue was steadied with a 23G needle
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attached to a disposable plastic 1ml insulin syringe. Originally, acupuncture needles were
used (Acumedic Ltd, 30mm x 0.25) but they proved too flexible.
Figure 2.1: These 3 panels show the step-wise dissection of an e20.5 fetal rat testis
into explants suitable for in vitro maintenance. Panel A shows an intact testis (T) with the
adjacent mesonephros (M) still attached. The vasculature of the attached tissue was still
clearly visible. The coelomic epithelium ( ) and rete regions (blue crescents), involved
in cell proliferation/ migration, are highlighted. The lines of dissection are also shown (—).
Panel B shows a midway point with the dissection almost completed in Panel C, the
quartered explants still required a final vertical dissection to generate 8 explants per testis.
The efferent ducts (EF) just needed to be trimmed away from the first explant.
2.5.2 Explant preparation from the human fetal testis
Where appropriate, the recovered fetal human testes were handled as similarly as possible to
the rat tissue.
2.5.2.1 Acquisition of human tissue
Human fetal testes were retrieved from medical terminations of pregnancy between 14-20
weeks of gestation (14-20w/40w). Termination of pregnancy was induced in the Simpson's
Maternity Hospital, Edinburgh as previously described (Gaskell et al., 2004; Robinson et al.,
2001). None of the terminations were for reasons of fetal abnormality, and all fetuses
selected for study appeared morphologically normal. The necessary ethical permission was
Chapter 2 General Methods and Materials 69
granted (Lothian Pediatrics/ Reproductive Medicine Ethics Subcommittee) to Professor
Richard Anderson at the MRC Human Reproductive Sciences Unit, Edinburgh. Relevant
informed consent according to the National Guidelines, was sought from and granted by the
female patients involved (Polkinghome, 1989). Though I don't know who they were, I am
indebted to them.
At all times, great care was taken to ensure minimal transfer of contamination between the
handler and the fetal tissue. Pathogen exposure from the fetal tissue was minimised further
by screening patients, prior to seeking consent, for high risk of contamination. Patients or
those whose partners were known to be drug users, were excluded as were those known to be
at risk of being, HIV+, AIDS+ or Hepatitis+ or who had tested positive for various sexually
transmitted diseases such as Chlamydia.
Unlike with the time-mated rats, the gestational age of the human fetuses was not accurately
known. Ultrasound examination prior to termination provided an estimate of gestational age,
this was checked by measuring fetal foot length (mm), from heel to tip of the big toe. This
has been used previously to confirm the developmental stage of the fetus (Anderson et al.,
2002; Gaskell et ah, 2004; Robinson et ah, 2001). The testes were readily distinguishable
from the ovary in all fetuses sampled.
The human fetuses were non-viable at the time of delivery and did not require death to be
caused or confirmed. On receipt of the carcass from the hospital, it was transferred to a
designated dissection suite in the research laboratory where the testes were removed for use.
The remains were then returned to the hospital for appropriate disposal. All actions were
carefully accounted for and archived. Sample availability was beyond the influence of the
investigators.
2.5.2.2 Dissection of the human fetal testis
Human fetal testes were dissected into small explants as per the rat tissue. As the human
organs were larger (>10mg) than the rat testes (~lmg), more explants could be generated per
specimen (Figure 2.2). Unlike for the rat, the size of the human testes precluded the
allocation of rete and coelomic epithelial regions between the explants.
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Figure 2.2: Panels illustrate the step-wise dissection of a 14/40w fetal human testis
into explants suitable for in vitro maintenance. Panel A shows an intact testis with its distinct
vasculature still clearly visible. Panel B shows the proposed lines of dissection. Panel C
shows the end-result: a collection of approximately evenly sized explants, ready for
incubation.
2.5.3 Primary tissue culture conditions
Cultures were incubated at 37°C, corresponding to the temperature of fetal testes in situ. The
environment within the incubator (Gallenkamp C02 incubator) was humidified and
maintained at 95% air/ 5% C02.
2.5.3.1 Culture Set-up
Once the testes were sliced into explants and the media made up to include any treatments,
the culture system could be assembled. Assembly took place in a sterile environment,
established in a class 2 safety cabinet. The explants were gently transferred from the holding
dish in chilled PBS to the synthetic membrane of a specially designed culture well insert
(Millicell 0.4pm PICM 01250, Millipore UK). The membrane was porous (0.45pm) and
raised by a plastic scaffold. This insert was placed in a well of a 24 well culture plate
(Corning). Pre-warmed (37°C) media was added, 200pl to the well and 200pl within the
scaffold to immerse the explants nesting on the insert membrane. Explants were distributed
evenly between the wells per experiment, with a maximum of 5 per insert. Up to 24
experiments could be set up per plate. This enabled replicates of both control and treated
samples to be run under identical conditions.
2.5.3.2 Culture contamination
A potential problem area encountered with explant cultures was the risk of contamination
with microorganisms, so practical measures were taken to minimise this possibility. It was
not practicable to procure the testis explants in an entirely sterile environment, so sterility
was compromised from the outset. Sterile techniques were practiced where possible. For
example, fresh sterile PBS was used during each phase of dissection. All media preparation
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and experiment set-up was carried out in a safety cabinet. Gloves were worn at all times to
ensure minimal transfer of any pathogens between the tissue and the handler, and changed
between the dissecting bench and the safety cabinet.
Anti-microbial chemicals were added to the media that surrounded the explants in vitro.
These chemicals are used routinely in this laboratory against a wide range of common
contaminants, bacterial and fungal, without causing any adverse effects on the viability of
the tissue explant. The antibiotic chemicals used were: Penicillin/Streptomycin: inhibits
bacterial cell wall synthesis and inhibits successful prokaryote protein synthesis (P-4333
Sigma, UK) and Amphotericin: a toxin that in small dose is used to disrupt fungal
membrane permeability, enabling small molecules to leak out (A-2942 Sigma, UK).
2.5.3.3 Culture Media
The basal media used by Robinson et al (2003) for human gonadal fetal explant cultures was
Alpha MEM (AMEM, Gibco Cat No. 41061-029) whereas Thomson et al (1997) cultured
fetal/ neonatal rat prostates in DMEM/F12 media (Gibco Cat No. 2104-025) (Robinson et
al., 2003; Thomson, 1997). The effect of these and alternative media regimes on fetal rat
testis viability in vitro was assessed and the results are detailed in Chapter 4 and summarised
below:
Robinson protocol Product code Thomson protocol Product code
Basic Media Alpha MEM 41061-029 DMEM/F12 21041-025
L-Glutamine G-7513 Transferrin (Bovine) 11107-018
Sodium Pyruvate S-8636 Insulin 1-0516
Supplements
ITS 1-3146 - -
BSA A-2153 - -
Table 3: Summary of media supplements used with two different complete media regimes,
used to support in vitro incubation of fetal testes. Note: all components were purchased from
Sigma, UK, except for the basic media and Transferrin, which were from Gibco, UK.
2.5.3.4 Culture treatments
Test compounds were added in known amounts to the explants via the culture media.
Explants were exposed to the chemicals for the entire culture period except for treatment
with BrdU. Stock solutions were stored at -20°C. When required, stock solutions were
diluted in culture media to give the desired concentration of test solution and stored at 4°C,
except for BrdU which was freshly prepared just prior to use in warmed (37°C) media.
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Equivalent amounts of the solvent were added into media for the control cultures. A
summary of the compounds used, their concentrations and solvents are tabulated below:










































Table 2.4: Summary of chemical treatments added to in vitro experiments.
Note: stock concentrations were typically at least lOOx the concentration required in the
media during the experiment (working concentration) to minimise any vehicle effects.
2.5.3.4.1 MBPand DBP
See sections 2.2.2 and 2.2.1 for more information about these chemicals. MBP is more
hydrophilic than its parent compound (DBP) but neither are easily water-soluble. To this
end, the compounds were first dissolved in DMSO before being diluted into media to make
the target working concentration for the in vitro experiments. This preparation method also
kept the compounds in solution.
It had been reported that at levels of >1%, DMSO has been shown to result in a variety of
cellular metabolic changes (Stocco et al., 1995) but at <0.1% it does not significantly affect
Leydig cell testosterone production in vitro (Akingbemi et al., 2000). IfDMSO did have an
inhibitory effect on steroidogenesis, this would be highlighted in the DMSO control samples,
but this did not prove to be the case.
2.5.3.4.2 human Chorionic Gonadotrophin (hCG)
Chorionic Gonadotrophin is a glycoprotein hormone produced by trophoblastic cells of the
developing placenta and has been used clinically to address androgen deficiency presenting
as cryptorchidism (Kiely, 1994). It binds to the cell surface receptor for luteinising hormone
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(LH-R), where it acts as a "super agonist" initiating a cascade of responses including
activating adenylyl cyclase and stimulating the concentrations of the second messenger
cAMP which in turn mediates a multitude of intracellular activities. In the testis, it binds to
the LH-R on Leydig cells, inducing an increase in the conversion of cholesterol to
testosterone. In these experiments, hCG is exploited for its 'super agonist" properties on the
LH-R, exciting a greater level of testosterone production than equivalent amounts of LH
(Zhou and Hutson, 1995). hCG is not normally expressed by the rat placenta so the
commercially available product used in these experiments is human derived, hence hCG and
(Habert and Picon, 1990). hCG concentration was used here at O.liu/ml, as reported, but can
be measured as g/ml which can be converted to international units (iu) using the following
scale: lmg = 10 OOOiu (Huhtaniemi et al., 1977)
2.5.3.4.3 22-(R)-Hydroxycholesterol (22-R-CHO)
One of the metabolic intermediates in the conversion of cholesterol to pregnenolone by the
cholesterol side-chain cleavage P450 cytochrome is 22-(R)-Hydroxycholesterol (Burstein,
1976; Burstein, 1975). As pregnenolone is the first steroid intermediate for all steroid
hormones, the rate at which it is formed determines the biosynthetic rate of overall steroid
production (Papadopoulos et al., 1991). By providing the testis explants with an excess of
this intermediate, 50uM, the rate limiting step is "skipped over", inducing a dramatic
increase in steroid biosynthesis downstream of the rate-limiting step, measured as
testosterone production (Akingbemi et al., 2000). It has no clinical applications.
2.5.3.4.4 Ketoconazole (KTZ)
Ketoconazole is used primarily as an anti-fungal agent due to its ability to inhibit the
synthesis of fungal sterols (Pont A, 1982). It is also used to control endocrinopathies in
humans (Gray et al., 1999). In mammals, KTZ competitively inhibits NADPH -cytochrome
P450 dependent enzymes (Higashi Y, 1987). In the testis, steroidogenesis is inhibited due to
the various cytochrome P450 enzymes including P450scc, 17a-hydroxylase (P450 cn) and
17,20-lyase (P450ci7_2o) (Miossec et al., 1997). The anti-androgenic action ofKTZ means it
has been used therapeutically for the treatment ofprostate carcinoma. In these studies it was
selected to demonstrate inhibition of fetal testis testosterone production in vitro at lOOpM,
based on previous experiments in this laboratory (PhD thesis, Qureshi, 1992).
2.5.3.4.5 Follicle Stimulating Hormone (FSH)
FSH is produced in the gonadotroph cells of the anterior pituitary, positioned below the
brain, after stimulation by Gonadotrophin Releasing Hormone (GnRH) from the
hypothalamus. FSH targets the Sertoli cells primarily and their inhibin production, though it
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can (indirectly) influence Leydig cell androgen production levels too. Inhibin-B secretion by
Sertoli cells is part of a complex negative feedback mechanism that suppresses FSH
secretion by the pituitary. FSH secretion affects final testis size through the regulation of
Sertoli cell proliferation in the perinatal/ prepubertal period and paracrine regulation of
Leydig cell steroidogenesis (Markkula, 1996; Matikainen et al., 1994). In these studies, FSH
was used at 50mIU/ml to investigate whether Sertoli cells in the explants were sensitive to
stimulation.
2.5.3.4.6 5-Bromo-2'deoxyuridine-5'-monophosphate (BrdU)
See section 2.2.3 for more details. BrdU is a synthetic chemical used as a marker of cell
proliferation. It was added to warm media for the last 4h of the in vitro experiments with rat
testis explants but the last 6-8h of the in vitro experiments with human testis explants.
2.5.3.5 Tissue Handling
At the end of the culture period, media was removed and stored at -20°C until assayed and
the tissue explants were carefully removed from the insert and processed as described for in
vivo treated tissue (see section 2.4). Due to their small size, explants were fixed for only 30
mins in Bouin's before transfer to 70% ethanol.
2.6 Protein Investigations
2.6.1 Immunohistochemistry
Antibodies were used to highlight the location of proteins of interest within fixed tissue. All
immunostaining, or its absence was reviewed in the context of the tissue morphology and
treatment, alongside proper experimental control tissue. The principles applied and the
protocols followed are outlined below.
• sectioning of fixed tissue and mounting of sections onto glass slides
• dewaxing and rehydration of sections
• retrieval of the target antigen for detection by the specific primary antibody
• blocking non-specific antigens
• incubation of tissue with specific primary antibody
• detection of the primary antibody by an amplification system
• visualisation of the amplified binding = staining
• counterstaining of non-stained tissue
• storage of stained sections for reference
2.6.1.1 Sectioning
Wax blocks containing processed fixed tissue, were cooled from room temperature prior to
being cut. Cooling made the wax more rigid and easier to slice. 5 pm sections were cut using
a Microtome (Leica, model RM 2135). The sections were floated in a water bath at 45-50°C
(Lamb RA, model E/65) to smoothen out any wrinkles in the cooled wax/ tissue by re-
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heating it gently. The heated sections were then mounted onto electrostatically charged glass
slides (BDH, Cat No.: 406/0179/00) and stacked in a metal rack. The slides were dried for at
least 3h at 50-60°C, usually overnight (Lamb RA, model E28.5). Once dry, the slides and
tissue could be stored in a dust free room temperature environment indefinitely or until used.
2.6.1.2 Dewaxing and re-hydration
Protective wax was removed from the tissue by immersing the slide in Xylene for 5 mins at
room temperature, x2. Longer immersion was occasionally required. Then the tissue was
rehydrated by immersion in absolute alcohol (AA) for 20s x2, 95% alcohol for 20s, 70%
alcohol for 20s and then rinsed in water.
2.6.1.3 Antigen retrieval
Fixatives such as Bouin's work by inducing intra-molecular cross-linkages. These can mask
target proteins (antigens) and thus prevent their immunodetection. Antigen retrieval
describes the process by which the cross-linkages are partially undone by the application of
heat and change in pH. It was not required for all immunodetection protocols.
Re-hydrated tissue was boiled in buffer. Different antigens required different buffers.
Retrieval took place in a commercially available domestic pressure cooker (Tefal, Clypso),
in which the slides were immersed in 2L of heated buffer and boiled under pressure for a
timed period, usually 5 mins. The slides were then left in the buffer as it cooled, typically 20
mins. Once cool enough to handle, the slides were rinsed in cold tap water.
Buffer Molarity PH
Citrate 0.01M 6
Glycine/0.1 %EDTA 0.05M 8
Glycine/0.1%EDTA 0.05M 3.5
Table 2.5 Summary of buffers used for antigen retrieval. Citrate buffer was the most
commonly used.
2.6.1.4 Blocking
Molecules other than the target antigen are revealed in these processes and may compromise
the specificity of antibody binding. This might be due to their affinity for the primary or
secondary antibody or even the chemicals used to visualise the antibody binding. This
undesirable binding was blocked deliberately before the primary antibodies were added.
Slides were washed between various stages.
Peroxidase block: Endogenous peroxidase activity was quenched by the immersion of
the retrieved slides in a solution ofmethanol and 3% hydrogen peroxide (H202) for 30 mins
at room temperature (30% H202, BDE1 Cat No.: 101284N). Without this step, there was a
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risk of these enzymes compromising the horseradish peroxidase step of amplification (see
2.6.1.6.1 ).
Serum block: Non-specific binding of components in the secondary antibody was
minimised by the application of a dilute solution of serum from the species in which the
secondary antibody was raised. For example swine serum was used for 30 mins at room
temperature to block tissue due to be exposed to a swine raised anti -rabbit secondary
antibody.
Avidin/Biotin block: Human tissues were prone to endogenous avidin or biotin
expression. This was minimised by incubating the tissue with avidin for 30 mins at room
temperature, followed by 2 washes in buffer (see below) and incubation of the tissue in a
pool of biotin in washing buffer for 15 mins at room temperature. A kit containing the
avidin/biotin was used (Vector, SP-2001). Endogenous expression would interfere with later
steps of the imunohistochemistry (see 2.6.1.6.1 ).
Washing Buffer: Where necessary, slides were washed by immersion in 0.05M Tris
buffered saline at pH7.4 (TBS). This was diluted as required from a 0.5M stock. Slides were
rocked (20-40rpm) for 2 x 5 mins with fresh buffer at room temperature.
2.6.1.5 Primary Antibodies
Following antigen retrieval and blocking, slides were washed then removed from TBS and
the area around the tissue was carefully dried to remove excess buffer. Care was taken at all
stages to avoid wiping the tissue off the slide but to keep the tissue hydrated. Sometimes it
was helpful to draw a perimeter around the tissue with a diamond pen on the underside of the
slide to highlight the location of small pieces or on the tissue side with a PAP pen to create a
waterproof perimeter that held the pool of solution over the tissue during incubation periods.
Blocking serum was added to slides maintained in a humidity chamber at room temperature,
for 30 minutes. This was replaced by a solution ofprimary antibody in blocking serum at an
optimised concentration. Typically the slides were left to incubate in the humidity chamber
overnight at 4°C. The exact conditions (concentration/ temperature/ duration) were optimised
for each primary antibody used. The table below summarises the general conditions used.
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1:200 Rabbit None Overnight, 4°C
SMA
(Smooth muscle actin) Sigma (A2547)











1:1000 Rabbit Citrate Overnight, 4°C
Table 2.5: Summary of primary antibodies used for immunohistochemistry. Santa
Cruz products supplied via Autogen Bioclear UK Ltd, Wiltshire, UK.
2.6.1.6 Secondary Antibodies
After incubation, the primary antibody was washed off the slides (2x 5mins in TBS).
It was necessary to amplify the localisation of the primary antibody. This was done using a
secondary antibody, raised against a species-specific sequence on the arm of the primary
antibody. This secondary was then amplified directly or indirectly (Figure 2.3).
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Figure 2.3: Schematic representation of the principles of the direct
immunohistochemistry protocol. Within cells (A), proteins are expressed (B) of which
particular parts are recognised as antigens (C) by specific primary antibodies (D), which then
bind to them. A secondary antibody (E) with its biotin conjugates (F) binds to species-
specific regions on the primary antibody. An avidin/biotin/ enzyme complex (G) associates
itself with the conjugated biotin. The enzyme (H) reacts with the chromogenic substrate to
create a visible colour change (I) at the site of the antigen expression.
The indirect method replaces E, F, G and H with a single intermediate complex.
2.6.1.6.1 Direct Method
The direct method was a three-step process. Firstly, the tissue was incubated with a specific
primary antibody (Table 2.5), which bound with a specific biotin labeled secondary antibody
(Table 2.6).
Target Antigen Species Source/ code Concentration Host species
Rabbit Dako, E0353 1:500 Swine
Sheep Vector, BA 6000 1:500 Rabbit
Goat Vector, BA 5000 1:500 Rabbit
Mouse Dako, E0464 1:500 Rabbit
ABC-HRP
(All secondary antibodies)
Dako, K0355 as supplied n/a
Table 2.6: Summary of secondary antibodies used for immunohistochemistry. They
all required incubation for 30mins at room temperature.
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Secondly, the biotinylated secondary antibody was bound to an avidin/biotin labeled
horseradish peroxidase enzyme conjugate (ABC-HRP) (see Table 2.6). The commercially
available amplification system (ABC-HRP, Dako, K0355) was used as instructed. Avidin
and biotin are two proteins that have a very high and specific binding affinity for each other
that is exploited in this conjugation system. The ABC-HRP mixture was solubilised in salt
free Tris pH 7.6 buffer and applied to the washed slides for 30 mins, at room temperature
and washed off as before (2x 5mins in TBS). Finally, this amplification complex was
exposed to a chromogenic substrate (see section 2.6.1.7) causing a colour change reaction in
the specific regions where the primary antibody was bound (Figure 2.3).
2.6.1.6.2 Indirect Method
The indirect method was a two-step process, using a secondary antibody/ polymer
("Envision +", Dako, K4007), available per species. The complex includes an HRP-labeled
polymer directly conjugated with the secondary antibody. This complex is avidin/biotin free,
reducing the risk of any non-specific binding, making it very sensitive. As for the direct
method, the amplification complex was exposed to a chromogenic substrate (see section
2.6.1.7) to cause a colour change reaction in the specific regions where the primary antibody
was bound.
2.6.1.7 Chromogenic Detection
In order to see where the primary antibody localised a visual colour change was needed, that
could be reviewed using a standard light microscope, to distinguish the specific protein
expression from the rest of the tissue. The colour of the precipitate generated at the site of
the original antigen, varied according to the chromogen substrate used.
Brown: DAB (3,3 DiAminoBenzidine), used most routinely and was bought in as a
concentrated solution (Dako, K3468) with specific buffer to be diluted just prior to use. It
was added to slides after unbound ABC-HRP complex was carefully washed away (2x 5mins
in TBS). Depending on antibody, it was incubated briefly from 30s to 5mins, timed per
experiment. Immersing the slide in tap water stopped the completion ofDAB development.
Blue: Fast Blue was used as the second stain in double staining experiments. Made up in-
house, this chromogen took longer to develop than did DAB (around 5-20 mins) and
produced a blue stain, similar to the haematoxylin counterstain, so they were not used
together. Chromogen was made up to lmg/ml with fast blue salt (Sigma, F3378), mixed well
and passed through a 0.2pm filter just before use. The completion of development was timed
per experiment and stopped by immersing the slide in tap water.
Buffer: this is made in a two-step process: 0.1M Tris (pH 8.2) = 12.lg Tris (BDH 271197K),
950ml distilled water. Make up to 11 at pH8.2 with concentrated HC1 acid. Per lOOmls: 20mg
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Napthol AS-MX phosphate (Sigma N-5000), 2ml Dimethyl formamide (Sigma D4254). Mix
together in glass tube, add 98ml 0.1M Tris (pH 8.2) buffer.
2.6.1.8 Microscopy
Photographed images were compiled using Photoshop 7.0 (Adobe Systems Inc., Mountain
View, CA).
2.6.1.8.1 Light microscopy
Nonfluorescent images were examined and photographed using a Provis microscope
(Olympus Optical, London, UK) fitted with a DCS330 digital camera (Eastman Kodak,
Rochester, NY).
2.6.1.8.2 Fluorescent microscopy
Fluorescent images were captured using an LSM 510 Axiovert 100M confocal microscope
(Carl Zeiss Ltd., Welwyn Garden City, UK). Fluorescent chromogens were used to
emphasize co-localisation as DAB could overwhelm Fast blue staining, making co-
localisation ofproteins difficult to interpret.
Fluorescence results when sensitive materials are irradiated by light at a specific wavelength.
This excites atoms within the compound to a higher energy level, which is released and
detected as visible light when they drop back down. This emitted light has a longer
wavelength and lower energy than the "exciting" light that is generated by a laser beam
incorporated into the microscope. To distinguish between the two types of light, the
microscope is fitted with two filters, one ofwhich enables the sample to be irradiated by
light at a specific wavelength, the second separates out the excitation light from the emitted
light. The colour of emitted light seen, depends on its wavelength, which varies depending
on the sensitive chemical used. The fluorescent chromogens used are summarized in Table
2.7.
Fixed tissue destined to be examined using fluorescent immunohistochemistry were pre-
treated as detailed in section 2.6.1 until the addition of the primary antibody, which is diluted
in the appropriate normal serum/PBS/BSA then incubated overnight at 4°C as before. After
washing in PBS, sections were incubated for 30min with the appropriate secondary antibody,
namely one that is conjugated to HRP (Dako) diluted in normal serum/PBS/BSA. After
washing in PBS, slides were incubated for 10 min with tyramide Cy3 (TSA plus cyanine 3
system; Perkin-Elmer Life Sciences, Boston, MA) diluted 1:50 in the buffer supplied, to
amplify the immunostaining and produce red fluorescence. Washing in PBS followed this
and all subsequent steps. Where co-localisation of the expression of two proteins was
required, slides were re-incubated for 30 min with the appropriate normal serum/PBS/BSA,
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followed by overnight incubation at 4°C with the additional primary antibody diluted in the
appropriate normal serum/PBS/BSA then incubated overnight at 4°C as before. After
washing in PBS, sections were incubated for 30min with the appropriate secondary antibody,
namely one that is a biotinylated secondary antibody (Vector Laboratories Inc.,
Peterborough, UK) diluted in normal serum/PBS/BSA. This was followed by a lh incubation
with streptavidin conjugated alexa 488 probe (Molecular Probes, Poort Gebouw, Holland)
diluted 1:200 in PBS, producing green fluorescent immunostaining. Slides were
counterstained by incubating for 2 min with a nuclear specific blue fluorescent label (To-Pro
3; Molecular Probes) diluted 1:2000 in PBS. Slides were then washed in PBS and mounted
in aqueous mounting medium (Permafluor; Beckman Coulter, High Wycombe, UK)














1:20 1 h, rtp 488/ green
To-Pro 3
(Molecular Probes)
1:2000 2min, rtp 655/ blue
Table 2.7: Summary of fluorescent labeled complexes used.
2.6.1.9 Terminal dUTP nick end labeling (TUNEL)
This established commercially available protocol enables cells undergoing programmed cell
death, apoptosis, to be highlighted by visualising their DNA fragmentation. This discerns
them from cells undergoing necrosis. Apoptotic cells were detected in situ by use of the
TUNEL method as described by Livera et al. (2000). This assay detects fragmented DNA in
apoptotic cells by catalytic incorporation of fluorescein-12-dUTP at the 3'-OH ends of the
DNA using the terminal deoxynucleotidyl transferase enzyme, visualised using DAB as
described previously (Figure 2.4).
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Figure 2.4: TUNEL positive staining of an intratubular cell, at the periphery of a
seminiferous cord within an e21.5 rat testis. Note the absence of brown staining from the
abnormally nucleated fetal germ cells at the centre of the cord (dashed circle). The panel
shows a cross section through an e21.5 rat testis at x40 and xlOO magnification.
Necrotic cells were recognisable microscopically by their darkly counterstained pyknotic
nuclei. Ideally, all necrotic tissue would have been discarded from further analysis but due to
the permanent appearance of this artifact in the centre of cultured explants, necrotic tissue
was noted but investigative focus was placed on the viable peripheral tissue per sample.
2.6.1.10 Haematoxylin and Eosin Staining (H&E)
These two dyes were used as counterstains for sections following immunohistochemistry but
were also used together when inspection of the tissue morphology was the only objective.
These stains are routinely used in medical and veterinary histopathological studies.
Harris's haematoxylin: Stains cell nuclei. Slides were immersed for 5 mins in a bath of
haematoxylin, rinsed in tap water, briefly immersed in 1% acid alcohol to remove any non¬
specific cytoplamsic staining and rinsed in tap water. The dye was developed by immersing
the slides in Scott's tap water for 30s until the reddish stain turned blue. This was checked
using a standard light microscope.
Eosin: Stains cell cytoplasm. Slides were immersed in a bath of Eosin for 30s then rinsed
thoroughly in tap water. The pink colouration was checked using a standard light
microscope.
Following staining, slides were removed from the bath of tap water and dehydrated before
mounting with a coverslip secured with Pertex™ as described below.
2.6.1.11 Coverslips
After tissue had been counterstained, it was protected by the application of a borosilicate
glass coverslip (VWR, 22x32mmxl,Cat No.: 631-0133). These were fixed in place by a drop
of glue and dried.
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Pertex™ (Cell Path, UK), a solvent based glue, required counterstained tissue to be
de-hydrated and cleared in xylene. Dehydration was almost the reverse of the rehydration
protocol followed in section 2.6.1.3. Slides were rinsed in water then immersed in 70%
alcohol for 20s, 85% alcohol for 20s, 95% alcohol for 20s, Absolute Alcohol (AA) for 20s
x2, HistoClear™ for 5mins and finally Xylene for 5mins.
Permafluor™ (Beckman Coulter, Cat No.: PNIM0752), a water based glue, required
no further treatment of the tissue after excess counterstain had been rinsed off. More prone to
air bubbles and incomplete rigidity after drying than Pertex, hence usually only used where
dehydration was incompatible with reagents used, typically fast blue and fluorescent dyes.
2.6.1.12 Storage
All H&E, DAB and Fast Blue stained slides were stored in a dry, room temperature
environment after review. They would be available for review indefinitely. Those slides
labeled with fluorescent dyes, faded within 2 weeks of the experiment being run and were
not stored.
2.6.2 Western Blotting
Western blotting separates protein mixtures according to molecular size by exploiting their
electro-mobility through a gel with specific sized pores. These proteins are then transferred
to a membrane that is then labeled with antibodies specific to the protein of interest. The
antibody binding is then visualised and quantified. The details of this protocol are outlined
below.
It is described as a Western Blot because it shares some similarities with the Southern Blot,
invented by EM Southern, a British biologist.
2.6.2.1 Protein extraction
Experimental tissue, stored at -80°C, was weighed whilst frozen where possible then
defrosted on ice. Meanwhile, a lysis buffer "RIPA" was prepared and protease inhibitors
freshly added. RIPA lysis buffer was used to break open the tissue and cells to release their
proteins. The lysed tissue was then separated by centrifugation and the protein enriched
supernatant stored at -80°C until needed. The protease inhibitors prevented any protein
degradation.
The RIPA buffer was made up from a 5x stock, diluted with distilled water and lOx protease
inhibitor (Sigma, P8340). RIPA recipe: 15ml 5M NaCl, 25ml 1M Tris-HCl pH 7.4, 5ml
0.5M EDTA, 5g deoxycholate sodium, 0.5g SDS made up 100ml with distilled water. SDS
was added to break non-covalent bonds within proteins and to give each protein a negative
charge to facilitate their separation by PAGE.
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Prepared RIPA was added and the mixture homogenised. Homogenisation helped disrupt the
tissue integrity and was facilitated by a cordless handheld motor driven grinder (Sigma,
Z35,997-1) with a pestle designed to fit the 1.5ml tube (Sigma, Z35,996-3). Approximately
lOOpl of lysis buffer was added per mg tissue. Following the homogenisation of the tissue
into a suspension, it was incubated at 4°C for lh. This incubation step improved the amount
of protein recovered from the small pieces of tissue used (Laslett et al., 2000). The tissue
lysate was centrifuged at 2500rpm for 10 minutes at +4°C after which the protein rich
supernatant was transferred to labeled, fresh 0.5ml eppendorf™ tubes and stored at -80°C
until used.
2.6.2.2 Protein Quantification
In order to make a relevant comparison between tissue samples, the total concentration of
protein per extract needed to be quantified. A routine protein quantification method was
established by Lowry in 1951, which has since been modified and commercialised by
BioRad to produce a fast reliable method. This method relied on a standard curve of known
protein concentration vs sample optical density at 450-750nm, usually 650nm. A scatter plot
was used to generate the standard curve and a linear regression equation and the correlation
coefficient, as calculated using Excel software (Microsoft, USA).
The standard protein used was Bovine Serum Albumin (BSA) as provided by BioRad at
2mg/ml and serially diluted in-house in prepared RIPA to maximise standardisation between
standards and unknowns. At least five standards were used per quantification run. The
optical density of the protein concentration was proportional to the colour change. An
example of a standard curve and regression equation generated is shown in Figure 2.6.
Occasionally, such a low concentration ofprotein was recovered in the lysis buffer that it
was almost undetectable using the quantification method described. These samples were
concentrated by removing the liquid buffer by ffeeze-drying at -80°C (Spin Freezer Model,
Life Sciences International, UK) and re-solubilising the frozen powder in a smaller volume
of buffer.
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Figure 2.6: A typical calibration curve for protein concentrations, quantified against
optical density of BSA standards at 690nm. Based on triplicate analysis of up to 7 standard
solutions across the linear range. The values were processed by Microsoft Excel software
and produced reproducible linear correlation coefficients (typically R2> 0.95). The curve was
linear across the entire range set between 0.25-1.5mg total protein/ml.
2.6.2.3 Electrophoresis
The amount of protein used was restricted by the sample availability, concentration and the
finite volume of the wells in the gels. All the products needed to perform the Western blot
were supplied by Invitrogen unless specified otherwise.
2.6.2.3.1 Sample preparation
The protein samples (typically lOpg) were heated (70°C, 5mins) with 1:4 v/v LDS sample
buffer, a glycerol rich dyed loading buffer (Invitrogen, NP0007) and 1:10 v/v reducing agent
(Invitrogen, NP0009). This mixture was carefully loaded into the wells of a pre-cast 10%
Bis-Tris gel (Invitrogen, NP0315BOX). These gels contained two parts, a large pored
stacking gel that contained the wells and concentrated the sample prior to separation and a
separating gel with smaller pores.
A pre-stained multi-coloured standard for SDS-PAGE (Invitrogen, LC5725) was loaded in at
least one lane per gel to enable monitoring of the protein migration during electrophoresis.
The marker included proteins of known molecular weight that could be used to compare
against the expected position of the target protein.
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2.6.2.3.2 Running the gel
Each gel was supplied encased in a plastic cassette and this was setup in an electrophoresis
tank. The gel type was carefully selected based on manufacturers recommendations
regarding the range of sizes of the anticipated proteins of interest. The gel was made from
polyacrylamide, hence the term PAGE: PolyAcrylamide Gel Electrophoresis. SDS-PAGE
relies on the ability of proteins to migrate through polyacrylamide gel pores when under an
electrical charge, from the cathode to the anode, following treatment with SDS to make them
all negatively charged.
The tank was filled as instructed by the manufacturer with a running buffer (MOPS: 3-(N-
morpholino) propane sulfonic acid) (Invitrogen, NP0001) and attached to a power pack. The
running buffer was carefully selected based on manufacturers instructions and approximate
size of proteins of interest. Antioxidant was added to maintain the denatured form of the
proteins during the electrophoresis (Invitrogen, NP005). Gels used had 10-15 lanes and ran
at 200v for 50 mins.
2.6.2.4 Western transfer of proteins
Having separated the proteins according to their molecular weight (kDa), they were
transferred from the gel and immobilised onto pre-cut PVDF membrane (Invitrogen,
LC2002). The dry membrane was rehydrated by immersion in methanol for 30s, dH20 for
2mins then transfer buffer for at least 15mins. A gel/ membrane sandwich was assembled in
accordance with the manufacturers recommendations, and secured in a transfer tank. The
sandwich arrangement of the gel and the membrane meant that the SDS treated proteins
moved laterally from the gel towards the anode until their migration was halted by the
membrane. The tank was filled as instructed by the manufacturer with a methanol rich
transfer buffer (in-house protocol, see below) and re-attached to the power pack. The transfer
took 4h at 40v or overnight at 20v.
Transfer buffer: per litre: 200ml Methanol, 14.4g Glycine, 3.03g Tris, made up with dH20.
2.6.2.5 Staining of gels
Following Western transfer of the separated proteins from the SDS gel to the PVDF
membrane, the gel was stained to highlight residual proteins and check that the
electrophoresis and blotting processes had worked. The gel was stained for lh at room
temperature using 20mls Gelcode Blue™ stain reagent (PerBio, Prod.24592) then rinsed in
dH20 overnight. This staining check was carried out routinely to ensure that each gel had run
and transferred properly, without damaging the blot. Reviewed gels were discarded.
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2.6.2.6 Protein Detection
Antibodies were used to identify proteins supported on the membrane, to facilitate their
detection.
2.6.2.6.1 Blocking of non-specific binding
As for the immunohistochemistry performed on sections of fixed tissue (section 2.6.1), an
initial block was used to saturate non-specific binding. At least lOmls of TBS-Tween buffer
with 2% BSA (w/v) (Sigma) was poured over each blot which was then left to incubate for at
least lh at room temperature, on a rocker.
2.6.2.6.2 Primary antibodies
Following incubation, the blot was rinsed in TBS-T for 2 x 5mins then replaced with the
primary antibody, directed against the protein of interest. The same primary antibodies were
used as for immunohistochemistry (section 2.6.1.5) but lOx less concentrated, made up in
TBS-T.
TBS-Tween® buffer: 0.05M Tris buffered saline at pH7.4 (TBS) + 0.05% (v/v) Tween®
(Sigma). Blots were rocked (20-40rpm) for either 2x5 mins or 3 x lOmins with fresh buffer.
2.6.2.6.3 Secondary antibodies
The secondary antibodies used on the Western blots were HRP-conjugated and directed
against the primary antibody host species as for immunohistochemistry (section 2.6.1.5). The
HRP reacted with the chemiluminescent substrate to create light emission at the site of
antigen expression. The specific pattern of light emission was captured by timed exposure to
photosensitive film in a dark room. The Enhanced Chemi-Luminescence reagents (ECL
Plus™, Amersham Life Science) were prepared immediately prior to use, after equilibration
to room temperature, in accordance with the manufacturers advice. Exposure duration was
adjusted according to the level of intensity achieved. The film used was designed especially
for use with ECL reagents (Hyperfilm™, Amersham Life Science). Exposed film was
developed by hand using Kodak reagents.
Expression levels of different proteins visualised in the same sample were quantified using
Image Quant computer software as detailed in section 2.6.3.1.
2.6.2.7 Stripping of blots
Bound antibodies could be stripped away and the same blot re-probed for another protein.
This enabled the same blot to have different protein expressions quantified against each
other. This was particularly useful when experiments involved only small amounts of tissue.
Blots could be stripped and re-probed successfully up to 4 times, though care was taken to
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avoid using more than one primary antibody that had been raised in the same species to
minimise background staining.
Antibodies were stripped by washing the blot after ECL exposure in TBS-T for 2 x 5mins
then with 10-20mls ofRestore™ (Pierce, Prod.No.:21059) at room temperature for 15-60
mins. Some monoclonal antibodies required a more severe method of stripping. This
involved incubation of the blot in a rotating hybridisation chamber at 70°C for up to lh with
the in-house buffer detailed below. This was carried out in a fume hood
Stripping buffer: 1.875ml 62.5mM Tris pH 6.8, 211 ul lOOmM 2-fl-Mercaptoethanol and 2%
SDS (w/v) per blot.
2.6.3 Image Analysis
The level of protein expression could be analysed using computer assistance from
immunostained fixed tissue with Image-Pro Plus software and from developed film after
exposure ofWestern blots with ImageQuant software. More details are provided below.
2.6.3.1 Image-Pro® Plus
Image-Pro® Plus version 4.5 (Media Cybernetics, Inc., USA) computer software was used to
accurately measure the distribution of positive staining of immunostained tissue sections.
Various different approaches were used but they all required digitisation of the tissue image,
collected using a microscope with a motorised stage (Prior Scientific Instruments Ltd.,
Cambridge, UK), and camera. Further analysis was undertaken using Sterology-pro-5.0
software (Datacell, Media Cybernetics, Inc., USA).
2.6.3.1.1 Determination of Sertoli cell nuclear volume/number
per testis
Standard stereological methods were used to determine whether Sertoli cell nuclear volumes
and/or number per testis were altered after treatment. Cross-sections of testes, previously
immunostained for the Sertoli cell nuclear protein WT-1, were examined by light
microscopy under oil-immersion. Three representative sections from each testis were
selected and immunostained for WT-1. The three sections chosen were those corresponding
to approximately 25, 50, and 75% intervals through the serially sectioned testis; at e21.5 this
corresponded to sections that were 20-30 sections apart from each other. Image-Pro Plus
4.5.1 with Stereologer-Pro 5 plug-in software (Media Cybernetics UK, Wokingham,
Berkshire, UK) was used to analyse images captured using an Olympus BH-2 microscope
fitted with a Prior automatic stage. An area of interest (AOI) was created by drawing around
the perimeter of the cross-section (at x40 magnification). The software was used to select
random fields within the AOI for counting and to place a grid over the tissue. The number of
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fields counted per animal (30 per slide) was dependent on obtaining a percentage standard
error value of <5%. The manual tag tool was used on Image-Pro® Plus to label all points
falling over the nuclei of Sertoli cell nuclei. These were scored and expressed as a
percentage of the total points counted, equivalent to the % of volume occupied by the cell
type counted (i.e. Sertoli cell % volume occupancy).
For each animal, the values for percentage nuclear volume were converted to absolute
nuclear volumes per testis by reference to testis volume (=weight) as shrinkage was minimal.
Sertoli cell nuclear volumes per testis equate to cell numbers per testis, assuming no change
in average nuclear size. However, as the individual nuclear volume of Sertoli cells might be
influenced by treatment, average Sertoli cell nuclear volume was also determined.
Absolute volume (mg) = (% volume occupancy /100) x testis weight (mg)
Briefly, images were captured and analysed using the equipment described above. Nuclear
measurements were made in Sertoli cell nuclei counterstained with haematoxylin as
immunostaining masked the nuclear perimeters. An area of interest was created by drawing
around the nucleus (at xlOO magnification). Three diameter measurements (pm), which
passed through the centre of the nucleus, per nucleus, were made using the Selector tool.
This was measured for a minimum of 70 nuclei per testis, and the mean nuclear volume was
then determined. Data for nuclear volume per testis was then converted to absolute numbers
of Sertoli cell per testis by dividing by the average nuclear volume. The area per nucleus
(pm2) and the mean nuclear volume (pm3) were calculated per sample by the software. The
calculations assumed that the nuclei were spherical in shape. However, fetal Sertoli cell
nuclei have irregular shapes but this assumption was made consistently for each of the
treatments. Other experiments in our laboratory have shown that this method for determining
Sertoli cell number yields comparable results to those obtained using an "unbiased" method
(optical dissector) in which shape of the nucleus is not a factor e.g. Atanassova et al (2005).
Number of cells = Absolute volume (mq) x 1000 (to account for mg to pm3)
(millions) mean nuclear volume (pm3)
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2.6.3.1.2 Proliferation Index (PI)
The PI is the percentage of cells (e.g. Sertoli cells) that positively express a proliferation
marker, in this case BrdU (section 2.2.3). The number ofBrdU positive and BrdU negative
Sertoli cells was counted in at least 15 seminiferous cords per section/ per animal.
Counts were made by tagging a captured image (as described previously, at x63
magnification) and tracked per section on a second screen with a tiled image (3x3 frames)
taken at x20. Images were captured and analysed using the equipment described above.
PI (%) = Number of positively stained Sertoli cell nuclei x100
Number of stained + unstained Sertoli cell nuclei
2.6.3.1.3 Determination of Leydig cell aggregation
Modified stereological methods were used to quantify the area of a testis cross-section
represented by Leydig cells, to determine whether the distribution of Leydig cells throughout
the testis was altered after DBP treatment (Mahood et al., 2005). Cross-sections of testes,
previously immunostained for the Leydig cell cytoplasmic protein 3|3-HSD, were examined
by light microscopy under oil-immersion. Three representative sections from each testis
were selected and immunostained for 3|3-HSD. The three sections chosen were those
corresponding to approximately 25, 50, and 75% intervals through the serially sectioned
testis; at e21.5 this corresponded to sections that were 20-30 sections apart from each other.
Images were captured and analysed using the equipment described previously. An area of
interest (AOI) was created by drawing around the perimeter of the cross-section (at x40
magnification).
Previously specimens immunostained for 3(3-HSD are usually of sufficient homogeneity,
high contrast, and low background to allow computer-assisted thresholding and subsequent
computer-assisted counting of Leydig cell (3(I-HSD -immunopositive) clusters and
determination of Leydig cell cluster area (Mahood et al., 2005). In the present experiments,
counterstained pyknotic nuclei in cultured testis explants were of equally high contrast so a
modified method was adopted. Computer-assisted segmentation was used as it could
distinguish between colours, i.e. brown stained Leydig cells and blue stained pyknotic
nuclei, rather than converting the captured image to greyscale as for thresholding.
Segmentation was used to identify and analyze clusters of 3(3-HSD -immunopositive cells,
generating data on cluster number, area, and the proportion of each section occupied by
Leydig cell clusters.
Chapter 2 General Methods and Materials 91
2.6.3.2 Image Quant TL ®
Following Western analysis, developed Flyperfilm was scanned to generate a greyscale ".tif'
file. The image was analysed by ImageQuant (Amersham Life Sciences, UK) and the area of
film exposed to the chemiluminescence was quantified per gel, per antibody and per sample.
The area of exposure equated to the amount of labeled protein present in the sample.
2.7 Hormone Analysis
Endocrine effects of in vivo and in vitro treatments were quantified by measuring the levels
of testosterone (Leydig cell product) and inhibin B (Sertoli cell product) within either media
retrieved at the end of in vitro experiments or in whole testis homogenates from in vivo
experiments. Protocols were already established for these hormone assays, though some
optimisation was required for these sample conditions.
It has been reported that pregnenolone contributes very little to the total steroid content at
any one time, perhaps due to the omnipresence of 3 fi-HSD, but also making it a poor
endpoint to use for assessment of any steroidogenic disruption, hence the use of testosterone
(Payne and Youngblood, 1995).
2.7.1 Testosterone
This steroid hormone had two in-house assay protocols established: one involving a
radioisotope labeled antigen and another a radiation free ELISA plate assay. Due to Health
and Safety regulations, and waste disposal costs, the radiolabelled assay is being phased out.
Both methods were used and are detailed below. For both methods, samples were assayed in
duplicate after appropriate dilution. Aliquots of standards, controls and quality control media
were incubated alongside samples for every assay run.
Unlike in the media samples, the whole tissue homogenates underwent an additional
extraction step to free up any testosterone bound in the tissue to proteins such as albumin.
2.7.1.1 Extraction of steroids from whole organs
Whole fetal testes were homogenised in chilled 0.5ml 0.1M PBS buffer. 100p,l aliquots were
placed in glass test tubes and vortexed for 5 minutes with 2ml di-ethyl ether. The shaken
tubes were placed in a bath ofmethanol and dry ice to freeze the aqueous portion, revealing
the unfrozen organic portion that was decanted into clean tubes. These tubes were left over
night in a fume hood to enable the organic solvents to evaporate. The dry residue was re-
suspended in assay buffer and stored at -20°C until quantified. This method has an extraction
efficiency of>85% in this laboratory.
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2.7.1.2 Radioimmunoassay (RIA)
This fluid phase technique measured the level of competition between a fixed concentration
of radiolabeled antigen (testosterone with I125, APB Biotech, UK) against the unknown
quantity of unlabelled antigen in the test sample. The more antigen in the test sample, the
lower the level ofbinding by the labeled antigen. After a three-hour incubation at room
temperature, a second antibody (Donkey-anti-sheep DAGS), raised against the sheep IgG,
was added and tubes were left overnight at 4°C to bind with the testosterone/antibody
complex to form a stable precipitate. The incubated tube received 2ml of wash buffer. The
amount of radiation in the precipitate was measured and the test sample values were
compared to a standard curve of known antigen concentrations. A gamma counter
(Multigamma 1261, LKB Wallac, Turku, Finland) was used to measure residual I125.
This is a precise and sensitive assay with a low intra-assay coefficient of variance (<10%).
Method blanks, quality control (QC) samples (spiked buffer), and standards were analysed
along with media samples. Where samples are presented on one graph, these were analysed
simultaneously. If the QC values measured outside 2 standard deviations from the mean, the
assay was rejected, this happened rarely. The source of the deviation (usually human error!)
was determined and corrected before the analysis was re-run. The inter-assay (6 runs)
coefficient ofvariance of the three QC samples ± standard errors are listed below. The mean
coefficient of variance = 16.5%. The limit of detection for this assay was 8pg/100ul.
• Low: 7.9 ± 0.4pg/100pl = 13.0%
• Medium: 26.5 ± 1.81g/100pl = 16.8%
• High: 135.7 ± 19.7pg/100pl = 19.7%
Data were expressed as pg testosterone per lOOpl sample. Results were analysed using a
computer programme (AssayZap, BioSoft, Cambridge, UK) specifically designed for this
purpose. For presentation purposes, data were converted to ng/ml media (= pg/lOOul x 0.01).

















Figure 2.7: Quality control plot for testosterone. The scatter plot shows the actual
values obtained and the median per QC. The graph is on a logarithmic scale to accommodate
the concentration range of the control samples.
2.7.1.3 Enzyme linked Immunosorbent assay (ELISA)
2.7.1.3.1 Testosterone
This solid phase technique measured the level of competition between a fixed concentration
ofbiotin-testosterone-testosterone (Sigma, T2168) and sample testosterone. A second
antibody (Donkey-anti-sheep, Binding Site, UK), raised against the sheep IgG, bound with
the testosterone/antibody complex to fix it to the plate. Unbound components were washed
away. The residual amount ofbiotin-labelled testoterone bound to the plate, was detected
using streptavidin-horseradish peroxidase (Amersham, UK) and resulted in a visual colour
change inversely proportional to the sample testosterone concentration. The colourimetric
change was quantified at 450nm by a plate reader (Victor). The colour change was measured
and the test sample values were compared to a standard curve of known antigen
concentrations. Data were expressed as pg testosterone per 100pl media collected. Results
were analysed using a computer programme (AssayZap, BioSoft, Cambridge, UK)
specifically designed for this purpose. For presentation purposes, data were converted to
ng/ml media (= pg/lOOpl x 0.01).
2.7.1.3.2 Inhibin-B
Levels of this dimeric glycoprotein hormone were quantified in using an established in-
house solid phase technique (Sharpe et al., 1999). This sandwich assay relies on two
antibodies, raised against different parts of the inhibin B molecule: the capture antibody
"C5" raised against the N-terminus of the (3B subunit and the F(ab) fraction of the label
antibody "Rl" was raised against the N-terminus of the inhibin a subunit. By using both of
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these antibodies, it is possible to quantify the level of the bioactive inhibin dimer (a-pB)
from the various forms of inhibin in circulation (Meachem et al., 2001).
The capture antibody coated the plate, the sample was added and the labeled antibody added.
The labeled antibody included an Alkaline Phosphatase complex. This caused a visual colour
change inversely proportional to the sample inhibin B concentration when the ELISA
substrate solution (Life Technologies) was added, amplified and developed. The optical
density changes were quantified at 490nm by a plate reader (Victor). The colour change was
measured and the test sample values were compared to a standard curve ofknown antigen
concentrations (recombinant inhibin B).
This is not a particularly precise assay, with a high intra-assay coefficient of variance
(>15%). Method blanks, quality control (QC) samples (spiked buffer), and standards were
analysed along with unknown used media samples. Where samples are presented on one
graph, these were analysed simultaneously. When QC values measured outside 2 standard
deviations from the mean, the assay was rejected. The source of the deviation was
determined and corrected before the analysis was re-run. The inter-assay (8 runs) coefficient
of variance of the three QC samples ± standard errors are listed below (Figure 2.8). The
mean coefficient of variance = 20.6%. The limit of detection for this assay was 99pg/100ul.
Data were expressed as pg inhibin-B per ml media sampled. Results were analysed using a
computer programme (AssayZap, BioSoft, Cambridge, UK) specifically designed for this
purpose. For presentation purposes, data were converted to ng/ml media (= (pg/ml) /1000).
500-
400-
• Low: 99.5 ± 12.1 pg/ml = 32.1%
• Medium: 162.8 ± 9.4 pg/ml = 16.3%












Figure 2.8: Quality control plot for inhibin-B. The scatter plot shows the actual values
obtained and the median per QC.
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2.8 Statistical analysis
Statistical analysis was used to evaluate morphological parameters and hormone
concentrations.
The difference between two means was determined using the unpaired two-tail t-test, with or
without logarithmic transformation of the data to obtain normal distribution.
The difference between more than two means was determined using analysis of variance
(one-way ANOVA). Where more than 4 values were present in a column of data, Bartlett's
test for equal variances was applied and if significant, data were subjected to logarithmic
transformation of the data to obtain normal distribution. The R2 value of a graph, where
reported, reflects the variability of the group means within the variability of the groups,
meaning a high value (close to 1) indicates that a large fraction of the variation seen is due to
the treatments applied to the groups.
Various post ANOVA analyses were undertaken where appropriate. The test for linear trend
assessed whether there was a trend across columns of data arranged in a systematic
sequence. Dunnett's test compared data sets from treated groups against the control data set
within an experiment, but not against each other. Boneferroni's test was used to compare all
possible combinations ofpairs of columns within an experiment except where >5 columns of
data were compared, when the Tukey-Kramer test was applied.
Where appropriate, values were presented as means ± S.E.M. The criterion for significance
for all tests was set at P< 0.05. Specific software was used to assist in the data analysis
(GraphPad Prism v4.0b for Macintosh, GraphPad Software, San Diego, USA).
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3 Studies using long-term exposure of the
fetal rat to DBP
In 2001, Skakkebaek et al described a hypothesis that the four male reproductive disorders,
collectively described as Testicular Dysgenesis Syndrome (TDS) all stemmed from the
disruption of gonadal development during fetal life, (Skakkebaek et al., 2001). It was
theorised that the recent and rapid rise in the incidence of TDS, across few generations and
many countries, was contributed to by the influence of environmental factors, which may
affect change upon genetically predisposed individuals. They went on to propose that as
these disorders all originated during fetal life, exposure to factors such as endocrine
disruptors during this vulnerable window of development must be considered as a potential
contributor to the rise in incidence of TDS. This attractive model might well account for
many of the reported epidemiological findings. The paper went on to emphasise that further
research was needed to explore the risk to humans posed by chemicals with the potential to
inflict disruption on normal development and whether any protection for the reproductive
health of future generations could be outlined.
3.1 Introduction
In order to understand more about this syndrome and investigate the proposed common fetal
source, it became imperative to develop an appropriate animal model. Given that the TDS
hypothesis suggested that exposure to chemicals capable of endocrine disruption could be a
risk factor, it seemed plausible that a known chemical could induce a profile of symptoms in
animals under laboratory conditions akin to TDS in man.
Various chemicals are known to affect male fertility. The profile of their effects on male
reproduction is specific to the mechanism of toxicity induced by each compound. Chemicals
can be categorised according to the profile of effects that they cause (Gray et al., 1999). By
reviewing the toxicity profiles of known testicular toxicants, it was possible that a candidate
to induce TDS would become apparent.
3.1.1 Phthalates
One class of compounds known to affect the male reproductive tract is the phthalates. These
anthropogenic chemicals are widely used, such as in the plastics industry to broaden the
function of the rigid plastic poly vinyl chloride (PVC). Since the 1970's, phthalates have
been investigated for their potential toxicity due to their high level of use (Sharpe, 2001).
There are many different phthalates with slightly different chemical properties hence their
varied industrial uses and potential toxicity. For example, di-ethylhexyl phthalate (DEHP) is
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a well-known hepatic peroxisome proliferator (peroxisomes are hepatic organelles that
metabolise xenobiotics) and a Sertoli cell toxicant. These properties were revealed through
toxicological assessment using laboratory animals (Dalgaard et ah, 2000; David et ah,
2000a; David et ah, 2000b; Mann et ah, 1985; Oishi, 1986).
The majority of toxicology studies were carried out in young/ adult rodents with DEHP
administered via the food, as DEHP absorbed through the gut and dietary administration
represents the most widespread exposure risk for humans (David et ah, 2000a; Kanda et ah,
1990)(Kanda et ah, 1990). All organs were examined for histopathology after 104 weeks of
exposure to DEHP at up to 6000ppm (mice) or 12500ppm (rats). Liver tumours were
observed at DEHP exposure levels >500ppm and peroxisome proliferation was evident in
mice exposed to lOOppm but not in rats below 500ppm. Bilateral aspermatogenesis was
observed in the testes of rats exposed to >500ppm and hypospermia in the 6000ppm exposed
mice (David et ah, 2000b). Uterine weights in the 6000ppm exposed female mice group
were significantly lower than for the controls (David et ah, 2000a). These studies confirmed
that chronic DEHP exposure did adversely effect the liver and testis pathology of rodents
exposed to >500ppm, but did not reproduce the syndrome of disorders comprising TDS. The
exposure timeframe and/or the chemical would have to be reconsidered.
Reports of chronic exposure of rodents to different phthalates were reviewed. For example,
Di-(C7-C9 alkyl) phthalate (D79P) is used as a plasticiser for PVC in flooring and fabric-
coating and Di-(CcrCii alkyl) phthalate (D91 IP) is used as a plasticiser for PVC in roofing
and automotive applications. Continuous chronic exposure of rats to 2.0% D79P or D91 IP
via the diet, across two generations, did not impair reproductive function of the F0 or the F]
offspring, even at levels that induced systemic toxicity and peroxisome proliferation typical
of this class of chemicals (Willoughby et ah, 2000). This was not consistent with the TDS
phenotype either.
Further studies with DEHP changed the timeframe of exposure and the dosing route.
Sprague-Dawley rat dams were dosed by gavage with corn oil or with up to 1,500 mg
DEHP/kg/day from e3 through to postnatal day (d) 21. Dose-related effects on the F] male
offspring included a high incidence of anterior prostate agenesis, a lower incidence ofpartial
or complete ventral prostate agenesis, occasional dorsolateral prostate and seminal vesicle
agenesis, reduced sperm counts, and testicular, epididymal, and penile malformations
(Moore et ah, 2001). This profile of effects was more consistent with the TDS hypothesis,
including the exposure during perinatal development. However, the prevalence of anterior
prostate agenesis following in utero and lactational DEHP exposure appears to be unique
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among all chemicals but is inconsistent with the malformations of the male reproductive
tract associated with the TDS phenotype (Moore et al., 2001).
The alterations in the development of the reproductive tract of male rats exposed to DEHP in
utero and during suckling were deduced to be associated with disruption of fetal testis
testosterone production (Parks et al., 2000). This was consistent with the proposed TDS
hypothesis of disrupted gonadal development during fetal life (Skakkebaek et al., 2001). The
DEHP studies reported by Parks et al (2000) were followed up with a comparison of
perinatal exposure of male rats between six different phthalate esters. Of these, only three
adversely affected sexual development (DEHP, BBP and DINP) but three (DOTP, DEP and
DMP) did not induce any changes at 750mg/kg/day from el4.5 to postnatal day 3 (Gray et
al., 2000). These data confirmed that the chemical structure of the phthalates affected their
potency and only those monoesters with an ester group 4-6 carbons long are developmental
toxicants (Gray et al., 2000).
3.1.2 Di-n-butyl phthalate
One such phthalate is Di-n-butyl phthalate (DBP, -CH2(CH2)2CH3). DBP was found to be the
most common phthalate ester with reprotoxic potential, that was measured in the urine of
American women of child bearing age (Blount et al., 2000). DBP is used as a plasticiser in
PVC products as well as a solvent in some personal care products (Foster et al., 2001). DBP
causes a variety of alterations of normal fetal development, depending on the dose and
window of exposure. For instance, pregnant rats given DBP by gavage at either 750, 1000 or
1500 mg/kg/day during early gestation (up to el5) (Ema et al., 1994) presented fetuses with
a range of terata:
• 100% post-implantation loss in the 1500 mg/kg/day dose group
• increased vertebral column malformations with 750 or lOOOmg DBP/kg/day on e7-9
• dose-dependent increased external and internal malformations such as cleft palate/
fusion of the sternebrae with 750 or lOOOmg DBP/kg/day on el 3-15
Exposure to DBP (400-650 mg/kg/day) in rodent and non-rodent species, during late
gestation, has resulted in a variety of organogenesis related malformations that persisted into
adulthood, just like TDS. In the parental generation, effects on reproduction were modest
(small decreases in litter size and pup weight following treatment) as seen with chronic
DEHP exposure. However, the Fi male offspring had marked decreases in fertility (at 650
mg/kg/day), with reduced sperm counts and reproductive tract malformations observed in
adulthood (Foster et al., 2000).
Multiple studies have investigated the effect of high levels ofDBP exposure in utero on the
development of the male reproductive tract (Foster et al., 2000; Foster et al., 2001; Marsman,
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1995; Mylchreest et al., 1998; Mylchreest and Foster, 2000; Mylchreest et al., 1999;
Mylchreest et ah, 2002; Mylchreest et ah, 2000). The gross changes in the pathology of the
male reproductive tract induced by this treatment regime included:
• testicular atrophy
• decline in number of ejaculated sperm / increased number of abnormal sperm
• cryptorchidism
• hypospadias
• aplastic or absent epididymides
• reduced anogenital distance
This range of specific male and reproductive tract abnormalities seen in rodents following
high-level DBP exposure during gonadal development, shares many parallels with human
TDS. This encouraged further exploration of this compound to generate a model system to
investigate the mechanisms that underlie TDS.
3.1.3 Experimental aims
However, at the time these studies were conceived, the specific histopathological changes
induced in the rat testis by in utero DBP exposure compared with those associated with
human testicular dysgenesis had not been reported. The aim of the present studies was to
investigate the effect on the testis of in utero exposure to 500mgDBP/kg/day over el 3-20 in
the fetal rat at e21.5 and 500mgDBP/kg/day over el3-21 in the adult male rat and compare
any findings with the reported TDS phenotype.
3.2 Methods and Materials
Further details on the general methods and materials used are listed in Chapter 2. Overall,
time-mated rats were dosed with 500mgDBP/kg/day at lml/kg from el3.5 until e20.5
followed by necropsy on e21.5 or until e21.5 followed by necropsy of the adult Fi males.
Following collection of the tissue, samples were assayed for testosterone and inhibin-B
levels or analysed for histological changes, with comparisons made between DBP exposed
samples and the relevant vehicle exposed controls.
3.2.1 Statistical analysis
The significance of any difference between two values was determined by an un-paired two-
tailed t-test, with or without logarithmic transformation of the data to obtain a normal
distribution. Where Bartlett's test showed significant differences in the variances between
the two data sets, even after log transformation, data were re-analysed using Welch's
correction.
The criterion for significance for all tests was set at P<0.05 and n = number of testes
examined, taken from at least 3 litters, unless otherwise stated.
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3.3 Results
The aim of these studies was to investigate the effects of in utero DBP exposure on the
developing testis of the rat. Fetal rats were exposed in utero to 500mgDBP/kg maternal
bodyweight from el3.5 until the day prior to necropsy (e20.5) or the end of gestation
(e21.5). Testes were collected for study on e21.5 or >d90 (adult) and compared with those
recovered from age matched animals, dosed to the same regime but with the vehicle
(Controls). Typically, the left testes were weighed, Bouin's fixed, paraffin embedded,
sectioned and immunostained as required: the right testes were snap frozen until processed
for protein or steroid level investigations. At e21.5, each major testis cell type was observed
and analysed separately: Sertoli cells, gonocytes and Leydig cells. The peritubular myoid
cells, that surround the developing testis cords, showed no obvious treatment related changes
at low magnification reviews, so were not more closely investigated. The consequences of
the changes observed in the fetal testes were followed up in adulthood.
3.3.1 Effect of fetal exposure to DBP on e21.5 testes
Testis weight was recorded in e21.5 rats and the mean testis weight per litter per treatment
regime was calculated. DBP exposure induced a significant decrease in testis weight
compared to control animals (Figure 3.1). The reason for this decrease in weight was



















Figure 3.1: Mean testis weight per litter (mg) of e21.5 fetal rat testes after el3.5-20.5
in utero exposure to vehicle or DBP. Individual mean per litter (n) and mean per treatment
(horizontal line) are plotted (n values are shown in parentheses). The DBP treated group
showed a significant (P=0.048) decrease in testis weight compared to the control testes.
3.3.1.1 Sertoli cells
It has been shown that the number of Sertoli cells determines the capacity of the testis to
produce sperm (Orth, 1982; Orth, 1984). The effect ofDBP exposure on the number of
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Sertoli cells per testis was quantified using established stereological techniques, detailed in
Chapter 2. Prior to analysis, testis sections were immunostained for WT-1, a protein found in
Sertoli cell nuclei (Figure 3.2). Low magnification review of the stained sections showed
WT-1 cells at the periphery of the testis cords for both treatment groups. Higher
magnification review of the sections showed normal WT-1 negative areas between the
developing cords in control and treated animals whereas the testes from DBP-exposed
animals showed areas of interstitial cells, some of which were WT-1 positive (Figure 3.2).
This abnormal staining pattern, suggestive of interstitial Sertoli cells, could not be explained
as a plane of section or non-specific staining artefact. This area was described as dysgenetic
and its relevance was followed up in adult animals (Figure 3.26). Cells that were WT-1
immunopositive within the dysgenetic areas or outside a cord were discounted as these cells
were unlikely to be capable of supporting germ cells so could not contribute to fertility in
adulthood (Figure 3.2).
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Figure 3.2: WT-1 immunostained sections of e21.5 fetal rat testes after el3.5-20.5 in
utero exposure to vehicle or DBP. Note the positioning of stained Sertoli cell nuclei, at the
periphery of the developing cords. Additional staining was seen within abnormal
"dysgenetic" interstitial areas of the DBP exposed testis (dashed outline). The top panels
were photographed using a xlO objective and a smaller area (solid rectangle) using a x40
objective.
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Stereological analysis showed no significant effect ofDBP on the mean nuclear volume of
the Sertoli cells (Figure 3.3) but a slight decrease in the percentage of the testis occupied by
Sertoli cells from a mean of 16.6% to 13.9% (Figure 3.4). These results suggested that
though Sertoli cell nuclei was unaffected by DBP exposure, treatment may have slightly
reduced their number. However, when these data were used to calculate the number of
Sertoli cells per testis, there was no significant difference (P=0.07) between the treatment
groups seen, though the data suggested a trend towards a decrease in the number of Sertoli
cells per testis following DBP exposure (Figure 3.5).
100 P=0.36
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Figure 3.3: Mean nuclear volume of Sertoli cells in e21.5 fetal rat testes after el3.5-
20.5 in utero exposure to vehicle or DBP. Values are means ± S.E.M. (n values are shown in




Figure 3.4: Percentage volume occupancy of Sertoli cells in e21.5 fetal rat testes after
el3.5-20.5 in utero exposure to vehicle or DBP. Values are means ± S.E.M. (n values are
shown in parentheses). The DBP treated group showed a significant (P=0.047) decrease in
the percentage occupancy of the testis by Sertoli cells, compared to the control testes.













Figure 3.5: Number of Sertoli cells in e21.5 fetal rat testes after el3.5-20.5 in utero
exposure to vehicle or DBP. Values are means ± S.E.M. (n values are shown in parentheses).
The non-significant effect of DBP on Sertoli cell number was followed up by investigation
of the rate at which the Sertoli cells were undergoing mitosis. The effect of in utero DBP
exposure on the rate of Sertoli cell proliferation was measured by immunostaining Bouins
fixed testis sections for incorporation of the BrdU, injected into the mother 1,5h prior to kill.
The Sertoli cell proliferation index was calculated from three pups per litter (n) (Figure 3.7).
Proliferation was also evident in non-Sertoli cells (e.g. interstitial cells, Figure 3.6) and
dysgenetic areas but this was not measured. No BrdU uptake was seen in any gonocytes.
There was no significant difference in the proliferation index for Sertoli cells in the DBP
exposed testes when compared to their respective controls (P=0.30) (Figure 3.7).
Immunostaining of Sertoli cells for markers of apoptosis (TUNEL) showed no staining (not
shown).
Finally, there was no significant effect of treatment on the testicular level of inhibin-B, a
hormone produced by the Sertoli cells (Figure 3.8).















/ r * ■ ; ' . % i,
\ # ' f' I ♦ ♦ •*
'./ i •
. , • 4 *
-• * d r ' * |
' f . * *' V
s »
* " i.x .
CS" ' • .; •» '
V #
- *. f*:: i- -• • * 77
-- *4*;'
> l&
»• *) ' * »





#/ •>•:,: / I
'





























Figure 3.6: BrdU immunostained sections of e21.5 fetal rat testes after el3.5-20.5 in
utero exposure to vehicle or DBP. BrdU was administered 1.5h prior to testis collection. It
was incorporated by the intratubular Sertoli cells (wide arrows). Interstitial cells were also
proliferating at this age (narrow arrows) but gonocytes appeared quiescent (asterix). The top
















Figure 3.7: Proliferation Index (%) of Sertoli cells in e21.5 fetal rat testes after el3.5-
2.0.5 in utero exposure to vehicle or DBP. Values are means ± S.E.M. (n values are shown in
parentheses). There was no significant effect of DBP treatment.





Figure 3.8: Testicular inhibin-B levels in e21.5 fetal rat testes after el3.5-e20.5 in
utero exposure to vehicle (control) or DBP. Values are means ± S.E.M. (n values are shown
in parentheses). The inhibin-B levels in treated testes were not significantly different from
control testes (P=0.17).
3.3.1.2 Gonocytes
Testis sections were immunostained for AMH, a protein expressed in the Sertoli cell
cytoplasm that surrounds the fetal gonocytes. Low magnification reviews of the AMH
staining demonstrated that the number of cords present per testis after DBP exposure was
reduced (Figure 3.9). This difference was quantified and revealed a significant reduction in
the number of cords per section following DBP exposure, compared to the control sections
(Figure 3.10). The effect of treatment on mean cord diameter was not quantified. Whether
this reduction was the result of fewer cords or reduced coiling of the same number of cords
could not be deduced by these studies (Figures 3.9 and 3.10). It should be noted that the
testes exposed to DBP were significantly smaller than the control testes (Figure 3.1) and that
the plane of section analysed per sample and per treatment were comparable.
Further review of the sections showed normal AMH negative areas between the developing
cords in control and treated sections. Treated sections also showed areas between cords with
AMH positive cells (Figure 3.9, inset). This observation was consistent with the WT-1
positive cells seen previously (Figure 3.2) in dysgenetic areas, supporting the suggestion that
some of these cells are not normal interstitial cells but abnormally situated Sertoli cells.
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Figure 3.9: AMH immunostained sections of e21.5 fetal rat testes after el3.5-e20.5 in
utero exposure to vehicle or DBP. The treated section shows a reduced number of distended
cords with gonocytes abnormally clustered in their centre. The inset shows AMH positive





Figure 3.10: Number of seminiferous cords per cross section of e21.5 fetal rat testes ±
in utero exposure to DBP. Values are means ± S.E.M. (n values are shown in parentheses).
The DBP treated group showed a significant (P=0.015) decrease in the number of
seminiferous cords per testis cross section compared to the control testes.
Examination ofAMH stained testis sections at higher magnification revealed the presence of
abnormally nucleated gonocytes in testes from DBP exposed tissue (Figure 3.11). Normal
e21.5 testes contain mononucleated gonocytes, with rare and infrequent multinucleated
gonocytes (Boulogne et al., 1999). The effect ofDBP exposure on the frequency of
multinucleated gonocytes was quantified using established stereological techniques, detailed
in Chapter 2. The percentage of cords per testis that contained at least one abnormal
multinucleated gonocyte (MNG) was calculated. A few MNG's were seen in the control
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testes (mean = 1.4%) but this increased significantly (P=0.0004) to a mean of 37% after
exposure to 500mgDBP/kg/day (Figure 3.12).
Immunostaining of gonocytes for markers ofproliferation (BrdU uptake, see Figure 3.6) and
apoptosis (TUNEL, see Figure 2.1) showed no gonocyte staining, indicating that the
abnormal gonocytes were quiescent, as per normal for this developmental stage (Boulogne et
al., 1999). Further studies showed that the abnormal gonocytes appeared between el8.5-
el9.5 but had disappeared by postnatal dlO.
Figure 3.11 AMH immunostained sections of e21.5 fetal rat testes after el3.5-e20.5 in
utero exposure to vehicle or DBP. The Control sections show normal mononucleated
gonocytes dispersed evenly across the cords (top left panel) compared to the distended cords
in the DBP-exposed testis (top right panel). Examples of typical multinucleated gonocytes
are highlighted in the bottom DBP-exposed testis (red circles) and remaining mononucleated
gonocytes (green circle). The top panels were photographed using a x40 objective and the
bottom panels were photographed using a xlOO objective.























Figure 3.12: Incidence (%) of multinucleated gonocytes in e21.5 fetal rat testes after
el3.5-e20.5 in utero exposure to vehicle or DBP. Values are means ± S.E.M. (n values are
shown in parentheses). The DBP treated group showed a highly significant (P=0.0004)
increase in the incidence ofmultinucleated gonocytes compared to the control testes.
3.3.1.3 Leydig cells
Clusters of Leydig cells between the developing testicular cords were defined using
immunostaining for 3|3-HSD, a steroidogenic enzyme present in Leydig cell cytoplasm
(Figure 3.13). Low magnification reviews of the 3(3-HSD stained testis sections highlighted
that the distribution ofLeydig cells after DBP exposure was altered (Figure 3.13).
Normal vehicle treated fetal testes, aged e21.5, contain small clusters of Leydig cells,
disseminated evenly throughout the testis. Normally, each cluster occupies <5% of the total
Leydig cell area per testis section, resulting in >20 clusters per section. Occasionally, control
Leydig cell clusters occupy between 5-15% of the total Leydig cell area per section but
clusters >15% were rarely seen in testis sections from control animals. Clusters were
categorised by these percentage areas, defined as either small (<5%), medium (5-15%) or
large (>15%) (Figure 3.14). The effect of DBP exposure on the distribution of Leydig cell
clusters was quantified using computer assisted stereological techniques, detailed in Chapter
2.
Statistical analysis of the data generated showed a significant decrease in the percentage area
of the testis occupied by small and medium sized Leydig cell clusters in DBP-exposed testis
compared to control testes. The increase in the percentage area occupied by large Leydig cell
clusters in DBP-exposed testis was not significant but continued the significant trend away
from small clusters. The relevance of this altered distribution pattern was further investigated
by comparing steroidogenic output (testosterone content) of control and DBP-exposed testis.
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Figure 3.13: 3(3-HSD immunostained sections of e21.5 fetal rat testes after el3.5-e20.5
in utero exposure to vehicle (control) or DBP. Note the altered Leydig cell clusters after
DBP-exposure, compared to the control image. Examples of each cluster category are
circled: small (orange), medium (blue) and large (red). A possible region of dysgenesis in a
large cluster is highlighted (dashed yellow circle). The top panels were photographed using a
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Figure 3.14: Frequency of each category of 3(3-HSD immunopositive cluster in e21.5
fetal rat testes after el3.5-e20.5 in utero exposure to vehicle (control) or DBP. Values are
means ± S.E.M. Data were log transformed prior to statistical analysis.
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It was noted that there were Focal areas within large Leydig cell clusters that were not
positive for 3(3-HSD staining (Figure 3.13, bottom right panel), suggesting an area of
dysgenesis where non-steroidogenic cells were enveloped, such as Sertoli cells, as was seen
with the WT-1 and AMH staining (Figures 3.2 and 3.9). Immunostaining of additional
sections for the androgen receptor (AR) protein, which was located in the nuclear membrane
of interstitial Leydig cells and peritubularmyoid cells, confirmed that most cells in the
dysgenetic areas were expressing proteins like normal Leydig cells (Figure 3.15). It is noted
that there appears to be a difference in the intensity of the staining between the cell types
with the peritubular myoid cells more intensely stained than the Leydig cells. Though the
relevance of this difference was not investigated further, it is likely to reflect a difference in
the concentration ofAR in the membranes.
Figure 3.15: AR immunostained section of an c21.5 fetal rat testis after el3.5-e20.5 in
utero exposure to DBP. Shows an area of normal cord formation next to a possible region of
dysgenesis (dashed outline), with a blood vessel (bv) between. Photographed using a x40
objective.
Further staining for the structural protein smoothmuscle actin (SMA), unique in the testis
cords to the peritubular myoid cells, showed that SMA-immunopositive cells were not
widely present in the dysgenetic areas (Figure 3.16).
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Figure 3.16: SMA immunostained sections of e21.5 fetal rat testes after el3.5-e20.5 in
utero exposure to vehicle (control) or DBP. Note the abnormal interstitial areas in the treated
testis, unstained by SMA (dashed circles). The absence of the distinctive pattern of blood
vessels (arrows) circling the perimeter of the treated testis is probably an artefact of
sectioning and not of DBP treatment. The irregular cords at the top of the pictures illustrate
the developing rete testis region. Photographed using a xlO objective.
The testosterone levels of whole testes per treatment were quantified using a radio¬
immunoassay (RIA), according to the method detailed in Chapter 2. DBP exposure induced
a significant decrease (P=0.047) in testis testosterone levels (Figure 3.17) compared to
control testes. The consequences of reduced testosterone levels could be far reaching, given
the critical role of testosterone in masculinisation and development of secondary sexual




Figure 3.17: Testicular testosterone levels in e21.5 fetal rat testes after el3.5-e20.5 in
utero exposure to vehicle (control) or DBP. Values are means ± S.E.M. (n values are shown
in parentheses). Treated testes had significantly reduced testosterone levels compared to
control testes (P=0.047).
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The DBP-induced decrease in testosterone levels (Figure 3.17) was further investigated by
comparing expression levels of steroidogenic enzymes in treated and untreated testes.
Immunostaining for the enzyme 3(3-HSD, followed by visual inspection of the sections using
light microscopy, had shown no obvious difference in expression levels associated with DBP
exposure (Figure 3.13), so alternative steroidogenic targets were considered. The availability
of cholesterol to the first enzyme in the steroidogenic cascade (P450scc) limits the rate of the
conversion of cholesterol to pregnenolone and hence the rate of steroidogenesis
(DiBartolomeis et al., 1987). The expression level ofP450scc protein per treatment was
compared with the level of another protein, one that was independent of the steroidogenic
cascade, a cytoskeletal protein: Smooth muscle actin (SMA). Expression levels of P450scc
and SMA were measured and compared per treatment following Western Blot analysis of
extracts of total testis protein (Figure 3.18).
DBP treatment showed a highly significant (P=0.0014) decrease in the level of P450scc
expression relative to SMA expression when compared to untreated testes (Figure 3.19).
This study demonstrated that the rate-limiting step of steroidogenesis was compromised by
DBP exposure, suggesting it was a significant target ofDBP toxicity in the steroidogenic
cascade.
Figure 3.18: Photograph of a Western blot showing the level of P450scc expression
relative to SMA expression in e21.5 fetal rat testes after el3.5-e20.5 in utero exposure to
vehicle (control) or DBP. It is noted that the antibody was very "clean" with no non-specific
bands seen on the blot.
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Control 500mg DBP/kg
In utero treatment
Figure 3.19: The relative amount of P450scc protein expressed by Western blot
analysis in e21.5 fetal rat testes after el3.5-e20.5 in utero exposure to vehicle (control) or
DBP was plotted, assuming expression of SMA was 100%. Values are means ± S.E.M. (n
values are shown in parentheses). The decrease in P450scc expression seen in the DBP
treated group was highly significant (P=0.0014).
An additional experiment compared the distribution of P450scc expression against 3|3-HSD
distribution. This investigated whether P450scc expression levels did vary across the testis or
whether any variations were localised. This experiment was facilitated by the use of
fluorescent co-localisation of immunostaining of P450scc and 3(3-HSD protein expression in
Bouin's fixed testis sections. The appearance of co-localisation in the DBP-exposed testis
was compared against the vehicle control testis (Figure 3.20). There was no obvious
treatment related change in the distribution of the two proteins. If there was a difference, this
was proposed to be evident as a shift from away from green (P450scc), reducing the amount
of yellow (co-localisation) and increasing the amount of red (3(3-HSD) staining seen. The
sections appeared to show little localisation with each cell expressing either of the two
proteins but not both, in a treatment independent fashion. Expression levels were not
quantified but qualitative assessment suggested that P450scc expression levels were varied
across control and treated clusters (Figure 3.20). This suggested that the reduction in
P450scc expression seen with the Western blot analysis (Figure 3.18) was not localised but
was more likely to be evenly distributed across the DBP-treated Leydig cells.
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Figure 3.20: Confocal analysis of immunostained sections of e21.5 fetal rat testes after
el3.5-e20.5 in ntero exposure to vehicle (control) or DBP. Sections were immunostained for
3(3-HSD (red) and P450scc (green) with co-localisation seen as yellow. Blue = nuclear
counterstain. There was no obvious effect of treatment on the co-localisation of the two
proteins. The altered Leydig cell distribution with DBP treatment is evidenced in the right
hand panel by the reduced number but larger size of Leydig cell clusters. Tiled images (7x7),
each tile captured using a x40 objective.
Overall, the histology ofall three of the major cell types in the fetal testis was affected at
e21.5 after el3.5-e20.5 in utero exposure to 500mg DBP/kg. The long-term consequences of
the DBP induced changes seen at e21.5, were followed up by observing adults rats,
following el3.5-e21.5 in ntero exposure to 500mg DBP/kg.
3.3.2 Effect of fetal exposure to DBP on the adult
testis
The previous studies investigated the effect of 500mg DBP/kg in utero exposure on the fetal
testis at e21.5. To follow-up the changes induced by DBP on fetal testis development,
fecundity, testis descent and plasma hormone levels were compared in adult animals, left to
mature under control conditions to at least 90 days of age, after in utero exposure to DBP or
the vehicle control. It may have been interesting to generate untreated animals with
cryptorchidism but this was not possible under the project license or with in-house surgical
skill base available.
Adult testis weights were measured and their position recorded at necropsy, prior to fixation.
The mean weight of testes in adult animals exposed in utero to 500mg DBP/kg was
significantly reduced compared to age matched vehicle control animals (Figure 3.21, panel
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A). However, when the data was re-analysed after accounting for testis position (Table 3.1),
there was no significant difference in mean testis weight of scrotal testes ± DBP treatment,
but an increase in the significance between the Control (scrotal) testes and the DBP-treated








Figure 3.21: Adult testis weight per rat after el3.5-e21.5 in utero exposure to vehicle
(control) or DBP. Values are means ± S.E.M. (n values are shown in parentheses). The DBP
exposed group showed a significant (P=0.004) decrease in adult testis weight when all data
was compared to the testes from control animals (panel A). There was no significant
difference in mean weight of scrotal testes ± DBP exposure, but a highly significant
difference in the mean weights of DBP exposed cryptorchid testes (PO.OOOl) (panel B)
compared to Control testes.
Six animals from each treatment group were paired with an untreated but proven female,
until a positive sign ofmating (plug) was detected. All of the control animals sired a litter of
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Table 3.1: Summary of testis position and fecundity in adult male rats (>90d) after in
utero exposure to vehicle control or 500mg DBP/kg over el3.5-e21.5. Testis position was
recorded at necropsy.




Figure 3.22: Fecundity of adult male rats after el3.5-e21.5 in utero exposure to vehicle
(control) or DBP. Control value shows mean ± S.E.M. and DBP values show mean ± range
(n values are shown in parentheses). The DBP exposed animals were sub-divided by testis
position: scrotal (normal), unilaterally cryptorchid (UCD) or bilaterally cryptorchid (BCD).
All DBP exposed animals sired less pups than the control animals, regardless of testis
position.
The level of two hormones was measured in plasma collected at necropsy. Inhibin-B and
testosterone were quantified using methods described previously in Chapter 2. The level of
inhibin-B was significantly reduced in the plasma of all DBP exposed animals, but was
further reduced in bilaterally cryptorchid animals compared to those with scrotal testes or
unilateral cryptorchidism (Figure 3.23). The reduced inhibin-B level in the treated animals
was paralleled by reduced fecundity (Figure 3.22). There appeared to be an inhibin-B cut-off
point, around 120ng/ml, below which the males were infertile, regardless of their testis
position. This data showed 1/6 animals exposed to DBP did have a plasma inhibin-B level
and litter size within the control range, albeit at the lowest end. There was no significant
effect of in utero DBP treatment on adult plasma testosterone levels (Figure 3.25) and no
correlation between testosterone levels and fecundity (Figure 3.26).
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Figure 3.23: Adult rat plasma inhibin-B levels after el3.5-e21.5 in utero exposure to
vehicle (control) or DBP. Values are means ± S.E.M. unless n=2 when values show mean ±
range (n values are shown in parentheses). In panel A, the DBP exposed group showed a
significant (PO.OOOl) decrease in inhibin-B level compared to the testes from animals
exposed to vehicle only. When the DBP exposed animals were sub-divided by testis
position: scrotal (normal), unilaterally cryptorchid (UCD) or bilaterally cryptorchid (BCD),
all treated animals showed a decrease in their inhibin-B level, with the most dramatic
reduction in BCD animals.
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Figure 3.24: Scatter plot comparing plasma inhibin-B levels with number of pups sired
by adult rats after long-term in utero exposure to control vehicle or DBP. Individual data are
presented (n = 6 for both groups). The DBP exposed group showed lower inhibin-B levels
and fewer pups sired, if any, compared to the vehicle-exposed adults.
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Figure 3.25: Adult rat plasma testosterone levels after el3.5-e21.5 in utero exposure to
vehicle (control) or DBP. Values are means ± S.E.M. unless n=2 when values show mean ±
range (n values are shown in parentheses). In panel A, the DBP exposed group showed a
non- significant decrease in testosterone level compared to animals exposed to vehicle only.
When the DBP exposed animals were sub-divided by testis position: scrotal (normal),
unilaterally cryptorchid (UCD) or bilaterally cryptorchid (BCD), all treated animals showed






















Plasma testosterone level (ng/ml)
3.0 3.5
Figure 3.26: Scatter plot comparing plasma testosterone levels with number of pups
sired by adult rats after long-term in utero exposure to control vehicle or DBP. Individual
data is presented (n = 6 for both groups). The DBP-exposed animals were sub-divided by
testis position: scrotal (normal), unilaterally cryptorchid (UCD) or bilaterally cryptorchid
(BCD). The treated rats showed similar testosterone levels but fewer pups sired compared to
the controls.
Low magnification review of SMA stained sections of adult testis showed abnormal staining
patterns in scrotal and cryptorchid testes from DBP-exposed animals (Figure 3.27). These
focal areas of tubule malformation were consistent with the dysgenetic areas seen in the
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e21.5 testis sections (Figures 3.2, 3.9 and 3.13). Normal spermatogenesis was not apparent in
these regions, contributing to the reduced fertility of testes exposed in utero to 500mg
DBP/kg. Finally, the penile shafts of the adult animals were examined for hypospadias. This
was never seen in untreated animals and mild ifpresent at all in treated animals.
Figure 3.27: SMA immunostained sections of adult rat testes after el3.5-e21.5 in utero
exposure to vehicle (control) or DBP. Panel A shows normal seminiferous tubules with
complete spermatogenesis in a control testis, with SMA immunostained peritubular cells and
blood vessel walls (inset). The DBP exposed animals were sub-divided by testis position:
scrotal (Panel B) or cryptorchid (Panel C). Panel B shows normal seminiferous tubules with
complete spermatogenesis surrounding an area of dysgenesis with malformed tubules
(dashed outline) in a scrotal testis compared to Panel C, which shows an area of dysgenesis
in a cryptorchid testis. Photographed using a xlO objective.
3.4 Discussion
These studies were conceived to investigate whether exposing male rats to the synthetic
compound DBP whilst in utero, would induce the array of changes in their testis
development akin to the hypothesised human condition Testicular Dysgenesis Syndrome
(TDS) (Skakkebaek et al., 2001). The successful development of an animal model for this
syndrome would provide scientists with a means to procure a better understanding of the
fetal origins and adult onset of the conditions. To this end, the gross histology of the rat testis
and its major cell types were compared between rat pups at e21.5 after exposure to
500mgDBP/kg/ day over el3.5-e20.5 or adult rats at >90d after exposure to 500mgDBP/kg/
day over el3.5-e21.5 with their respective vehicle exposed controls.
In TDS, the most common finding is reduced sperm count in adulthood, with up to 30% of
young Danish men affected (Jensen et al., 2002). It is well known that a decrease in sperm
numbers in adults can result from a reduction in Sertoli cell numbers (Orth, 1982; Orth,
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1984). In the present studies neither inhibin-B production nor the Sertoli cell size, number or
rates of proliferation and apoptosis in rat testes at e21.5 were affected by in utero exposure to
DBP but there was a decrease in the volume of the testis occupied by Sertoli cells (P=0.047).
This suggests that though the proliferation index (%) was not significantly affected by
treatment with DBP in the present studies, the fall from a PI% of 35.9% to in the control
animals to 29.5% in treated testes, did suggest a trend towards a slight decrease in Sertoli
cell proliferation following DBP exposure. Considering that any reduction in Sertoli cell
numbers due to decreased proliferation prior to puberty can result in a decreased testis
weight, reduced sperm numbers and reduced fertility in adults, this observation was followed
up in adult rats following in utero DBP exposure (Orth, 1982; Orth, 1984). The effect of this
treatment regime on the number of Sertoli cells in the adult testis is under investigation by
other members of this research group.
The level of inhibin-B, a Sertoli cell product, was significantly reduced in the plasma of all
DBP exposed animals, regardless of testis position. Inhibin-B is used clinically as a marker
of spermatogenesis (Anderson and Sharpe, 2000). It is affected by testis position as seen by
the analysis of human plasma for inhibin-B from a group ofmen with scrotal testes who had
a significantly (P<0.01) higher median level of inhibin-B (144ng/l) than did cryptorchid
patients (98ng/l) (de Gouveia Brazao et al., 2003). In the present studies, two thirds of the
DBP exposed rats had cryptorchid testes at necropsy. The level of plasma inhibin-B was
further reduced in bilaterally cryptorchid animals compared to those affected unilaterally.
There was an inhibin-B cut-offpoint (around 120ng/ml serum) below which the males were
infertile, regardless of their testis position and all adult rats exposed to DBP in utero showed
a dramatic decrease in their fecundity as seen by the lower number of pups they sired
compared to vehicle-exposed controls.
Additional work carried out in this laboratory further investigated the effect of in utero DBP
exposure on the maturation of the Sertoli cell using immunohistochemistry (Fisher et al.,
2003). Three protein markers were used: Wt-1 as expressed by Sertoli cell nuclei at all ages,
AMH as expressed in immature Sertoli cell cytoplasm and p27kip seen in nuclei of
differentiated Sertoli cells. The results showed that p27kip was notably absent in abnormal
tubules in adulthood such as those without germ cells or adjacent to dysgenetic areas, though
p27kip was present in normal tubules of scrotal testes ofDBP exposed rats at d25 postnatal
and in adulthood.
Together, these data suggest that Sertoli cells can be permanently damaged following in
utero exposure to DBP, consistent with the reduced fertility phenotype of the adult animals
and the low sperm counts of TDS.
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The high incidence of adult cryptorchidism in the DBP-exposed rats of the present studies is
consistent with the significant decrease in testosterone measured in treated testes at e21.5.
Cryptorchidism describes the maldescent of the testis and is a two-phase process, of which
the second, inguino/scrotal, phase is androgen dependent (Ivell and Hartung, 2003). The first
phase involves the development of the gubemaculum and the regression of the cranial
suspensory ligament, pulling the fetal testis down the abdominal cavity ready for
inguino/scrotal descent. In a recent study using the same DBP-exposure regime as the
present studies, DBP exposure suppressed Insl-3 protein expression in fetal Leydig cells but
no effect was seen in testes exposed to the androgen receptor antagonist flutamide,
suggesting that DBP has an androgen independent effect on fetal testis descent (McKinnell
et al., 2005).
Cryptorchidism is associated with abnormalities in other androgen dependent organs such as
hypospadias as androgens are required for the formation of the penile urethra and the
scrotum from the bipotential genital tubercle (Klonisch et al., 2004). Disruption in the levels
of androgens during this phase of development can result in malformation of the penis such
as hypospadias, the malpositioning of the penile urethra. In these studies, the presence of
mild hypospadias was noted in adult rats exposed to DBP in utero.
Together, these data suggest that secondary sexual phenotype including testis position and
penile shaft development can be permanently damaged following in utero exposure to DBP,
producing a phenotype in the adult animals consistent with the cryptorchidism and
hypospadias that form part of the profile of TDS.
Similar experiments to those presented here were carried out by a different laboratory and
using a different strain of rats and are reported by Barlow et al (2004). Time-mated Sprague-
Dawley dams were treated by gavage with 500mg DBP/kg/day from el2-e21 and the male
pups necropsied at 6, 12 or 18 months of age. The gross lesions of the reproductive tract
induced in adult animals exposed to DBP in utero were similar to those described in the
present studies. Additional observations of a decreased anogenital distance (AGD) on
postnatal day 1 (dl) and increased retention of areolae on dl3 were reported as well (Barlow
et al., 2004). Neither AGD nor areolae retention were assessed for the animals in the present
studies as they are not part of the TDS profile of disorders, but their maldevelopment is
indicative of disturbed fetal androgen levels (Mclntyre et al., 2001). The present studies
extended the observations of gross malformations of the reproductive tract induced by in
utero DBP exposure, to include immunohistochemistry studies of the androgen producing
cells of the fetal testis.
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Analysis of the distribution of the Leydig cells, using immunohistochemical staining for the
steroidogenic enzyme 3(3-HSD, indicated that in utero DBP exposure significantly altered
the distribution of the Leydig cells within the developing testis at e21.5, inducing the
formation of fewer but larger clusters of Leydig cells. Abnormal aggregation of human
Leydig cells into clusters, termed micronodules, has been reported to be more frequent in
testes with impaired spermatogenesis and thus a histological marker of testicular failure in
man (Holm et al., 2003).
Additional work in this laboratory (M.Walker) showed that there was no significant change
in the actual number of fetal Leydig cells (around 150000 per testis) or their rate of
proliferation at e21.5, associated with DBP exposure. However, the cytoplasmic volume of
the treated Leydig cells was significantly reduced (Mahood et al., 2005). The adverse impact
of this change was reflected in the highly significant decrease in testicular testosterone
measured in DBP exposed testes at e21.5. Considering that steroidogenesis occurs in Leydig
cell mitochondria and cytoplasm, further study was made into the expression levels of
P450scc, the enzyme responsible for the conversion of cholesterol into the androgen
precursor pregnenolone. The highly significant decrease in P450scc expression but lack of
effect on 3|3-HSD expression measured in exposed e21.5 testes suggested a highly selective
mechanism of toxicity was induced by DBP exposure, worthy of further and detailed
investigation.
As well as disrupting the production of hormones by the fetal testis, the DBP exposure
regime described in the present studies also upset the compartmentalisation of the
developing testis, creating areas of dysgenesis. Immunostaining of the peritubular myoid
cells in adult testes following in utero DBP exposure, revealed regions of irregular tubules
with an inappropriate mixture of cell types compared to normal testicular architecture.
Further study into the ontogeny of the formation of these areas, was carried out by other
members of this laboratory. Dysgenetic areas as such were not evident in the fetal testes of
DBP-exposed animals but Sertoli cells and peritubular myoid cells were detected within the
abnormal Leydig cell aggregates (Fisher et al., 2003; Mahood et al., 2005). By d4, these
aggregates appeared to be re-organising into misshapen seminiferous cords that also
contained Leydig cells, relocating them to an intra-tubular position along with germ cells. By
adulthood, tubules with intra-tubular Leydig cells had lost their germ cell complement. Not
all tubules without germ cells had obvious intra-tubular Leydig cells and these Sertoli cell
only (SCO) tubules were often situated alongside the dysgenetic regions. Focal areas of
dysgenesis were found in adult testes exposed in utero to DBP regardless of whether the
testes were scrotal or cryptorchid, though the scale of abnormality appeared to reflect the
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level of cryptorchidism (Mahood et al., 2005). The development of dysgenetic areas reduces
the capacity of the adult testis for normal spermatogenesis, and presumably lowers the sperm
count output.
Dysgenetic features, including immature Sertoli cells and multiple SCO tubules as well as
immature or morphologically distorted tubules, have been reported in human testes
contralateral to those with a diagnosed germ cell tumour (Hoei-Hansen et al., 2003).
Additionally, the biopsies revealed the presence of calcium deposits within the seminiferous
epithelium, termed microliths (Skakkebaek et al., 2003). These formations can be detected
non-invasively using ultrasound and have been shown to be an indicator of germ cell cancer
because of their association with carcinoma in situ (CIS) cells (Kim et al., 2003). This
association in the testes of adult rats following in utero DBP exposure cannot be
investigated, due to the absence of CIS cells in rat testes.
CIS cells are believed to originate from fetal germ cells and though are non-invasive in them
selves (they differentiate into invasive cell types), they are associated with the majority of
germ cell tumours, the most common type of testis tumour in man. CIS cells are used as an
indicator of dysgenesis in human adult testes and are even found in up to 9% of biopsies
from testes contralateral to those with a diagnosed germ cell tumour (Hoei-Hansen et al.,
2003). CIS cells in human testes can be detected following immunostaining for PLAP
(Placental alkaline phosphatase) but this antibody does not work in the fetal or adult rat
testis. However, the appearance of abnormal germ cells in fetal rat testes (multinucleated
gonocytes) and the degeneration of the adult seminiferous epithelium into SCOs following in
utero DBP exposure are described in the present studies and reported by others (Barlow et
al., 2004; Fisher et al., 2003; Mahood et al., 2005).
Overall, the aim of these studies was to test whether the profile of abnormalities that make
up the hypothesised Testicular Dysgenesis Syndrome could be reproduced in the male rat
following its in utero exposure to 500mg DBP/kg/day over el3-21. Three of the four gross
disorders of the syndrome were induced in the rat, following the disturbance of fetal testis
development by DBP. This data supports the hypothesis outlined by Skakkebaek et al (2001)
that TDS is the result of disruption of gonadal development during fetal life.
Of the changes reported in the dysgenetic human testis, SCO tubules and immature Sertoli
cells, abnormal Leydig cell aggregation (micronodules) and dysgenetic areas were also seen
in the present rat DBP model. CIS cells and microliths were not observed in the present
animal studies, nor have these findings been reported in adult rat testes by other laboratories
following this treatment regime. However, this regime did induce abnormal fetal germ cells
and areas of germ cell depleted tubules in the adult rat testis. It may be that testis germ cell
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cancer does not have a comparable fetal origin between the rat and the human. This outcome
was not seen as a limitation of the model as it should be noted that low sperm count,
cryptorchidism and hypospadias are all individual risk factors for the development of
testicular cancer and were all induced by this treatment regime (Sharpe, 2001). Therefore it
is believed that detailed characterisation of the mechanisms through which DBP induces its
repertoire of effects are probably of direct relevance to studies of human TDS (Skakkebaek
et al., 2001). By understanding how particular chemicals induce TDS in rats, it might
become possible to identify comparable mechanisms and potential causes in humans.
To this end, novel in vitro experiments were conceived using explants of fetal testes. In vitro
studies would allow time- and dose- controlled exposure to the treatment, applied directly to
the testis and help towards the elucidation of the mechanism behind DBP toxicity. Following
rigorous optimisation of the novel in vitro system, explants were exposed to the DBP
metabolite MBP and the resulting changes in testis architecture and hormone production
were compared. The data generated from explants with fetal rat testes are reported in Chapter
4 and data from explants of fetal human testes are reported in Chapter 5. Further
investigations into the effects on fetal rats testis morphology and steroidogenesis of acute
DBP exposure are described in Chapter 6. An overall discussion of the role of this model in
elucidating the possible environmental causes behind the increasing levels of TDS and
current theories regarding the mechanism of toxicity employed by DBP are described at the
end of this thesis in Chapter 7.
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4 Studies using fetal testis explants from the rat
The previous chapter demonstrated that in utero exposure of the rat fetus to doses of 500mg
DBP/kg/day from embryonic day 13 (el3) induced reproducible phenotypic changes in the
fetal testis. It was therefore investigated which, if any of the changes could be induced in
fetal testes using an in vitro system of exposure. In vitro studies would allow time- and dose-
controlled exposure to the treatment, applied directly to the testis and help towards the
breakdown of the phthalate mechanism of action. The experiments described in this chapter
extend the analysis of the actions ofDBP on fetal testis development seen with the in vivo
model and examine the effect of this treatment during development in vitro.
4.1 Introduction
In these studies, an organotypic culture experimental approach was proposed to assess any
effects of the DBP metabolite MBP, on the in vitro production of hormones and the
development of the testicular somatic and germ cells. This approach provided a unique
method to study testis development while largely maintaining normal structural relationships
amongst the different testicular cell types. To investigate whether MBP might induce similar
affects in the human, parallel studies were carried out using second trimester fetal human
testes collected from legally terminated pregnancies. These experiments are described in
Chapter 5.
At the time when these studies were conceived, the range of published work that described
the effects of DBP on fetal rats, largely examined the adverse effects ofphthalate
administration on fetal rats via maternal exposure. There was little work describing ex vivo
fetal testis exposure to phthalates though this exposure route had been used to investigate
other test compounds and their physiological effects on the growth and development of the
fetal testis in vitro. These studies formed the background to the experiments described in this
Chapter.
4.1.1 The in vitro approach
The very nature of the in vitro approach meant that the developing testes would be removed
from their natural environment and blood supply, in the body cavity. However, studies using
ex vivo aggregates of fetal testis tissue (el 2-20) showed they could re-form into recognisable
testicular tissue after at least 24h in culture (Grand et al., 1986). These observations
supported studies with decapitated fetuses which had no access to pituitary products but
underwent normal testis cord formation (Habert and Picon, 1982). Similarly, transgenic mice
reported by Kendall et al (1996), were devoid of the biologically active forms of the
gonadotrophins LH, FSH and thyroid stimulating hormone (TSH), yet, fetal and neonatal
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development of the genital structures of both sexes was normal. More recently, studies
looking at the ontogeny ofplasma LH levels and steroidogenesis in the rat fetal testis,
confirmed that basal testosterone production rises from el6.5 to a peak between el8.5-el9.5,
though plasma LH levels were almost undetectable until el9.5 but increased significantly
thereafter (El-Gehani et al., 1998). Together these experiments confirm that fetal testis
development and testosterone production in the rodent must occur normally with very low if
any gonadotrophin influence.
Unlike a dispersed cell culture system, the organ culture system preserves testicular
architecture including the many and varied intercellular communications. The organotypic
system has the advantage of not dispersing secreted factors immediately into the media as in
a cell culture system but enables the secreted factors to influence the adjacent testicular cells
to develop as if in vivo (Livera et ah, 2000). This approach has been successfully applied to
experiments investigating the development of fetal testes which would form the basis for this
optimised system (Habert et ah, 1991; Lecerf et ah, 1993; Livera et ah, 2000).
Experiments carried out by Richards et al (1999), highlighted that culture conditions
optimised for one set of cells may not be optimal for another similar set or even the same
cells at a different developmental stage. In their case, murine migratory primordial germ
cells required different conditions than did the older gonadal germ cells (Richards, 1999).
This emphasised the importance of culture condition optimisation.
4.1.2 Endocrine disruptors and DBP in vitro
Studies have shown that even at low levels of exposure, at micromolar (pM) concentrations,
synthetic endocrine disruptor chemicals can induce changes in the architecture of the
developing testis. For example, methoxychlor (an alternative to the banned pesticide DDT) is
biotransformed in the liver to two potent metabolites; of these, HPTE was proposed to be
weakly oestrogenic as it binds to the oestrogen receptor more strongly than does the parent
compound (Akingbemi et al., 2000). HPTE and methoxychlor were assessed in vitro to
investigate their effect on embryonic rat testis cord formation (Cupp and Skinner, 2001).
El 3.5 testes cultured ± the two compounds for 3 days, at doses of up to 20pM, showed
treatment related alterations in the growth and proliferation pattern of the cells within the
developing testis cords. In another study, the in vivo and in vitro oestrogenic activities of
eight phthalate esters were compared (Zacharewski et al., 1998). DBP demonstrated weak
oestrogen receptor mediated activity at high concentrations (lOpM) in vitro but no
significant estrogenic effects were observed in vivo (up to 2000mg/kg). Effects ofDBP on
whole e9.5 rat embryo cultures at dose levels from lpg/ml to lmg/ml, exposed for 48h, were
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reported by Rhee et al (2002). Along with two other phthalates (DEHP and BBP), this short-
term in vitro assay demonstrated that all three phthalates inhibited growth in a dose-
dependent manner. At high concentrations, all three phthalates had an adverse effect on
whole embryo growth and development including induction of severe head abnormalities,
short tails and short limbs. In further tests with limb bud and mid-brain cell cultures, DBP
was found to exhibit the most embryotoxic potential. The authors went on to say that with
phthalates, as with many other chemical classes, the toxicity can vary with chemical
specification (Rhee, 2002).
4.1.3 Experimental Objectives
The aim of these studies was to set up a culture system that allowed normal fetal testis
development to occur autonomously in vitro, and then to investigate whether that normal
development was disrupted with in vitro exposure to DBP. For that purpose, the
development of the testis explants was assessed using 3 main criteria:
• maintenance of tissue architecture and protein expression
• analysis of the somatic cell proliferation rate
• measurement of hormone production ± stimulation/ inhibition
The system would be considered optimised when measurements of the three criteria showed
minimal differences between in vitro cultured explants and the expected development in vivo
over time. Only then would phthalates be introduced as a treatment for comparison. The
three criteria set for optimisation would also be used to compare the endpoints seen in the
testes exposed to DBP in utero with any seen in the explants exposed in vitro.
These studies were designed to investigate the effects of the DBP metabolite MBP on testis
growth and development through evaluation of hormone production and morphology in
cultured fetal rat testis explants. Response to treatment involved comparison of histology and
hormone production in explants cultured in treated media with other explants from the same
incubation experiment cultured in untreated media, using an optimised organotypic culture
system.
4.2 Methods and Materials
Further details on the general methods and materials used are listed in Chapter 2. Overall,
following completion of the incubation, media were stored at -20°C before being assayed for
hormone production and explants were analysed for histological changes.
4.2.1 Explant preparation
Fetal rat testes were collected and explants prepared as detailed in Chapter 2. Testis explants
were cultured on a 0.45pm pore size culture insert with tripod scaffold (Millipore, UK),
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secured in a well of a 24-well tissue culture plate, as previously described (Habert et al.,
1991). Up to six explants were placed carefully on the filter and covered in 0.2ml media. A
further 0.2ml of media were placed between the well and the scaffold. Explants were
incubated at 37°C in an atmosphere of 5% C02 for up to 72h. Media were not changed
during the experiment but collected at the end and stored at -20°C until assayed. At the end
of the culture period, tissue was preserved, either by chemical fixation in Bouin's fixative or
by freezing for storage at -80°C and media were preserved by freezing for storage at -20°C.
4.2.2 Explant culture conditions
4.2.2.1 Optimisation
To establish optimal in vitro culture conditions for the fetal testis explants, various
incubation durations, media, media supplements and developmental ages were investigated.
All incubations were carried out at 37°C, in a humidified atmosphere of 95% air/5% C02.
The culture conditions that enabled the explants to maintain the most in vivo-like
development were used for extended experiments. The starting point for the incubation
media were a comparison of two methods already established in house, though for the




























Table 4.1: Summary of media and supplements used with the three media regimes, used for
in vitro incubation of fetal rat testes. Further details are listed in Chapter 2.
4.2.2.2 In vitro treatments
Following selection of the most optimal culture regime, extended experiments were
performed with various treatments added in vitro. The treatments were mixed with the
culture media prior to addition to the culture well and incubation of the testis explants. The
treatments used, their rationale, preparation and dose levels, are detailed in Chapter 2.
4.2.3 Testis architecture and protein expression
Up to six explants were incubated on a single filter, in a single well. Explants from the same
well were fixed and embedded together in the same paraffin block. Each block was serially
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sectioned (5pm slices), mounted on numbered slides then stained and subjected to analysis
as a single replicate. Explants that were fixed in Bouin's were examined microscopically
after immunohistological processing. Biological markers were used to reveal the explant
morphology. Markers used in these experiments are detailed below.
4.2.3.1 Distribution of peritubular myoid cells
Formation of the seminiferous cord requires peritubular myoid cells (Cupp et al., 2003).
These can be visualised using immunostaining for the cytoskeletal protein Smooth Muscle
Actin (SMA). One slide per block was stained and analysed at low magnification. SMA
distribution between treatments was compared.
4.2.3.2 Quantification of Leydig cell distribution
Three numbered slides per block (at least five serial sections apart) were deparaffinised,
rehydrated and immunostained for 3|3-HSD using a mouse anti-3p-HSD monoclonal
antibody (gift, Professor JI Mason, University of Edinburgh) and lightly counterstained with
haematoxylin, according to the protocol described in Chapter 2. The total area of stained
tissue per slide was measured and the distribution and size of brown clusters
(immunopositive Leydig cells) within the outlined blue (counterstained) area was quantified,
using a light microscope and a x63 objective and computer-assisted image analysis as
described in detail in Chapter 2 and similar to that published (Mahood, et al. 2005). At least
four blocks per treatment were analysed.
4.2.3.3 Quantification of multinucleated gonocytes
One slide per block, the same numbered section per block, was deparaffmised, rehydrated
and immunostained for AMH using a goat anti-AMH polyclonal antibody (Santa Cruz) and
counterstained with haematoxylin, according to the protocol described in Chapter 2. The
large spherical nuclei of the gonocytes were easy to distinguish, amongst the AMH stained
Sertoli cell cytoplasm, under a light microscope at x63 magnification, as were the
counterstained perimeters of the nuclear membrane(s). The number of seminiferous cords per
cross section was counted and each cord assessed for containing none or at least one
gonocyte with >1 nuclei per cytoplamsic membrane (a multinucleated gonocyte). The
percentage of cords containing at least one multinucleated gonocyte (MNG) was calculated
per block. At least ten blocks per treatment were analysed.
4.2.4 Analysis of the somatic cell proliferation rate
During fetal testis development, the Sertoli cells are proliferating. The rate ofproliferation
can be measured by exposing the testes to the nucleotide base dUTP, supplied in vitro as the
parent compound 5-Bromo-2'-deoxyuridine (BrdU), which is incorporated into the
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reproduced DNA in place of the dTTP base. The incorporation of the dUTP base can be
visualised by immunostaining with a relevant antibody. In order to ensure that proliferation
was quantified in Sertoli cells and not another testis cell type undergoing proliferation,
sections were double immunostained for BrdU and the Sertoli cell nuclear specific marker
WT-1. WT-1 staining was visualised with Fast blue which co-localised with the brown DAB
developed BrdU antibody, together they uniquely identified proliferating Sertoli cell nuclei.
The incidence of Sertoli cell apoptosis was also investigated by labelling fragmenting
(apoptotic) DNA by catalytic incorporation of fluorescein- 12-dUTP at the 3'-OH ends of the
DNA using the terminal deoxynucleotidyl transferase enzyme. This method could discern
apoptotic cells from cells undergoing necrosis, also recognisable microscopically by their
darkly counterstained pyknotic nuclei.
4.2.4.1 Quantification of BrdU incorporation index
Measurement of the 5-Bromo-2'-deoxyuridine (BrdU) incorporation index was possible after
the cultured testis explants were treated with BrdU during the last 4h of the culture as based
on Livera et al (2000). Three numbered slides per block (at least five serial sections apart)
were deparaffinised, rehydrated and immunostained for BrdU incorporation using a sheep
anti-BrdU polyclonal antibody (Fitzgerald Laboratories) and counterstained with
haematoxylin, according to the protocol described in Chapter 2. The number of Sertoli cell
nuclei that showed a clear positive immunoreaction to BrdU per 1000 counted, under a light
microscope and a x63 objective, was converted to a percentage = the BrdU incorporation
index. As BrdU was only incorporated in cells during proliferation, this value was also
referred to as the proliferation index (PI). A mean from each block was calculated and at
least seven blocks per treatment were analysed.
4.2.4.2 Quantification of apoptosis
Apoptotic cells were detected in situ by use of the TUNEL method as described by (Livera et
al., 2000). There were no apoptotic cells seen in the in vitro experiment sections investigated,
though the positive control sections (rat testis, dl8) did confirm the protocol was successful.
This finding is consistent with the absence of apoptosis in fetal rat testes over el9.5-e21.5 in
vivo (Olaso and Habert, 2000).
4.2.5 Analysis of hormone secretions
Hormone measurements are one of the most sensitive endpoints for studying endocrine
active compounds (O'Connor et al., 2002). To ensure that the explant culture system was
viable, four separate treatments were added to the media to manipulate the hormone
production level of the testis explants. The fetal testis has two major endocrine products:
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testosterone and inhibin-B. Both of these hormones were targeted by the different treatments
chosen and their effects compared to basal hormone production levels as measured in the
media of untreated explants. More details on the doses and rationale behind these choices are
provided in Chapter 2.
4.2.5.1 Measurement of testosterone production
The testosterone secreted into the media was measured by radioimmunoassay (RIA) as
described in Chapter 2. No extraction step was performed as the only steroid that
significantly cross-reacts with the testosterone antibody (17|3-hydroxy-5a-androstane-3-one)
is secreted in minute amounts by the fetal testis (Habert and Picon, 1984). Typically, a
1/1000 dilution of culture media was prepared for assay.
4.2.5.2 Measurement of inhibin-B production
The inhibin-B secreted into the media were measured in duplicate by an Enzyme Linked
Immunosorbent Assay (ELISA) as described in Chapter 2. No pre-treatment of the media
were necessary. Typically, a 1/20 dilution of culture media were used for assay.
4.2.6 Phthalate exposure
In studies where DBP is administered orally in vivo, the vast majority ofDBP is reported to
be converted to its metabolites, inlcuding MBP and MBP-glucuronide, which are then
rapidly transferred to the embryonic tissues. As DBP metabolism is normally carried out by
the liver, its metabolite MBP was utilised in the organ cultures to examine its effects on testis
development (Saillenfait et al., 1998).
In their placental transfer study, Saillenfait et al. (1998) determined that just 0.12-0.15%, of
the 500mg [14C]DBP/kg administered maternal dose, was recovered from the embryonic
tissue. This equated to each fetus being exposed to just 0.6mg DBP/kg/day = 0.00216mM
DBP/kg/day in a dam exposed to 500mgDBP/kg/day (1.8mM DBP/kg/day). It was
considered useful to provide an equivalent dose ofMBP in vitro to that received by the fetus
following maternal treatment with 500mgDBP/kg in vivo. With these exposure levels in
mind, the following experiments provided MBP or DBP at a maximum concentration of
ImM/ml (1x10"3M), decreasing by tenfold each time to a minimum of lOOpM/ml (10"10M).
4.2.6.1 Phthalate effect on hormone stimulation
The details of the mechanism by which phthalates induce change in the development of the
fetal testis is unclear, but appears to be associated with Leydig cell testosterone biosynthesis
(Akingbemi et al., 2001). Initial experiments compared the level of testosterone and inhibin-
B produced in vitro by explants treated with a range of doses ofMBP, from 10"10M to 10"3M,
against the levels produced by untreated, control, explants.
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Further experiments were conducted to try to pinpoint the site of action ofMBP. Explants
were exposed to MBP together with hCG and 22-R-CHO which stimulate testosterone
production by acting at different points in the steroidogenic cascade. By comparing whether
the steroidogenesis stimulants exerted a reduced effect on testosterone production with MBP
present, it could be pinpointed where in the steroidogenic pathway the DBP metabolite was
having its inhibitory effect. These experiments were repeated with different concentrations
ofMBP to investigate any dose response effect.
4.3 Results
4.3.1 Optimisation of explant culture conditions
Studies were carried out to refine the conditions for the in vitro culture of fetal rat testis
explants based on established in-house methods for the in vitro incubation of fetal human
gonads, fetal rat Wolffian ducts and fetal rat prostate. Testes from fetuses at a range of
embryonic ages were used, from el5.5 to e21.5, and several alternative culture conditions
were investigated. One of the normal in vivo roles of the fetal testis is testosterone secretion,
so levels of this hormone secreted into the culture media were measured as a means of
quantifying the experimental outcomes. It was decided that increased testosterone production
was an indication of better explant viability. Where possible, additional means of
quantification were also employed, such as histological examinations or measurements of
inhibin-B production.
4.3.1.1 Effect of incubation duration
Preliminary studies to measure the effect of incubation time were carried out for el7.5 and
el9.5 fetal rat testis explants over 4-72h. The effects on the hourly rate of testosterone
production and tissue histology were assessed. Fetal rat testis explants at el7.5 and el9.5
were incubated in vitro at 37°C for 4-72h without changing the media.
Differences in secreted testosterone were measured in media collected at the different
timepoints. The greatest total testosterone secretion and hourly output was found in the
media collected after 48h incubation for both ages (see Figures 4.1 and 4.2). It was
concluded that an incubation length of48h would be the focus for further studies.
The two experiments showed that the level of testosterone production differed with fetal age,
this was followed up in further experiments (see section 4.3.1.4).
It is not clear from these studies how the level of testosterone decreased between 48-72h, as
a linear effect of time on concentration was anticipated. It is considered that some of the
testosterone must have undergone further metabolism after 48h.
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Figure 4.1: Testosterone production in vitro by el7.5 rat testis explants after culture for 4-
72h at 37°C. Graph A shows the total amount of testosterone secreted over the incubation
period and graph B shows average testosterone production per hour of incubation, (n values
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Figure 4.2: Testosterone production in vitro by el9.5 rat testis explants after culture for 24-
72h at 37°C. Graph A shows the total amount of testosterone secreted over the incubation
period and graph B shows average testosterone production per hour of incubation, (n values
are shown in parentheses). Where n=2 values are means ± ranges but where n=3 Values are
means ± S.E.M.
4.3.1.2 Effect of incubation media
The two in-house protocols for in vitro tissue culture used different culture media for explant
incubation at 37°C. The effects of the different basic media on the fetal rat testis explants
were assessed. The levels of testosterone secretion and quality of tissue histology were
compared. The two basic media used were Alpha Minimum Essential Media (AMEM) and a
1:1 mixture of Dulbecco's Minimum Essential Media with F12 (DMEM/F12), both supplied
by Gibco™. Identical anti-microbial products were added to all media. Following
termination of the incubation, the residual media were collected per well and its testosterone
level measured.
4.3.1.2.1 Effect of incubation media on testosterone production
A noticeable difference in the level of testosterone production between the media was
observed after 48h incubation (Figure 4.3). Though this difference was not statistically
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significant (P=0.081), it was decided that DMEM/F12 should be used for future experiments
due to the greater mean secreted testosterone value produced with this medium. The low




















Figure 4.3: Testosterone produced in vitro by e20.5 rat testis explants after culture
with two different media for 48h at 37°C. Values are means ± S.E.M. (n values are shown in
parentheses). Data were log transformed prior to statistical analysis.
4.3.1.2.2 Effect of incubation media on tissue architecture
Following incubation, the explants were Bouin's fixed then processed into paraffin blocks
and sectioned. Prior to analysis, testis sections were immunostained for two cell-specific
markers (Figure 4.4). Low magnification examination of the sections reviewed the
steroidogenic potential of the explants following immunostaining for the enzyme 3|3-FISD.
This protein is unique to the Leydig cells in the fetal testis and is critical to the biosynthesis
of testosterone. All cultured explants showed a decrease in the intensity of 3(3-HSD staining
compared to uncultured control sections. At 24h, the 3(3-HSD staining intensity was
comparable between the media, but by 48h, the AMEM cultured tissue showed markedly
less intense staining. Explant architecture was examined using immunostaining for the
cytoskeletal protein Smooth Muscle Actin (SMA). This protein is unique to the peritubular
myoid cells in the fetal testis and contributes to the physical support of the developing
seminiferous cords. All cultured explants showed a change in SMA staining intensity with
time and a markedly changed pattern of expression at 48h compared to Oh control sections.
Review of the counterstained regions of the sections revealed pyknotic cell nuclei in all
cultured explants though none in the Oh controls. For both media, the most vulnerable cell
types were the intratubular gonocytes and interstitial Leydig cells. However, those explants
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cultured in DMEM/F12 appeared to have less frequent pyknotic cell nuclei though this was















Figure 4.4: Histological examination of e20.5 fetal rat testis explants after culture for
0, 24 or 48h in AMEM or DMEM/F12 media. Sections were immunostained for the Eeydig
cell marker 3|3-HSD or the peritubular cell marker SMA. Scale bars denote 100p.m.
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4.3.1.3 Effect of media supplements
The two established in-house protocols for in vitro tissue culture not only used different
media but added different supplements too, prior to fetal tissue incubation at 37°C. The
effects of the different supplements on the fetal rat testis explants were assessed. Three
supplement regimes were tested (details in section 4.2.2).
• A: the original AMEM regime for fetal human gonad culture
AMEM media + L-Glutamine + sodium pyruvate + ITS + BSA
• B: the original DMEM/F12 regime for the rat tissue culture experiments
DMEM/F12 media + transferrin + insulin
• C: a hybrid of the 2 regimes with a modified DMEM/F12 regime
DMEM/F12 + L-Glutamine + sodium pyruvate + ITS + BSA
These studies were run in parallel with the media trial (section 4.3.1.2). The levels of
testosterone secretion and Sertoli cell proliferation rates were compared between regimes.
The highest mean level of testosterone after 48h incubation (28.2ng/ml media) was measured
in media from explants incubated with the modified DMEM/F12 regime (Figure 4.5).
Proliferation of the explants towards the end of the experiment was measured by
immunostaining the explant sections for BrdU, which had been added to the media for the
last 4h of incubation. The Sertoli cell proliferation index was calculated from sections double
immunostained for BrdU and WT-1 (Figure 4.7). There was no obvious difference between
the media regimes on the proliferation rate though the greatest mean PI% (3.4%) was
measured in explants incubated with the modified DMEM regime (Figure 4.6). The
differences seen were not statistically significant but it was decided that future culture





















Figure 4.5: Testosterone production in vitro by e20.5 rat testis explants after culture
with three different media regimes for 48h at 37°C. Values are means ± S.E.M. (n values are
shown in parentheses). There was no significant effect ofmedia regime (P=0.67).
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Figure 4.6: Proliferation Index (%) of Sertoli cells in e20.5 fetal rat testes following
4h in vitro exposure to BrdU at the end of a 48h incubation. Values are means ± range, (n
values are shown in parentheses).
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Figure 4.7: BrdU and WT-1 double-immunostained section of e20.5 fetal rat testis
after in vitro exposure to BrdU during the last 4h of a 48h incubation. Proliferating
intratubular Sertoli cells (long arrows) were identified by immunostaining for WT-1 (blue)
as well as BrdU (brown). Interstitial cells (short arrows) were also proliferating at this age
but gonocytes (asterixes) were quiescent. Photographed using a x20 objective.
4.3.1.4 Effect of fetal age on explant number and testosterone
production
The number of explants that could be generated from a fetal testis increased as the testis
enlarged with age (Table 4.1). Previous studies (section 4.3.1.1) suggested that the age of the
testis donor, at the time of explant preparation, influenced the level of testosterone produced
by the explant in culture, so this was investigated. It was not possible to reproducibly retrieve
the male gonad from fetuses younger than el5.5 and it has been reported that testosterone
production is not detected prior to el5.5 (Rouiller-Fabre et al., 2003). The level of
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testosterone produced over 48h during in vitro incubation by explants retrieved from fetuses
aged from el5.5 to e21.5 was compared.
The mean levels of testosterone produced increased from el5.5 (+48h) to el7.5 (+48h) and
then fell steadily until e21.5 (+48h). The fall in testosterone production after el7.5 (+48h)
showed a highly significant linear trend (P=0.004) (Figure 4.8). The rise and fall in
testosterone production with fetal age seen in vitro, mimicked the previously reported pattern
of fetal testosterone production in vivo (El-Gehani et al., 1998).
It was concluded that further studies would be carried out using el9.5 rat fetal testes as these
were large enough to generate 6 explants per testis but still showed a high level of
testosterone production. This would mean more replicates could be generated per testis so
fewer animals would be needed to achieve the same sample size per experiment.
Fetal age (e) 15.5 17.5 18.5 19.5 20.5 21.5
No. explants per testis 1 2 4 6 8 8+
Mean in vitro testosterone production (ng/ml medium) 36.3 41.4 37.5 27.7 17.0 5.25
Table 4.1 A summary of the effect of fetal age on the number of explants generated





























Fetal age (embryonic day at start of 48h incubation)
Figure 4.8: Testosterone production in vitro by rat testis explants from fetuses of
various ages after incubation for 48h at 37°C. Values are means ± S.E.M. (n values are
shown in parentheses). Data were log transformed prior to statistical analysis. Testosterone
levels peaked with the el7.5 explants then fell steadily with increasing age (linear trend
analysis of decrease P=0.004**).
4.3.1.5 Effect of dissection plane on explant function
The fetal testis has an organised architecture that is populated by cells proliferating in situ
(e.g. Sertoli cells) and by cells that initially migrate in from surrounding tissue, from the
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mesonephros and/or coelemic epithelium (e.g. peritubular myoid cells, Leydig cells) or the
yolk sac (i.e. gonocytes) (Karl and Capel, 1998; Olaso and Habert, 2000; Ross et al., 2003).
Explants were generated for in vitro culture by slicing whole fetal testes into even sized,
smaller pieces. It was proposed that slicing of the ovoid testis would unavoidably disrupt any
on-going cell migration from the coelomic epithelium or the dispersal of cells from the rete
after migrating from the mesonephros. Regulating the plane of dissection would minimise
any disruption of residual migration, or at least ensure it was consistent between explants.
Equally the uneven distribution of the different cell types within each explant, associated
with migration or cell number, was minimised using this approach.
The benefit of this precaution was assessed by comparing testosterone output between
samples generated either with careful orientation of the whole testis and specific planes of
dissection or by slicing the whole testis with random regard for the organ's orientation.
Following incubation for 48h at 37°C, the media were collected and testosterone levels were
compared (Figure 4.9). It was not possible to track the orientation of explants after they were
generated, thus prohibiting any quantitative histological comparisons.
There was no significant effect of dissection plane on the level of testosterone production
(P=0.41) but it was decided that future culture experiments would employ the specific
orientation method. This method would generate explants that were comparable in testicular
architecture and the extra preparation time required had not been detrimental to the explants'



















Figure 4.9: Levels of testosterone (ng/ml media) produced in vitro by el 9.5 rat testis
explants with different explant dissection orientation after culture for 48h. Values are means
± S.E.M. (n values are shown in parentheses). Data analysis showed no significant difference
between the two groups (P=0.41).
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4.3.1.6 Optimisation procedures: conclusion
Optimisation of culture condition has been shown to be critical to ensure a useful in vitro
representation of in vivo development (Richards, 1999). The in vitro organotypic system
developed in these studies was assessed using three main criteria:
• maintenance of tissue architecture and protein expression (Figure 4.5)
• measurement of hormone production (Figure 4.6)
• analysis of the somatic cell proliferation rate (Figure 4.7)
Regime C, as described in section 4.3.1.3, was the most successful set-up based on these
criteria so was used to incubate rat el9.5 testis explants for 48h during subsequent
experiments.
The level of testosterone produced by the fetal testis explants varied depending on the fetal
age at which they were collected. This trend was consistent with the pattern of testicular
testosterone content seen in whole testes, confirming that the in vitro explant culture system
did mimic in vivo testosterone production (El-Gehani et al., 1998). The number of explants
that could be generated per testis was proportionate to the age and hence size of the testis
(Livera et ah, 2004). The most explants were produced from the oldest testes (e21.5). This
benefit (more explants per testis = more experiments per animal = reduced animal usage)
was carefully weighed against the fall in testosterone production with age. The optimal
situation decided upon was to collect testes on el9.5, when testosterone production had
peaked but not plummeted and 2-3 times more explants could be generated per testis than at
el7.5. This would enable more replicates per experiment to be generated to highlight any
effect of treatment on development parameters such as testosterone production apart from in
vitro effects. Gonocytes behaved as expected, being quiescent across the developmental
period used (el9.5 +48h), undergoing neither mitosis nor apoptosis. In this organotypic
culture system, the absent mitotic and apoptotic activities of the gonocytes were similar to
those observed in vivo (Boulogne et ah, 1999). Additionally, Sertoli cells and Leydig cells
underwent proliferation and secreted hormones (inhibin-B and testosterone, respectively) as
per in vivo.
The optimised incubation duration of 48h was not considered a limitation of the technique as
this timeframe enabled chronic exposure effects to be assessed. There were certain artefacts
induced by this experimental approach that could not be removed despite method
optimisation. For example, most explants showed poor tissue morphology in their centre
after 48h incubation. The necrotic cells were recognisable microscopically by their darkly
counterstained pyknotic nuclei. Ideally, all necrotic tissue would have been discarded from
further analysis but due to the consistent appearance of this artefact in the centre of cultured
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explants, necrotic tissue was noted but investigative focus was placed on the viable
peripheral tissue per sample.
4.3.2 Manipulation of hormone secretion in vitro
The refined in vitro model with fetal rat testis explants was exposed to four agents, three of
which are known to affect steroidogenesis, to investigate whether hormone production could
be manipulated. hCG and 22-R-CHO were selected to stimulate testosterone production, at
different points in the steroidogenic cascade, and to assess Leydig cell vitality. Ketoconazole
(KTZ) was chosen as an inhibitor of testosterone production. FSH treatment was intended to
stimulate inhibin-B production and assess Sertoli cell vitality, which might have an indirect
effect on steroidogenesis. Further details on these compounds and the rationale behind their
selection are provided in Chapter 2.
4.3.2.1 Manipulation of testosterone secretion
Fetal rat testis explants at el9.5 were incubated in vitro at 37°C for 48h. Media were
prepared with or without the four treatments described above and were collected after
termination of the incubation. Analysis ofmedia for testosterone from preliminary studies
(Figure 4.10 A, B and C), illustrates the range of levels for basal testosterone production and
the magnitude of response, if any, the treatments induced. In all experiments shown, the 22-
R-CHO and hCG treatments induced increased testosterone production, as anticipated. In
contrast, the addition ofFSH or KTZ had inconsistent effects on testosterone levels
compared to the control samples. Because of the variability in results, these studies were
repeated in several experiments.
The media collected from multiple studies (repeated 4-7 times) were assayed together prior
to overall analysis (Figure 4.11). Data were log transformed prior to statistical analysis.
For testosterone, ANOVA showed PO.OOOl with high significance (P<0.01) for both 22-R-
CHO and hCG compared to basal control. The maximal increase in hCG induced
testosterone production (mean = 177ng/ml) under these conditions, was almost 6 fold greater
than basal levels (mean = 31ng/ml) but a 13 fold increase was induced by the addition of 22-
R-CHO (mean = 396ng/ml).








Basal Control KTZ 22-R-CHO hCG hFSH
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Figure 4.10: Testosterone production in vitro by el9.5 rat testis explants after culture
for 48h with different culture media additions. Each graph (A, B, C) represents data from a
different single experiment. Individual experiments were from a single litter. All treatment
groups had the same amount of tissue, as determined by number of explants and their size.
In contrast, there was no significant effect ofFSH or KTZ on testosterone production
compared to untreated samples (P>0.05) (Figure 4.11 A). No significant effect ofFSH was
expected on testosterone production, so these results were consistent with expectations.
However, the lack of adverse effect on testosterone level by KTZ was unexpected. It must be
that the concentration used was ineffective under these culture conditions, though it was
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previously used successfully in this laboratory to reduce testosterone production by adult rat
Leydig cells (Qureshi 1992, PhD thesis).
Inhibin-B levels were not significantly affected by any of the treatments used (Figure 4.11 B)
though media collected from explants exposed to 22-R-CHO showed some evidence of
higher inhibin-B levels. The lack of a significant effect ofFSH on inhibin-B secretion was
unexpected but may be normal because even in vivo, the role of FSFI and its production is
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Figure 4.11: Production of testosterone (A) and inhibin-B (B) in vitro by el9.5 rat
testis explants after culture for 48h with different media additions. Values are means ±
S.E.M. (n values are shown in parentheses). For testosterone data, values were log
transformed prior to analysis to normalise the wide range of values obtained. ANOVA
showed P<0.0001 with high significance (** P<0.01) for both 22-R-CFIO and hCG
compared to control. ANOVA analysis showed no effect of treatment on inhibin B levels
(P=0.19) compared to untreated control samples.
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A comparative summary of the two hormones and the mean effect of each in vitro treatment
is presented in Figure 4.12 which plots the relative increases in overall hormone production
per treatment. It was possible neither to reduce the level of testosterone production using
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Figure 4.12: Comparative summary of changes in levels of testosterone and inhibin-B
produced in vitro by el9.5 rat testis explants after culture for 48h with different media
additions. Values are means per treatment per hormone. Data were log transformed for
presentation to accommodate the range of values obtained. Basal mean values are plotted
(testosterone = 1.45 (—), inhibin B = 1.58 ( )) to highlight significant effects of treatment
as detailed in Figure 4.11 A and B.
4.3.3 Effect of MBP on testis explants
The ultimate aim of the in vitro model was to reproduce the adverse effects of DBP on fetal
testes, such as decreased testosterone production, seen in vivo (Chapter 3). In rats, the vast
majority ofDBP is metabolised in the liver to monobutyl phthalate (MBP), which is
understood to be the toxic agent (Foster et al., 1983). As the in vitro testis model cannot
perform liver metabolism, MBP rather than DBP was added to the culture media.
Fetal rat testis explants at el9.5 were incubated in vitro at 37°C for 48h, with or without
MBP at concentrations varying from 10"3M (ImM) to 10"10M (lOOpM). Media collected after
48h incubation was assayed for testosterone and inhibin-B and explants were Bouin's fixed,
sectioned and immunostained as required.
4.3.3.1 Effect of MBP on testis explant hormone production
Testosterone levels measured in media from preliminary studies showed wide variability
between the experiments (Figure 4.10) so these cultures were repeated 5-17 times. The
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samples from multiple studies were assayed together prior to overall analysis (Figure 4.13).
Data were log transformed prior to statistical analysis.
Analysis of data from repeated studies, showed that basal testosterone production by el9.5
explants was unaffected by MBP at any of the concentrations used, compared to untreated
explants (ANOVA P=0.23) (Figure 4.13). Inhibin-B production by el9.5 explants was not
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Figure 4.13: Testosterone production in vitro by el9.5 rat testis explants after culture
with different MBP concentrations for 48h at 37°C. Values are means ± S.E.M. (n values are
shown in parentheses). ANOVA analysis showed no effect of dose level (P=0.23) compared
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in vitro treatment
Figure 4.14: Inhibin-B production in vitro by el9.5 rat testis explants after culture with
or without MBP(10"3M) for 48h at 37°C. Values are means ± S.E.M. (n values are shown in
parentheses). T-test analysis showed no effect of MBP (P=0.41) on inhibin production
compared to basal samples.
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4.3.3.2 Effect of MBP on testis explant histology
The ultimate aim of the in vitro model was to reproduce the adverse effects ofDBP on fetal
testes, seen in vivo (Chapter 3). Fetal testes at e21.5 exposed to DBP in utero over el3.5-
e20.5, showed reproducible changes in certain aspects of their cellular architecture (section
3.3). The same parameters were assessed in fetal testes, explanted at el9.5 then incubated in
vitro with or without the DBP metabolite MBP for 48h. Following in vitro incubation,
explants were Bouin's fixed, sectioned and immunostained as required.
4.3.3.2.1 Sertoli cells
Sertoli cell proliferation of the explants towards the end of the experiment was measured by
immunostaining the Bouins fixed explant sections for incorporation ofBrdU, which had
been added to the media for the last 4h of incubation. The Sertoli cell proliferation index was
calculated (Figure 4.15).
No significant effect ofMBP (10"3M) was seen on the Sertoli cell proliferation index of fetal
testis explants compared to untreated explants (P=0.74). No significant effect of DBP
exposure on the Sertoli cell proliferation index was seen in e21.5 testes with the in vivo
model either, following in vivo el3.5 -e20.5 DBP exposure, though a small reduction in
Sertoli cell number was measured (section 3.3.1.1). Sertoli cell number was not measured in
fetal testis explants after incubation in vitro due to the necrosis mentioned earlier (section
4.1.1.6). BrdU uptake was evident but the PI% was not measured for extratubular cell types
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Figure 4.15: Proliferation Index (%) of Sertoli cells in el9.5 rat testis explants during
the last 4h of 48h in vitro incubation with or without MBP(10 3M), at 37°C. Values are
means ± S.E.M. (n values are shown in parentheses). There was no significant effect ofMBP
on the Sertoli cell PI%.
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Figure 4.16: BrdU immunostained sections of el9.5 fetal rat testis explants after
culture for 48h, with or without MBP(10~3M). BrdU was administered 4h prior to incubation
termination and was incorporated by the proliferating cells including intratubular Sertoli
cells (wide arrows) and interstitial cells (narrow arrows) but gonocytes appeared quiescent
(asterixes). The top panels show cross sections through testis explants photographed with a
x20 objective, with focal areas enlarged below.
4.3.3.2.2 Gonocytes
Normal untreated/ uncultured fetal testes contain mononucleated gonocytes, with rare and
infrequent multinucleated gonocytes (MNG). However, studies of testis architecture
following in utero exposure to DBP revealed a highly significant treatment related increase
in the incidence ofMNG's (section 3.3.1.2). As gonocytes were not typically mitotic during
the fetal age examined (Boulogne et al., 1999), a MNG was defined as having more than one
nucleus per cell membrane. The AMH immunostained sections from cultured explants were
analysed and the percentage of seminiferous cords per section that contained at least one
MNG was recorded.
No significant effect was seen on the incidence ofMNG's in fetal testis explants treated with
MBP(10"3M) compared to untreated explants (P=0.31) (Figure 4.17). The unexpectedly high
incidence ofMNG's, seen with the control explants, was considered abnormal and is
presumed to be a consequence of the in vitro culture, and may perhaps have masked any
significance of the greater mean incidence ofMNG's seen in the fetal testis explants treated
with MBP(1CT3M) compared to untreated explants (Figure 4.18).

























Figure 4.17: Incidence (%) of multinucleated gonocytes in el9.5 rat testis explants
after in vitro culture with or without MBP(10"3M), for 48h at 37°C. Values are means ±
S.E.M. (n values are shown in parentheses). There was no significant treatment effect and t-
test analysis showed P=0.31.
Figure 4.18: Examples of mononucleated (green arrows) and multinucleated (red
arrows) gonocytes in el9.5 rat testis explants after in vitro culture with or without MBP(10"
3M), for 48h at 37°C. Sections were immunostained for AMH (Sertoli cell cytoplasm in
brown) and counterstained with haematoxylin (blue). The montage shows cross sections
through explants photographed with a x40 objective in the top panels and re-photographed
with a xlOO objective in the lower panels.
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4.3.3.2.3 Leydig cells
Normal untreated/ uncultured fetal testes aged between el9.5-e21.5, contain small clusters of
Leydig cells. However, the previous studies of testis architecture following in utero exposure
to DBP recorded a shift from small to larger clusters ofLeydig cells with treatment (section
3.3.1.3). Without treatment, each cluster has an area of less than 5% of the total Leydig cell
area per section. Occasionally normal Leydig cell clusters would represent between 5-15%
of the total Leydig cell area per section but clusters >15% were only seen in testis sections
from DBP-exposed animals. Clusters were defined by these percentage area categories as
either small (<5%), medium (5-15%) or large (>15%).
Sections of cultured explants were immunostained with the Leydig cell marker 3fl-HSD and
the number of Leydig cell clusters per category was analysed. Three sections per sample
were analysed and the mean values per sample compared between treatments. There was a
trend away from smaller clusters towards an increase in the incidence of medium and large
clusters seen in explants exposed in vitro to MBP (10~3M) compared to untreated explants
(Figures 4.19 and 4.20). Though the change was not statistically significant for any cluster









stained area in el9.5 rat testis explants after in vitro culture with or without MBP(10~3M), for
48h at 37°C. Values are means ± S.E.M. (n values are shown in parentheses). MBP(10 3M)
treated explants showed a trend towards an increase in larger cluster sizes though t-test
analysis showed no significant difference in any of the cluster categories between control
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Figure 4.20: 3(3-HSD immunostained sections of el9.5 rat testis explants after in vitro
culture with or without MBP(10 3M), for 48h at 37°C. Note the range of Leydig cell cluster
sizes, exaggerated after MBP-treatment, compared to the control image. The panels show
cross sections through testis explants photographed with a x40 objective.
4.3.3.3 Effect of MBP on testosterone production by fetal
testis explants stimulated by 22-R-CHO or hCG
There was no significant change in the level of testosterone produced by testis explants
incubated with MBP (Figure 4.13) compared to untreated explants. Further studies were
carried out to investigate whether a range of doses ofMBP (10"9M to 10"3M MBP) could
blunt the stimulatory effect of hCG or 22-R-CFIO on fetal testis explant testosterone
production previously demonstrated (section 4.3.2.1).
Fetal rat testis explants generated at el9.5 were incubated in vitro at 37°C for 48h, with or
without two stimulators of testosterone production, namely hCG or 22-R-CHO and with or
without MBP at one of three concentrations (10~9M, 1 (T6M or 10"3M). Nine different
combinations were used. Media collected after the incubation was assayed for its
testosterone level.
Analysis ofmedia from preliminary studies for testosterone (Figure 4.21 A and B) saw a
wide range of responses. Graph A data fits with the hypothesis that MBP could blunt
stimulated testosterone production in a dose related manner but this result was not supported
by the repeat experiment in graph B. In both the experiments shown, hCG combined with
MBP (10"3M) saw blunted testosterone production compared to hCG alone. No reduction in
the 22-R-CHO stimulated testosterone level was induced consistently by any MBP
concentration.






















































Figure 4.21: Testosterone production in vitro by el9.5 rat testis explants after culture
for 48h at 37°C with or without hCG and 22-R-CHO, with or without one of three
concentrations of MBP. Each graph (A and B) represents data from a different single
preliminary experiment.
Because of the variability in results, these studies were repeated (Figure 4.22). The samples
from multiple studies were assayed together prior to overall analysis and data were log
transformed prior to statistical analysis. Analysis of media for testosterone from multiple
studies, showed that both stimulants increased testosterone production compared to untreated
explants achieving 7.8 and 3.7 mean fold increases induced by 22-R-CHO and hCG
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respectively (PO.Ol). The apparent reduction in 22-R-CHO stimulated testosterone
production by MBP (10 3M) and (10~6M) was not statistically significant (P>0.05). However,
hCG stimulated testosterone production was significantly decreased (P<0.01) by addition of
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Figure 4.22: Testosterone production in vitro by el9.5 rat testis explants after culture
for 48h at 37°C with or without hCG and 22-R-CHO, with or without one of three
concentrations of MBP. Values are means ± S.E.M. (n values are shown in parentheses).
Data were log transformed prior to analysis. Both stimulants increased testosterone
production compared to untreated explants (**P<0.01) but only hCG stimulated testosterone
production was significantly decreased by addition of 10"3M MBP (x P<0.01).
4.4 Discussion
Previous studies (Chapter 3) demonstrated that in utero exposure to DBP caused abnormal
development of the rat fetal testis including decreased production of testosterone. The
primary aim of these experiments was to optimise an organotypic culture system for the rat
fetal testis. Secondly, this approach examined the influence ofMBP, at a maximum dose of
10"3M, on testis cell morphology as well as hormone production. These results extend
previous findings obtained with the in vivo exposure experimental system (Chapter 3).
Analysis of testis architecture following 48h incubation of fetal rat testes demonstrated that
expression of specific proteins (SMA, 3(3-HSD, AMH) was still evident in the cultured tissue
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with this in vitro explant culture system, as per the in vivo studies. Explants from further
experiments following 10"3M MBP exposure in vitro, were examined by light microscopy
following immunohistochemistry. Data analysis revealed a treatment related trend towards
an increase in the size of Leydig cell clusters and a treatment related trend towards an
increase in the incidence of multinucleated gonocytes (MNG's). These endpoints, though not
statistically significant, were consistent with the data obtained in the in vivo studies reported
in Chapter 3 and as published by different groups (Kleymenova, 2005; Mahood et al., 2004).
BrdU uptake was also evident using immunohistochemistry, though there was no significant
difference in the Sertoli cell proliferation rates ± MBP. Cell division and differentiation in
culture has been reported to occur at a lower rate than that observed in vivo, which may
explain why the 48h treatment period may have been insufficient to induce a treatment
related change in the rate of Sertoli cell mitosis (Merchant-Larios, 1998; Richards, 1999).
Perhaps more relevantly, it should be noted that there was only a trend towards a DBP-
induced decrease in the proliferation rate of Sertoli cells seen in the in vivo experiments
rather than a significant difference, so perhaps this endpoint was unobtainable in the in vitro
studies.
Testosterone levels were measured to determine the optimal organotypic culture regime of
those tested, as hormone measurements are one of the most sensitive endpoints for studying
endocrine active compounds (O'Connor et al., 2002). Original studies presented here,
compared the effect of 10"3M MBP on el9.5 rat testis explants in multiple studies, against
untreated explants, after 48h incubation. The lack of a significant effect of 10"3M MBP on
basal testosterone production led to further studies. These additional experiments
demonstrated that 10"3M MBP could blunt the stimulatory effect of hCG on fetal testis
explant testosterone production when co-administered. hCG works by binding to the cell
surface receptor for luteinising hormone (LH-R), activating adenylyl cyclase and
stimulating the concentrations of the second messenger cAMP which in turn mediates a
multitude of intracellular activities, including an increase in the rate of steroidogenesis
(Moyle et al., 1980). LH is not normally required by the testis to initiate or maintain
testicular steroidogenesis until late gestation, around e20.5 in the rat, but fetal-type Leydig
cells are responsive to stimulation by LH prior to detection of this hormone in plasma at
el7.5 (Gangnerau and Picon, 1987).
Studies have shown that the rat placenta does not produce chorionic gonadotropin (CG)
removing any source for the fetal testis (Habert and Picon, 1990). However, chronic hCG
exposure used in the present in vitro studies induced a significant increase in the level of
testosterone produced, demonstrating that fetal testis explants were responsive to trophic
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hormone stimulation under these optimised culture conditions. It has been reported that long-
term high-level exposure to hCG can cause a de-sensitisation of the adult Leydig cells to
further hCG stimulation (Akingbemi et al., 2000) but other studies have shown that fetal
Leydig cells are not desensitised by LH/hCG exposure (Tsai-Morris et al., 1987). Whether
the explants in the present studies became insensitive to chronic hCG stimulation cannot be
assessed from these experiments.
Parallel studies combining the steroidogenic intermediate 22-R-CHO with 10~3M MBP
produced no significant blunting of 22-R-CHO stimulated testosterone production. By
providing the explants with 22-R-CHO, it was possible to bypass the start of the
steroidogenic cascade to beyond the rate-limiting step at P450scc. This helped determine
where in the cascade the MBP was affecting hCG stimulated steroidogenesis. Together,
these studies suggest that the steroidogenic target ofMBP toxicity is prior to and/ or during
the mitochondrial phase of the testosterone biosynthesis cascade. Recent publications
confirm that DBP and other phthalates target many of these steps (Akingbemi et al., 2004;
Barlow and Foster, 2003; Parks et al., 2000; Thompson et al., 2004). These recently reported
studies confirm that the absence of an effect ofMBP on 22-R-CHO stimulated testosterone
production was a logical result.
In the present experiments, no consistent inhibition of basal in vitro testosterone production
by Ketoconazole was observed. Ketoconazole works by inhibiting steroidogenesis via
suppressing activity of the various cytochrome P450 enzymes including P450scc, 17a-
hydroxylase (P450 cn) and 17,20-lyase (P450cn.2o) (Miossec et al., 1997). The dose of
Ketoconazole used (lOOpM), was selected based on previous work carried out in our
laboratory using adult human and rat Leydig cells (Qureshi 1992, PhD Thesis). Pilot studies
to confirm that the concentrations of Ketoconazole used were effective should have been
carried out to confirm that it was possible to induce a decrease in testosterone production in
this model system, as an anticipated outcome of phthalate exposure. It could be that the fetal
rat Leydig cells, as used in the present experiments, are less sensitive to Ketoconazole than
adult rat Leydig cells used in previous studies (Gray et al., 1999; Powlin et al., 1998).
However, as repeated studies would demonstrate there was no effect ofMBP on basal
testosterone production, this negative control was less critical. The effect of 100pM
Ketoconazole was also investigated in fetal human testis explants as described in the next
Chapter, and shown to have inhibitory effect on testosterone production.
In addition to testosterone production, the secretion of inhibin-B was measured to assess
Sertoli cell function in this model system. FSH is critical for the initiation of
spermatogenesis in young animals. It binds to the FSH receptor (FSH-R) which, like LH-R
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activation described above, activates adenylyl cyclase and produces an increase in cAMP
secretion, initiating a multitude of intracellular responses (Lloyd and Foster, 1988).
FSH treatment did not induce any increase in inhibin-B secretion, though a slight increase in
testosterone production in response to FSH was observed in the overall analysis. This
suggested that the Sertoli cells could be reacting to the FSH stimulation by increasing output
of a signal to Leydig cells promoting an increase in testosterone production. The inverse
relationship between FSH and inhibin-B seen in the adult rat was not reported in studies with
neonatal rats nor could it be assessed under these experimental conditions (Sharpe et al.,
1999). As the repeated studies presented here demonstrated no effect ofMBP on basal
inhibin-B production and as there are no recent reports ofMBP having an adverse effect on
inhibin-B levels in vivo, this treatment was not pursued further.
In conclusion, these data show that fetal testes can be successfully cultured under the
outlined conditions for up to 48h. Rat testes dissected at this age show characteristic
progression of normal development as demonstrated by continuing testosterone production
and Sertoli cell proliferation. However, not all of the adverse effects on rat fetal testis
development induced by in utero DBP exposure were successfully modeled using primary
cultures of fetal rat testis explants, exposed in vitro to the active DBP metabolite MBP. This
suggests that this approach has only limited utility for investigating the changes in fetal testis
development associated with DBP exposure.
Additional studies, using the same culture regime, were carried out but with fetal human
testis explants and the results are described in Chapter 5.
In order to confirm whether 48h exposure to MBP in vitro was sufficient to induce the range
of changes seen following 8 days of DBP-treatment in vivo, new in vivo studies involving
just 48h ofDBP exposure from el9.5-e21.5 were performed and data compared with those
obtained using treatment lfom el3.5-e21.5. These data are reported in Chapter 6.
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5 Studies using fetal human testis explants
Studies using the human fetal testis, parallel to those performed in the rat fetal testis (Chapter
4), would theoretically enable a comparison of the relative sensitivity of the two species to
the DBP metabolite MBP, contributing to the assessment of the risk that phthalates pose to
human reproductive health.
5.1 Introduction
At the time when these studies were initiated, the range of published work that described the
effects of DBP on fetal testis development largely examined the adverse effects of phthalate
administration on fetal rats via maternal exposure. There was little work describing fetal
human exposure to phthalates directly but there were reports of adult human urine containing
higher than anticipated levels of phthalate metabolites (Blount et al., 2000a).They measured
the phthalate metabolite levels in the urine rather than parent compound levels in serum for
these main reasons:
• previous studies that measured total phthalate di-ester in serum were fraught with
technical problems, such as contamination as a consequence of ubiquitous exposure
to the parent compound, which masked low level measurements in samples (Harvan
et al., 1980; Luster et al., 1978).
• phthalate mono-esters only exist as a consequence ofmetabolism and do not
bioaccumulate so act as accurate biomarkers of recent di-ester exposure. Metabolism
of the di-esters is rapid in humans and growing evidence hints that the primary
metabolites, the mono-esters, rather than the parent compounds, induce the toxic
effects that are seen (Foster et al., 1983; Saillenfait et al., 1998).
One outcome of the Blount studies was the observation that though DBP was not the
phthalate produced in the greatest quantities (which is DEHP), it was being internalised by
humans at a much higher levels than anticipated (Blount et al., 2000b). This has since been
supported by additional studies where the estimated DBP intake by Germans = 16.2ug/kg
bodyweight per day compared to DEHP at 13.8pig/kg bodyweight per day (Koch et al.,
2003). These data suggested that internalisation ofDBP was much greater than previously
thought. However, it should be noted that the low urine measurements of the metabolites of
DEHP (e.g. MEHP) could be the consequence of low exposure but also of storage in adipose
tissue or excretion via an alternative route e.g. faecal secretion for these more lipophilic
compounds. The MEHP levels measured were consistent with those reported previously in
the urine after occupational exposure (Dirven et al., 1993).
Interestingly, a sub-population of people, predominantly women of child-bearing age, had
urinary MBP levels in the range 312-2763 pg MBP/g creatinine, whereas the majority of the
samples had <60ug MBP/g creatinine (Blount et al., 2000b). This is ofparticular concern to
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public health given the reproductive potential of the sub-population at greatest exposure and
the published reports of reproductive toxicity seen in DBP exposed laboratory animals. More
research into the developmental effects of phthalates on fetal development, especially by
DBP was called for.
5.1.1 The in vitro approach
In order to make useful comparisons between the in vitro findings with the rat and human
fetal testis explants, a comparison of the development of the testis in the two species was
appropriate in order to highlight their similarities and differences (see Chapter 1 for more
detail).
For both species, gonadal differentiation may be divided into four stages: pregonadal,
indifferent, primary sex differentiation, and secondary sex differentiation (Voutilainen,
1992). By week six of gestation (6/40w) in the human (el2 in the rat), the hitherto indifferent
XY gonad starts to differentiate and move from its position high in the abdominal cavity to
become a complex organ, the testis positioned outside the abdominal cavity in the scrotum
(Malas et al., 1999). The testis of both species has two major roles: the production of male
gametes, accompanied by hormone production, primarily testosterone. The biggest
difference in testis development between the two species is the timing. In the rat, the
initiation of gonadal development is postponed until the mid-trimester, of the 22-day
embryonic period (e). In the human, there is a 40-week (/40w) gestation period and gonadal
differentiation is initiated around 6/40w then progresses steadily throughout the pregnancy.
However, the extended time of development in the human may mean that there is prolonged
vulnerability to any adverse effects ofphthalate exposure. It may also mean that the maximal
duration of in vitro exposure of testis explants is insufficient to provoke the same level of
response in the human tissue as seen in the rat tissue, due to the differences in development
rate, i.e. slower in the human.
5.1.2 Experimental Objectives
The aim of these studies was to set up a culture system allowing normal fetal testis
development to occur in vitro and then investigate whether normal development was
disrupted after in vitro exposure to phthalates. For this purpose, the development/ function of
the testis explants was assessed by three main criteria, as was done for the optimisation of
the fetal rat testis in vitro system (Chapter 4):
• maintenance of tissue architecture and protein expression
• analysis of the somatic cell proliferation rate
• measurement ofhormone production ± stimulation/ inhibition
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These three criteria would also be used to compare the endpoints seen in the human fetal
testis explants with those seen in the rat fetal testis experiments (Chapter 4).
In vitro incubation of human testis explants at different fetal ages will provide quantitative
information regarding their steroidogenic potential, their sensitivity to known steroidogenic
agents and susceptibility to the effects ofMBP treatment. Moreover, these experiments
exploit the only means by which human tissue can be exposed to phthalates at known
concentrations for designated durations. This is a unique method by which meaningful
information about the effects of direct MBP exposure on fetal testis development can be
obtained.
5.2 Materials and Methods
Further details on the general materials and methods used are listed in Chapter 2. Overall,
following completion of the incubation, media were stored at -20°C before being assayed for
steroid production and explants were analysed for histological changes. The methods used
were consistent with the procedures developed for the experiments with fetal rat testis
explants in Chapter 4 with any species specific differences outlined below.
5.2.1 Sampling of human fetal testes
In November 2004, the Human Tissue Act was introduced, in most part due to the public
enquiries held at Alder Hey and Bristol Royal Infirmary hospitals. This Act provided new
legislation covering the removal, storage and use of human organs and tissue, from dead and
living people. It does not come into affect until 2006 and even then will not apply in
Scotland, where this research was performed. However, the Medical Research Council
(MRC), that funded my work, had previously issued a set of guidelines: "Human Tissue and
Biological Samples for use in Research" (April 2001), primarily aimed at its relevant
researchers and ethics committees. It is under the MRC 2001 guidelines that these studies
were conducted. It should be noted that even with the Act in place, embryos outside the
human body are excluded from its governance.
5.2.1.1 Explant preparation
Fetal human testes were collected and explants prepared as detailed in Chapter 2. At least
one pair of testes per gestational week was stored (one after fixation in Bouin's, the other
intact at 80°C) and not dissected into explants for culture.
Testis explants were cultured on a 0.45pm pore size culture insert with tripod scaffold
(Millipore, UK), secured in a well of a 24-well tissue culture plate, as previously described
and as in Chapters 2 and 4 (Habert et al., 1991). Up to six explants were placed carefully on
the filter and covered in 0.2ml medium. A further 0.2ml ofmedium was placed between the
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well and the scaffold. Explants were incubated at 37°C in an atmosphere of 5% C02 for up to
48h. At least one explant was always fixed in Bouin's prior to incubation, as a baseline
control (t=0h).
5.2.2 Explant culture conditions
The same in vitro conditions were used to incubate the fetal human testis explants as were
optimised for the fetal rat testis explant experiments detailed in section 4.1.1.1.
5.2.2.1 In vitro treatments
In order for the incubated testis explants to be exposed to specific treatments, the chemicals
were mixed with the culture medium prior to addition to the culture well and incubation of
the testis explants. The treatments used, their preparation and dose levels, are detailed in
Chapter 2. Medium was not changed during the experiment but was collected at the end and
stored at -20°C until assayed. At the end of the experiment, explants were fixed in Bouin's
for lh and then processed into paraffin blocks or snap frozen and stored at -80°C.
5.2.3 Analysis of testis architecture and protein
expression
Up to six explants were incubated on a single filter, in a single well. Explants from the same
well were fixed and embedded together in the same paraffin block. Each block was serially
sectioned (5pm slices), mounted on numbered slides then stained and subjected to analysis
as a single replicate. Explants that were fixed in Bouin's were examined microscopically
after immunohistological processing. Biological markers were used to reveal the explant
morphology. Markers used in these experiments are detailed below.
5.2.3.1 Distribution of peritubular myoid cells
Formation of the seminiferous cord requires peritubular myoid cells (Cupp et al., 2003).
These could not be visualised using immunostaining for the cytoskeletal protein Smooth
Muscle Actin-a (SMA) as used for the experiments in Chapter 4, as the human peritubular
myoid cells did not express this protein, though they could be recognised morphologically,
and the expression of this SMA protein was observed in blood vessels (Figure 5.0). It has
been reported that SMA-a is marker of terminal differentiation of smooth muscle cells in the
rat testis so it maybe that these cells were undergoing differentiation in the fetal human testis
(Palombi et al., 1992). Therefore, possible treatment effects of SMA distribution between
species could not be compared.
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Figure 5.0: SMA immunostained sections of human fetal testis explants without in
vitro culture. Note that the blood vessel walls are stained (brow) but cord perimeters (locale
of the peritubular myoid cells) are immunonegative (arrows). Note the scattered distribution
of the interstitial cells (including Leydig cells) The left panel was photographed using a xlO
objective and a focal area re-photographed (rectangle) with a x40 objective as shown in the
right panel.
5.2.3.2 Quantification of Leydig cell distribution
Three numbered slides per block (at least five serial sections apart) were deparaffinised,
rehydrated and immunostained for 3(3-HSD (3(3-HSD antibody gifted by Professor JI Mason,
University of Edinburgh) and lightly counterstained with haematoxylin, according to the
protocol described in Chapter 2. The total area of stained tissue per slide was measured and
the distribution and size ofbrown clusters (immunopositive Leydig cells) within the outlined
blue (counterstained) area, was quantified using a light microscope with a x63 objective and
computer-assisted image analysis as described in detail in Chapter 2 and similar to that
published for the rat (Mahood et al., 2005).
5.2.3.3 Quantification of multinucleated gonocytes
One slide per block was deparaffinised, rehydrated and immunostained for AMH using a
goat anti-AMH polyclonal antibody (Santa Cruz) and counterstained with haematoxylin,
according to the protocol described in Chapter 2. The large spherical nuclei of the gonocytes
were easy to distinguish, amongst the AMH stained Sertoli cell cytoplasm, using a light
microscope with a x63 objective, as were the counterstained perimeters of the nuclear
membrane(s). The number of seminiferous cords per cross section was counted and each
cord assessed for containing none or at least one gonocyte with >1 nuclei per cytoplasm
membrane (a multinucleated gonocyte). The percentage of cords containing at least one
multinucleated gonocyte (MNG) was calculated per block.
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5.2.4 Analysis of the Sertoli cell proliferation rate
During fetal testis development, the various testis cell types undergo proliferation. The rate
ofproliferation can be measured by exposing the testes to the nucleotide base dUTP,
supplied in vitro as the parent compound 5-Bromo-2'-deoxyuridine (BrdU), which is
incorporated into the reproduced DNA in place of the dTTP base. The incorporation of the
dUTP base can be visualised by immunostaining with a relevant antibody. In order to ensure
that proliferation was quantified in Sertoli cells and not another testis cell type undergoing
proliferation, different sections were immunostained for WT-1. This staining within the
tubules was exclusively localised to the Sertoli cells and any extratubular staining was
undefined.
The incidence of Sertoli cell apoptosis was also investigated by labelling fragmenting
(apoptotic) DNA by catalytic incorporation of fluorescein-12-dUTP at the 3 '-OH ends of the
DNA using the terminal deoxynucleotidyl transferase enzyme. This method could discern
apoptotic cells from cells undergoing necrosis, also recognisable microscopically by their
darkly counterstained pyknotic nuclei.
5.2.4.1 Quantification of BrdU incorporation index
Measurement of the 5-Bromo-2'-deoxyuridine (BrdU) incorporation index was possible after
the cultured testis explants were treated with BrdU during the last 4h of the culture as based
on Livera et al (2000). Three numbered slides per block (at least five serial sections apart)
were deparaffmised, rehydrated and immunostained for BrdU incorporation using a sheep
anti-BrdU polyclonal antibody (Fitzgerald Laboratories) and counterstained with
haematoxylin, according to the protocol described in Chapter 2. The number of Sertoli cell
nuclei that showed a clear positive immunoreaction to BrdU per 1000 counted, using a light
microscope with a x63 objective, was converted to a percentage i.e. the BrdU incorporation
index. As BrdU was only incorporated in cells during proliferation, this value was also
referred to as the proliferation index (PI). A mean from each block was calculated and at
least seven blocks per treatment were analysed.
5.2.4.2 Quantification of apoptosis
Apoptotic cells were detected in situ by use of the TUNEL method as described by Livera et
al (2000). There were no TUNEL positive (apoptotic) stained cells seen in the human fetal
testis sections investigated. The positive control sections (rat testis, dl 8) did work which
confirmed that the protocol was followed successfully (see Chapter 2).
Chapter 5 Studies using fetal testis explants from the human 162
5.2.5 Analysis of hormone secretions
Hormone measurements are one of the most sensitive endpoints for studying endocrine
active compounds (O'Connor et al., 2002). To ensure that the explant culture system was
viable, four separate treatments were added to the media to manipulate the testosterone
production level of the testis explants. Testosterone production was manipulated by specific
treatments and their effects were compared to basal hormone production levels as measured
in the media of untreated explants. More details on the doses and rationale behind these
choices are provided in Chapter 2.
5.2.5.1 Measurement of testosterone production
The testosterone secreted into the media was measured in duplicate by radioimmunoassay
(RIA) as described in Chapter 2. No extraction was performed as the only steroid that, in
addition to testosterone, significantly cross-reacts with the testosterone antibody (17(3-
hydroxy-5a-androstane-3-one) is secreted in minute amounts by the fetal testis (Habert and
Picon, 1984). Typically, a 1/10,000 dilution of collected culture media was prepared for
assay.
5.2.5.2 Measurement of inhibin-B production
Though the human fetal testis is able to synthesize and secrete inhibins, previous
experiments (Chapters 3 and 4) showed no significant effects of any treatment on inhibin-B
production levels, so the focus of these studies centred on effects of treatment on
testosterone production and inhibin-B data was not generated (Voutilainen, 1992).
5.2.6 Phthalate Exposure
In the previous Chapter, explants of fetal rat testes were incubated with the DBP metabolite
MBP at doses of up to 10"3M. Parallel studies were conducted with fetal human testis
explants and the results are presented in this Chapter.
The details of the mechanism by which phthalates induce change in the development of the
rodent fetal testis is unclear, but appears to be associated with Leydig cell testosterone
biosynthesis (Akingbemi et al., 2001). As with the rat studies, fetal human testis explants
were exposed to MBP together with the steroidogenic stimulants hCG or 22-R-CHO which
stimulate testosterone production by acting at different points in the steroidogenic cascade.
By comparing whether the steroidogenesis stimulants exerted a reduced effect on
testosterone production with MBP present, it could be pinpointed where in the steroidogenic
pathway the DBP metabolite was having its inhibitory effect. These experiments were
repeated with different concentrations ofMBP to investigate any dose response effect.
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5.2.7 Statistical Analysis
For analysis of the testosterone production data, the mean level per treatment was
determined for each experiment. These values were plotted and subject to statistical analysis
(ANOVA, Dunnett's test). Additionally, the relative change in mean testosterone production
per treatment was plotted, expressed as a percentage of the basal production per experiment
and subject to statistical analysis (ANOVA, Dunnett's test). Where the format of the data
affected the statistical significance of the treatments, the two plots are presented together.
For all data, where sample size was less than 3 (i.e. 1 or 2), the range of the data (standard
deviation from the mean (S.D.)) was plotted, rather than the standard error from the mean
(S.E.M.), unless otherwise stated. A sample size of less than three was not subjected to
statistical analysis. It should be noted that any differences between treatment groups might
be the consequence of the small sample pool. A small sample size (n) is more vulnerable to
being skewed by any extreme responses by outlier data points. Alternatively, because
samples at different developmental ages were pooled, age specific effects of treatment may
have been diluted by the varying sensitivity of differently aged samples. The pooling
approach was considered appropriate as the aim of the studies was to try to induce gross
changes in testis architecture and hormone production with treatments, to compare with the
results from parallel experiments with the rat fetal testis, described in Chapter 4.
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5.3 Results
The in vitro methods used for the culture of the available human fetal testes were based on
the optimised rat model as detailed in Chapter 4. Availability ofhuman fetal samples was
sporadic and samples were of unpredictable fetal age. For presentation and purposes of
statistical analysis, data of all ages was pooled per treatment prior to analysis, unless stated
otherwise.
5.3.1 Age effect on testis weight and testosterone
production
The effect of human fetal age at the time of testis explant preparation was investigated.
Changes in testis weight and testosterone production with increasing age were compared
between 2nd trimester fetal human testes, aged between 14-20w/40w.
Testes were weighed following retrieval from the body cavity and removal of remaining
non-testicular tissue. Testis weight increased with fetal age and linear trend analysis showed
that this was highly significant (PO.OOOl) (Figure 5.1). The increase in testis weight
correlated with the number of explants that could be generated per testis (data not shown), as
seen with the rat tissue (Table 4.1).
6CH
Fetal age (gestational week/40w)
Figure 5.1: Testis weight by human fetal age (gestational week/40w). Values are
means where n=2 and means ± S.E.M. where n>2 (n values are shown in parentheses). Testis
weight increased significantly with gestational age.
The level of basal testosterone produced over 48h during in vitro incubation by testis
explants retrieved from fetuses aged 14-20w was compared. Mean testosterone production
levels rose with fetal age from 14w to a peak at 17w (74 and 558 ng testosterone/ml medium,
respectively), then dropped over 18-20w achieving a mean production level of 92 ng
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testosterone/ ml media (Figure 5.2a). The rise and fall in testosterone production with fetal
age seen in vitro, mimicked the previously reported pattern of fetal human testis testosterone
production in vivo (Voutilainen, 1992). There was no correlation seen between testis weight
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Figure 5.2a: Basal testosterone production by explants of human testis from fetuses of
increasing ages, incubated in vitro at 37°C, over 48h. Values are means where n=l-2 and
means ± S.E.M. where n>2 (n values are shown in parentheses). There was no significant
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Figure 5.2b: Scatter plot comparing basal testosterone production levels by explants of
human testis of increasing weight, incubated in vitro at 37°C, over 48h. Values are means of
the data in Figure 5.2a. There was no significant trend between testis weight and the level of
basal testosterone production.
Note: due to the small number of testes that were available and their varying ages, assay
results were adjusted per testis (per experiment) as a relative amount (%) of the basal
testosterone production level. This meant that the basal value would always be 100%.
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5.3.2 Manipulation of testosterone secretion in vitro
Testis explants were exposed to four agents, three of which are known to affect
steroidogenesis, to investigate whether testosterone production could be manipulated.
Further details on these compounds are provided in Chapter 2.
Testis explants were incubated at 37°C for 48h. Media were prepared with or without the
four additions described above and were collected at the end of the experiment. Samples
from multiple studies were assayed in a single run prior to assay data analysis (Figure 5.3).
ANOVA was significant with PO.OOOl. FSFI showed no consistent effect on testosterone
production, consistent with the rat data (Chapter 4). Data analysis showed no effect of hCG
treatment on testosterone production compared to untreated explants, unlike seen with the rat
tissue. The media from explants incubated with the steroidogenic inhibitor KTZ consistently
showed a significantly reduced (P<0.01) level of testosterone compared to untreated
explants. This decrease was in contrast to experiments with rat testis explants, which were
unable to show an inhibitory effect ofKTZ. Treatment with 22-R-CHO consistently
increased testosterone production relative to basal levels consistent with the rat data (Chapter
4). Overall, these results suggest that steroidogenesis in the fetal testis of the two species is
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Figure 5.3: Production of testosterone in vitro by fetal human testis explants aged
between 14w-20w gestation, after culture for 48h with different media additions. Values are
means ± S.E.M. (n values are shown in parentheses). KTZ significantly reduced testosterone
production (**P<0.01) and 22-R-CHO significantly increased testosterone production
(**p<0 oi) when data were analysed as relative values. There was no significant effect of
hCG or FSH.
Chapter 5 Studies using fetal testis explants from the human 167
5.3.3 Effect of DBP and MBP on testis explants
5.3.3.1 Effect of DBP or MBP on testosterone production
Analysis of testosterone levels, measured in media from phthalate treated explants, showed
no effect of increasing phthalate concentration on testosterone production, compared to basal
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Figure 5.4: Relative testosterone production by fetal human testis explants after
culture with different phthalate concentrations, for 48h at 37°C. Values are mean ± S.E.M. (n
values are shown in parentheses). ANOVA showed no significant effect of neither MBP nor
DBP on testosterone production, compared to basal levels.
5.3.3.2 Effects of phthalates combined with steroidogenic
stimulants on testosterone secretion in vitro
In previous experiments with fetal rat testis explants, neither MBP nor DBP had an
inhibitory effect on basal testosterone production but MBP co-incubated with hCG did blunt
the stimulatory effect of hCG alone on testosterone production. No effect ofMBP on 22-R-
CHO stimulated testosterone production was seen in the fetal rat experiments. These
experiments were repeated using fetal human testis explants, incubated with a combination
of 22-R-CHO or hCG plus 10"5M MBP or 1 (T3M MBP or 10"3M DBP. Testosterone data
were compared against basal and stimulant treated levels.
The level of 22-R-CHO stimulated testosterone output was not significantly reduced when
either MBP or DBP were co-administered (Figure 5.5). This was consistent with previous
Chapter 5 Studies using fetal testis explants from the human 168
experiments (Chapter 4) in which no significant effect ofMBP on testosterone production by



























in vitro treatment (48h)
Figure 5.5: Testosterone produced in vitro by fetal human testis explants after culture
for 48h at 37°C, with 22-R-CHO (R) and 10"3M MBP or 10"3M DBP. Values are mean ±
S.E.M. (n values are shown in parentheses). There was no significant effect of either
phthalate on 22-R-CHO stimulated testosterone production. ANOVA of relative levels
showed a significant difference (P=0.031) in testosterone production between basal and all
22-R-CHO incubated explants.
Different explants were incubated with a combination of hCG plus 1 0~5M MBP or 10 3M
MBP. Testosterone production data from co-incubated explants were compared against
levels of testosterone production from explants incubated with just hCG. Co-incubation of
the explants with hCG in a single experiment revealed a trend towards a reduction in the
amount of testosterone produced with both concentrations ofMBP (Figure 5.6a). When the
individual co-incubation data were analysed against the pooled basal and hCG data (as in
Figure 5.3), then a significant difference was achieved (P<0.01) (Figure 5.6b).


















in vitro treatment (48h)
Figure 5.6a: Testosterone produced in a single experiment by explants from a fetal
human testis after culture for 48h at 37°C, with hCG ± 10"5M MBP or 10"3M MBP. Values
show a mean ± range where n=2 or ± S.E.M. where n>2 (n values are shown in parentheses).




in vitro treatment (48h)
Figure 5.6b: Testosterone produced by fetal human testis explants after culture for 48h
at 37°C, with hCG ± 10"5M or 10~3M MBP. Relative basal and hCG values from multiple
experiments were plotted with the co-incubation data from Figure 5.6a. ANOVA = PO.OOOl
and further analysis showed that co-incubation with 10"5M or 10"3M MBP significantly
(**p<0 oi) reduced testosterone production to below basal levels.
5.3.3.3 Effects of MBP on testis cell histology
It was hypothesised that in vitro incubation of human fetal testis explants, exposed to MBP,
might induce similar histological changes to those seen with rat fetal testis explants
incubated with MBP (Chapter 4). For comparison, the same parameters were assessed in
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fetal human testis explants after incubation in vitro, with or without 10~3M MBP. The effects
ofDBP in vitro on explant histology were not assessed.
5.3.3.3.1 Effect of MBP on Sertoli cell proliferation
The level of cell proliferation ongoing for the last 6-8h of incubation of the experiment was
assessed after immunostaining sections of the explants, for the incorporation of BrdU. No
BrdU immunostaining was detected in Sertoli cell nuclei (Figure 5.7) so it was concluded
that Sertoli cells were not proliferating in testis explants, aged 14-19/40w. The expression of
known Sertoli cell proteins was confirmed by immunostaining for the nuclear protein WT-1
(Figure 5.8) and the cytoplasmic protein AMFI (Figure 5.9). As Sertoli cells were the only
cell type for which a PI was calculated in the rat testis experiments, both in vivo and in vitro,
a comparison of the effect ofMBP on the proliferation index between the species could not
be made. The proliferation indices of non-Sertoli cells were not determined but this
observation was consistent with previous studies of ex-vivo human testes across a similar
age range (Murray et al., 2000; Voutilainen, 1992).
Figure 5.7: BrdU immunostained section of fetal human testis explants after culture
for 48h, with or without MBP (10"3M). BrdU was incorporated by peritubular myoid cells
(narrow arrows), interstitial cells (wide arrows) and round intratubular germ cells (asterix)
but no intratubular Sertoli cells (arrow heads). The top panels were photographed using a
x40 objective with focal areas enlarged in the panels below. Any difference in colouration is
an artefact of the image processing and was not evident visually.
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Figure 5.8: WT-1 immunostained section of fetal human testis explants after culture
for 48h, ± MBP (10 3M). WT-1 is used as a marker of intratubular Sertoli cell nuclei
(brown); WT-1 negative intratubular cells are most likely to be fetal germ cells (arrow).
These panels are focal areas enlarged from images photographed using a x40 objective.
5.3.3.3.2 Effect of MBP on gonocytes
Gonocytes were undergoing normal mitotic proliferation during the fetal ages examined,
hence an abnormally nucleated gonocyte was defined as having more than two nuclei per
cell membrane as normal untreated/ uncultured fetal human testis cords contain
mononucleated gonocytes, with rare and infrequent multinucleated gonocytes (MNG's).
AMH immunostained sections from cultured explants were analysed and the percentage of
seminiferous cords per section that contained at least one MNG was recorded.
Only a single MNG was seen amongst all the sections examined, in an untreated explant,
therefore the significance ofMBP exposure on MNG incidence could not be evaluated nor
could any comparison of the effect ofMBP on the incidence ofMNG's, between the species,
be made (Figure 5.10).
Figure 5.9: AMH immunostained sections of human fetal testis explants after in vitro
culture ± MBP (10"3M), for 48h at 37°C. Note that gonocyte nuclei are mononuclear
(arrows) and surrounded by stained Sertoli cell cytoplasm. There was no discernible effect
on the gonocyte nuclei with MBP-treatment. These panels show cross sections through testis
explants photographed using a x40 objective.
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5.3.3.3.3 Effect of MBP on Leydig cell aggregation
Leydig cell aggregation has been previously measured in the rat (Chapters 3 and 4) using a
computer assisted stereological method, after fixed testis sections were immunostained for
the steroidogenic enzyme 3|3-HSD (3 |3-hydroxysteroid dehydrogenase), to highlight Leydig
cell distribution. Compared to the fetal rat testis sections analysed in the previous two
Chapters, the distribution of the Leydig cells in the fetal human testis explants was scattered
(Figures 5.0 and 5.10) rather than aggregated (Figure 4.20), prohibiting computer assisted
analysis of their distribution. Alternative Leydig cell markers to 3(3-HSD were investigated,
including P450scc, StAR and SR-B1 (not shown) but none of these could be "read" by the
computer software either. This meant that the Leydig cell distribution of in vitro cultured
human fetal testis explants could not be successfully quantified. Qualitative assessment
showed no obvious difference in Leydig cell distribution between untreated explants or those
treated with MBP and there was no obvious, reproducible, effect of treatment on the
intensity of the immunostaining achieved with any of the Leydig cell markers tried.
However, in support of the present experiments, the testicular steroidogenic enzyme
expression data generated in these studies, correlated well with previously reported changes
in gonadal steroidogenesis with human gestational age (Voutilainen and Miller, 1986).
Figure 5.10: 3P-HSD immunostained sections of human fetal testis explants after in
vitro culture with or without MBP(10~3M), for 48h at 37°C. Note the dispersed arrangement
of the Leydig cells (brown). There was no discernible change in Leydig cell distribution with
MBP-treatment, compared to the control explants. These panels show cross sections through
testis explants photographed using a x40 objective.
5.4 Discussion
Previous studies (Chapters 3 and 4) were able to demonstrate that exposure to DBP in utero
or MBP in vitro caused abnormal development of the rat fetal testis, including decreased
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production of testosterone. The primary aim of these experiments was to use an in vitro
organotypic culture system for the human fetal testis to investigate the influence ofMBP, at
a maximum dose of 10"3M, on testosterone production and testis development. Whether fetal
age affected their sensitivity, could not be assessed from these experiments.
Analysis of testis architecture and cell proliferation in fetal human testes, demonstrated that
protein expression indicative of the cell distribution, did differ from the fetal rat testis
explants, even for untreated samples. In the human explants, there was little if any staining
of the peritubular myoid cells with SMA, used to highlight the perimeters of the developing
seminiferous cords, and the Leydig cells were less aggregated, prohibiting cluster analysis.
These were not artefacts of the culture process as they were evident in uncultured tissue (not
shown). The Sertoli cells were not proliferating at all, though other testis cell types were,
including the fetal germ cells, again in contrast to the findings with the fetal rat testis
cultures (Murray et al., 2000). This observation was consistent with previous observations of
uncultured human testes across this age range (Murray et al., 2000). The viability of the
Sertoli cells was confirmed by the expression of the proteins WT-1 and AMH, as necrotic
cells present in the cultured tissue did not express cell-specific proteins (Sharpe et al., 2003).
The absence ofmultinucleated gonocytes in the treated samples was different from the rat in
vitro experiments where MNG's were found in all cultured explants, with or without MBP
exposure. Polyploidism, of fetal germ cells (though different to multi-nucleation is still
associated with abnormal cell division) is hypothesised to be an early indicator of germ cell
tumourigenesis so though it may not have been induced in these samples under these
conditions, it may yet be inducible by phthalate exposure over different timepoint, dose level
or exposure duration and in vivo (Chemes et al., 2003).
Testosterone production was measured as a means of determining whether MBP (10"6M, 10"
5M, 10"4M or 10"3M) had any effects comparable to those found in the experiments with the
fetal rat testis explants (Chapter 4). There was no effect of up to 10"3M MBP or 10"3M DBP
on basal testosterone production by the fetal human testis explants, consistent with the in
vitro rat studies. Incubation of explants with 22-R-CHO produced an increase in the level of
testosterone produced, also consistent with the in vitro rat studies.
Experiments in which explants were incubated with the steroidogenic stimulant hCG had no
effect upon basal testosterone production. This was contrary to the idea that placental hCG
may regulate testosterone synthesis during this phase of gestation (Voutilainen, 1992).
Additional studies where fetal testicular testosterone production was measured following
long term, high dose gonadotropic stimulation of cultured human, rhesus monkey, and rabbit
fetal testes, reported that fetal Leydig cells were capable of responding to gonadotropins (0-
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100 ng/ml hCG) and could secrete testosterone at high levels for up to 24h (Leinonen and
Jaffe, 1985). Further studies also demonstrated the role of hCG in the regulation of testicular
steroid production in human fetuses from 14 to 20 weeks gestational age using saturable
binding of 125I-hCG to testicular homogenates. The greatest increase in testosterone
production occurred when the hCG concentration was increased from 0.5 to 5 ng/ml (=
0.005 to 0.05iu (physiologically relevant range, compared to the O.liu/ml used in the present
studies (Huhtaniemi et al., 1977). However, Word et al (1989) were unable to show a
response to hCG stimulation in homogenates of fetal testes obtained from first and second
trimester human abortuses, consistent with the present studies. These findings suggest that it
is unclear whether the onset of testosterone formation in human fetal testes is independent of
gonadotropin control (Word et al., 1989).
Additional experiments involved incubating explants with a mixture of hCG and MBP (10"
5M or 10"3M) and revealed that both doses of MBP reduced the amount of testosterone
produced compared to when explants were incubated with hCG alone. This result was
consistent with the rat in vitro experiments. Though the human explants appeared to be
sensitive to MBP at a lower concentration (10"5M) than the in vitro rat experiments when co-
incubated with hCG, the rat explants were exposed to MBP at slightly different
concentrations of (10"6M or 10"9M). It cannot therefore be determined whether the rat system
would have shown an effect ofMBP on testosterone production at 10"5M MBP. The
reduction of testosterone output when MBP was co-incubated with hCG but not with 22-R-
CHO, suggests that MBP targets part of the testosterone biosynthesis cascade initiated by the
binding of hCG to the LH receptor, but upstream of the point at which 22-R-CHO exerts its
effect. This conclusion was comparable with the results of the parallel experiments using
fetal rat testis explants.
It has been reported that rodents differ conspicuously from primates in their manner of
metabolizing phthalates so the relevance of any differences must be clarified before rodent
species can be understood as models for the effects of phthalates in humans (Albro et al.,
1982). However, the findings from these present studies do indicate the possibility of a
reproducible effect ofMBP exposure on testosterone production in both fetal rats and fetal
humans but further experiments are required to reconcile these findings.
But, it must be emphasised that as neither hCG nor MBP had a significant effect on basal
testosterone production, it is not readily explained why the combination of these two
compounds should reduce testosterone production consistently and at two concentrations of
MBP, other than the possibility of these data being chance results, perhaps due to culture
variability. One of the limitations of the present studies is the multiple-comparison situation:
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only a small number of samples were available and each testis was divided into explants that
underwent different treatments. Thus, the number of statistical tests performed was restricted
and some may randomly reach statistical significance. It is possible that this phenomenon
could account for the significant reduction in the level of testosterone produced when
explants were co-incubated with 10"5M MBP and hCG compared to hCG alone (section
5.3.3.3). However, this result was reproduced at two doses ofMBP and was seen with 10 3M
MBP and hCG in the in vitro rat experiments and furthermore is consistent with current
understanding of the mechanism ofMBP toxicity.
Not all the adverse effects on rat fetal testis development induced by in vitro MBP exposure
were successfully reproduced in fetal human testis explants incubated under identical
conditions for the same duration. The inability of this system to reproduce all of the same
endpoints as the in vitro studies reported in Chapter 4, is considered most likely to be the
consequence of the species difference and not the method used. Such a difference has been
reported before. Lin et al (1995) compared lipid synthesis in human and rat hepatocytes and
reported that propionate inhibited cholesterol synthesis in 50% of the rat cells at 0.1mM/l but
human hepatocytes required 10-20mM/l propionate to achieve an equal level of inhibition
under identical primary culture conditions (Lin, 1995). This species-specific difference in
sensitivity to metabolic agents could contribute to the difference in sensitivity to inhibition
by Ketoconazole, seen with the human explants but not seen in the rat experiments.
It is difficult to compare the dose of a compound delivered to rodents experimentally to the
dose of the same compound delivered to humans through uncontrolled low level
environmental exposure. The ultimate aim of using animal models to investigate medical
problems is to obtain findings that are predictive of the situation in humans. Second trimester
human fetal testes (14-20w/40w) were available from legal abortuses, enabling parallel
studies to those undertaken with rat fetal testis explants, to be undertaken with human fetal
testes.
However, the lack of developmental parallels between these two species and the
developmental stage of the samples available (second trimester fetal human testes vs. late
gestation fetal rat testes) restricted the degree to which these aims could be achieved.
For example: the main cell types of the testis were at inconsistent phases ofproliferation or
maturity, germ cells were quiescent in the rat but proliferating in the human samples whereas
the opposite was true of Sertoli cells, quiescent in the human yet proliferating in the rat.
Also, the steroidogenic cells showed a disperse arrangement in the human samples compared
to their distinct aggregation in the rat testes. However, both systems used testes explanted
Chapter 5 Studies using fetal testis explants from the human 176
around their peak of testosterone secretion, 12-16/40w in the human and el 8-19.5 in the rat
(El-Gehani et al., 1998; Voutilainen, 1992).
In conclusion, these data show that fetal human testes can be successfully cultured under the
outlined conditions for up to 48h. The incorporation of the proliferation marker BrdU and
the production of testosterone confirm that the explanted testes, dissected at 14-20/40w, were
viable in this organotypic culture system.
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6 Studies using short-term exposure of the fetal rat
to phthalates
6.1 Introduction
The original in vivo studies reported in Chapter 3, aimed to investigate whether in utero exposure
ofmale rats to 500mg DBP/kg/day from el3-e21.5 would induce a range ofmalformations in the
reproductive tract that paralleled human TDS. The extent, to which this was achieved, is discussed
at the end of Chapter 3. The inability to induce the same disorders or effects after exposure of fetal
testis explants to the DBP metabolite MBP over a 48h period in vitro, raised the question of
whether this was related to the age of the fetus at first exposure to MBP/DBP (i.e. el9.5) and/or
the short (48h) duration of exposure (Chapter 4).
Hence, in vivo studies were set up to investigate whether it was feasible for 48h exposure, from
el9.5-e20.5 (DBP 500 S), to induce any of the changes in testis morphology and testosterone
production seen in the original studies involving exposure to DBP from el3.5-e20.5 (DBP 500 L).
6.2 Methods and Materials
The aim of these studies was to establish whether it was feasible for DBP to induce phenotypic
changes to the fetal rat testis collected at el9.5, then maintained in vitro for 48h (Chapter 4). For
the in vivo model, pregnant rats were treated on el9.5 and e20.5 only and the testes collected for
study on e21.5. These were compared with age-matched animals subjected to a longer DBP
treatment regime (el3.5 to e20.5) as reported in Chapter 3. Three additional treatments were used
in these preliminary investigations, all administered on el9.5 and e20.5:
• DBP 500 S = 500mgDBP/kg/day (n=3)
• MBP 500 S = 500mgMBP/kg/day (n=l (1 dam died prior to end of treatment)
• MBP 185 S = 185mgMBP/kg/day (n=2)
These were compared to previous studies with longer dosing regimes, daily from el3.5 to e20.5:
• Control = 1ml Corn oil/kg/day (n>4)
• DBP 500 L = 500mgDBP/kg/day (n>4)
There were no obvious differences between the testes exposed to vehicle from el3-e20.5
compared to el9-e20.5 (n=l), so control data were combined for statistical analysis. The focus for
the investigations was the comparison of the two DBP treatment regimes. The MBP 500 S animal
(n=l) was added to enable a comparison between effects induced by the metabolite as used in the
in vitro studies and the parent compound (DBP) as used for the in vivo studies. Two dams were
treated with a dose of 185mg MBP/kg bodyweight. This dose level was calculated to approximate
the top dose of ImM MBP used in the in vitro experiments. It has been determined that a fetus
receives 0.12-0.15% of the administered maternal dose (Saillenfait et al., 1998).
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Therefore, 0.12% = 1/833, so if the in vitro studies exposed the fetal testis to ImM, the equivalent
maternal dose would be 833mM. Given that the molecular weight ofMBP = 222, ImMol =
0.222g/l, 833mMol = 185g/l = 185mg/ml of vehicle, dosed at lml/kg = 185mg/kg.
Tissue was analysed using the same general methods as used in Chapter 3.
6.2.1 Statistical analysis
Due to the small sample size used for these studies, statistical analysis was not always possible.
Specific computer software was used to assist in the data analysis, as previously described in
Chapter 2 (GraphPad Prism v4.0b for Macintosh, GraphPad Software, San Diego, USA).
6.3 Results
Following in vivo treatment, fetal testes were recovered at e21.5; left testes were weighed,
Bouin's fixed, sectioned and immunostained as required, whereas right testes were snap frozen
until processed for protein or steroid level investigations. At e21.5, each major testis cell type was
observed and analysed separately, namely Sertoli cells, gonocytes and Leydig cells. The
peritubular myoid cells, that surround the developing testis cords, had not shown any obvious
treatment related changes with the longer dosing regime so were not investigated.
6.3.1 Effect of fetal exposure to DBP on e21.5 testes
Testis weight was recorded in e21.5 rats and the mean testis weight per litter per treatment regime
was calculated. DBP 500 L treatment induced a significant decrease in testis weight compared to
Control treatment as reported previously and DBP 500 S induced a slight decrease from the
control mean of 1.384mg to 1.345mg (Figure 6.1). The reason for this consistent decrease in
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Figure 6.1: Mean testis weight per litter (mg) of e21.5 fetal rat testes after in utero
exposure to vehicle (control) or 500mgDBP/kg/day from el3.5-e20.5 or el9.5- e20.5. Individual
mean per litter (n) and mean per treatment (horizontal line) are plotted (n values are shown in
parentheses).
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6.3.1.1 Sertoli cells
Immunostaining of testis sections for the Sertoli cell nuclear marker WT-1, showed Sertoli cell
nuclei at the periphery of the testis cords in all samples at low magnification (not shown). Review
of the slides at higher magnification, revealed WT-1 stained cells in the interstitium of treated
testes (Figure 6.2). This abnormal staining pattern was consistent in testes following either the
long-term or the short-term exposure regime and was absent from vehicle-exposed testes.
Control DBP500 L DBP500 S
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Figure 6.2: WT-1 immunostained sections of e21.5 fetal rat testes after in utero exposure to
vehicle (control) or 500mgDBP/kg/day from el3.5-e20.5 or el9.5- e20.5. Note the positioning of
stained Sertoli cell nuclei, at the periphery of the developing cords. Additional staining was seen
within abnormal "dysgenetic" interstitial areas of both DBP exposed testes (dashed outlines). The
panels show a cross section through a whole testis photographed using a x40 objective.
The effect of in utero DBP exposure on the rate of Sertoli cell proliferation was measured by
immunostaining Bouin's fixed testis sections for incorporation ofBrdU, injected into the mother
1.5h prior to kill. Proliferation was also evident in non-Sertoli cells (e.g. interstitial cells, Figure
6.3) but this was not measured. No BrdU uptake was seen in any gonocytes (Figure 6.3, inset).
There was no significant difference in the proliferation index for Sertoli cells in the DBP 500 S
exposed testes when compared to DBP 500 L or the respective Controls (Figure 6.4).
Immunostaining ofSertoli cells in DBP 500 S exposed testes for markers of apoptosis (TUNEL)
showed no staining (not shown); this was consistent with the DBP 500 L data as detailed in
Chapter 3.
Given that there was no significant effect of treatment on the levels of inhibin-B production seen
in either the original in vivo or the in vitro studies, inhibin-B levels were not compared between
the two in vivo regimes.
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Overall, regarding Sertoli cell effects, the DBP 500 S exposure regime showed a similarly low
level of adverse effects on testis development, as did the DBP 500 L regime.
Figure 6.3: BrdU immunostained sections of e21.5 fetal rat testes after in utero exposure to
vehicle (control) or 500mgDBP/kg/day from el3.5-e20.5 or el9.5- e20.5. BrdU administered 1.5h
prior to testis collection, was incorporated by intratubular Sertoli cells (arrow) as well as
interstitial cells (arrow head) but not intratubular gonocytes (inset). There was no obvious effect
of treatment on the level of BrdU staining. The panels were photographed using a x40 objective,
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Figure 6.4: Proliferation Index (%) of Sertoli cells in e21.5 fetal rat testes after el3.5-20.5
or el9.5-e20.5 in utero exposure to: vehicle (combined data = Control) or either el3.5-20.5 (DBP
500 L) or el9.5-20.5 (DBP 500 S) in utero exposure to 500mgDBP/kg/day or el9.5-20.5 in utero
exposure to 500 or 185 mgMBP/kg/day (MBP 500 S and MBP 185 S respectively). Values are
litter means where n=l-2 and litter means ± S.E.M. where n>2 (n values are shown in
parentheses). There was no significant effect of any treatment regime on Sertoli cell PI.
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6.3.1.2 Gonocytes
Testis sections were immunostained for AMH, a protein expressed in the Sertoli cell cytoplasm
that surrounds the fetal gonocytes. Low magnification reviews of the AMH staining demonstrated
that the number of cords present per testis after DBP exposure was altered (Figure 6.5). This
difference was quantified and revealed a significant reduction in the number of cords per section
following even short-term DBP exposure, compared to the control sections (Figure 6.6). Whether
this reduction was the result of fewer cords or reduced coiling of the same number of cords could
not be deduced by these studies. The effect of treatment on mean cord diameter was not
quantified. It should be noted that the plane of section analysed per sample and per treatment were
comparable.
Further review of the sections showed normal AMH negative areas between the developing cords
in control and treated sections. DBP 500 L treated sections also showed areas between cords with



























Figure 6.5: AMH immunostained sections of e21.5 fetal rat testes after in utero exposure to
vehicle (control) or 500mgDBP/kg/day from el3.5-e20.5 or el9.5- e20.5. The sections from DBP-
exposed animals show a reduced number of cords with altered gonocyte distribution (abnormally
clustered in the centre of the cords). The panels were photographed using a x4 objective.
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Figure 6.6: Number of seminiferous cords per cross section of e21.5 fetal rat testes after
el3.5-20.5 or el9.5-e20.5 in utero exposure to: vehicle (combined data = Control) or either el3.5-
20.5 (DBP 500 L) or el9.5-20.5 (DBP 500 S) in utero exposure to 500mgDBP/kg/day or el 9.5-
20.5 in utero exposure to 500 or 185 mgMBP/kg/day (MBP 500 S and MBP 185 S respectively).
Values are liter means where n=l-2 and litter means ± S.E.M. where n>2 (n values are shown in
parentheses). ANOVA showed a significant (P=0.0005) decrease in the number of seminiferous
cords per testis cross section for both DBP treated groups compared to the control testes, though
further analysis showed that DBP 500 L testes had significantly less (***P<0.001) cords than did
the DBP 500 S testes (**P<0.01).
Examination of AMH stained testis sections at higher magnification (>x40) revealed the presence
of abnormal multinucleated gonocytes (MNGs) in testes subjected to the DBP 500 S exposure
regime (Figure 6.7). This was consistent with the observations of the DBP 500 L exposed testes
reported in Chapter 3. It was noted that the mean incidence value for MNGs was higher with the
short-term DBP regime (53.6%) than for the long-term DBP exposed testes (37.1%) (Figure 6.8).
The dose ofMBP administered appeared to affect the incidence ofMNGs inversely, though this
was not investigated further. Overall, regarding gonocyte effects, the short-term phthalate
exposure regime showed at least an equivalent level of adverse change as did the long-term
regime, if not slightly more severe.
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Control DBP 500 L DBP 500 S
Figure 6.7: AMH immunostained sections of e21.5 fetal rat testes after in utero exposure to
vehicle (control) or 500mgDBP/kg/day from el3.5-e20.5 or el9.5- e20.5. The Control sections
show normal mononucleated gonocytes (green circles) dispersed across even-sized cords
compared to the distended cords in the sections from DBP-exposed animals and their abnormal
gonocyte positioning. Abnormal multi-nucleated gonocytes (red circles) were present in the testis
cords following both DBP exposure regimes. The top panels were photographed using a x40
objective and the lower panels were photographed using a xlOO objective.
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Figure 6.8: Incidence (%) of multinucleated gonocytes (MNGs) in e21.5 fetal rat testes
after el3.5-20.5 or el9.5-e20.5 in utero exposure to: vehicle (combined data = Control) or either
el3.5-20.5 (DBP 500 L) or el9.5-20.5 (DBP 500 S) in utero exposure to 500mgDBP/kg/day or
el9.5-20.5 in utero exposure to 500 or 185mgMBP/kg/day (MBP 500 S and MBP 185 S
respectively). Values are litter means where n=l-2 and means ± S.E.M. where n>2 (n values are
shown in parentheses). All DBP exposed groups showed a highly significant increase in the
frequency ofMNGs (*** P0.001).
6.3.1.3 Leydig cells
Normal untreated/ uncultured fetal testes aged e21.5 contain small clusters of Leydig cells,
disseminated throughout the testis. Normally, each cluster occupies <5% of the total Leydig cell
area per testis section, resulting in >20 clusters per section. Occasionally, control Leydig cell
clusters occupy between 5-15% of the total Leydig cell area per section but clusters >15% were
rarely seen in testis sections from untreated animals. Clusters were categorised by these
percentage areas and defined as either small (<5%), medium (5-15%) or large (>15%). The effect
ofDBP exposure on the distribution ofLeydig cell clusters was quantified using computer
assisted stereological techniques, detailed in Chapter 2.
Three sections per sample were assessed in three pups per litter and the mean values compared
between samples (Figure 6.9). The percentage of the total testis section area that was occupied by
Leydig cells and for each of the cluster categories was analysed (Figure 6.10).
The distribution of the Leydig cells showed a trend away from small clusters with phthalate
exposure, compared to vehicle controls, with the largest shift seen in testes from animals exposed
to DBP under the DBP 500 L regime.
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Figure 6.9: 3(3-HSD immunostained sections of e21.5 fetal rat testes after in utero exposure
to vehicle (control) or 500mgDBP/kg/day from el3.5-e20.5 or el9.5- e20.5. Note the markedly
larger Leydig cell clusters in the DBP 500 L sections, compared to the control sections. The top
panels were photographed using a xlO objective and the lower panels were photographed using a
x40 objective.
decontrol (n=4)
dJDBP 500 L (n=4)
■DBP 500 S (n=3)
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e21.5 rat testis Leydig cell cluster category
large (>15%)
Figure 6.10: Leydig cell cluster size index (%) of 3|3FISD immunopositive stained areas in
e21.5 fetal rat testes after in utero exposure to vehicle (control) or 500mgDBP/kg/day from el 3.5-
e20.5 (L) or el9.5- e20.5 (S). Values are litter means ± S.E.M. (n values are shown in
parentheses). Both DBP exposure regimes produced a decrease in the percentage of Leydig cells
in small clusters and a shift towards an increase in medium and large clusters, though this change
was only significant for the el3.5-e20.5 (L) exposed testes (** P<0.01, * P<0.05).
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6.3.1.3.1 Testosterone production
One testis per litter was homogenised, the steroids were extracted then assayed for testosterone
levels by RIA and the values compared between treatments (Figure 6.11). Both in vivo DBP
exposure regimes induced a significant decrease in the total level of testosterone per testis
(ANOVA P=0.014), from 17.8ng per control testis (100%) to 10.4ng per DBP 500 L testis (59%)
and 5.9ng per DBP 500 S testis (33%). This result suggests that the 48h exposure of testis explants
in vitro to the DBP metabolite MBP, was of sufficient duration to induce a decrease in basal
testosterone production, if the in vitro model was capable of reproducing phthalate induced
changes as seen in vivo.
Control DBP 500 L DBP 500 S
In utero treatment
Figure 6.11: Relative testicular testosterone levels in e21.5 fetal rat testes after el3.5-20.5 in
utero exposure to vehicle (Control) and either el3.5-20.5 (DBP 500 L) or el9.5-20.5 (DBP 500 S)
in utero exposure to 500mgDBP/kg/day. Values are litter means ± S.E.M. (n values are shown in
parentheses). ANOVA was significant (P=0.003). The DBP 500 L regime induced a significant
decrease (*P<0.05) in the level of testosterone produced compared to the vehicle control, but a
bigger difference was induced by the DBP 500 S regime (**P<0.01).
6.3.1.3.2 Steroidogenic enzyme expression
The expression level of the rate-limiting enzyme for testicular steroidogenesis (P450scc) was
compared between the three treatment groups to investigate the difference in testosterone level
induced by the different in vivo treatments (Omura and Morohashi, 1995). The expression level of
testicular P450scc protein per treatment was compared against that of the non-steroidogenic protein
Smooth Muscle Actin (SMA) as described previously (section 3.3.1.3). Expression levels of
P450scc and SMA were measured and compared per treatment following Western Blot analysis of
extracts of total testis protein (Figure 6.12). The expression levels were quantified using computer
assisted image analysis (Image Quant) and relative expression data for P450scc was subject to
statistical analysis (Figure 6.13).
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DBP treatment showed a highly significant (P=0.0014) decrease in the level of P450scc expression
relative to SMA expression when compared to untreated testes. This study demonstrated that the
rate-limiting step of steroidogenesis was compromised by both DBP exposure regimes.





Figure 6.12: Comparison of protein expression in e21.5 fetal rat testes after el3.5-20.5 in
utero exposure to vehicle (Control) and either el3.5-20.5 (DBP 500 L) or el9.5-20.5 (DBP 500 S)
in utero exposure to 500mgDBP/kg/day. An example of a Western blot showing the level of
P450scc expression compared with SMA expression is illustrated. This was quantified using























Figure 6.13: Relative P450scc protein expression in e21.5 fetal rat testes after el3.5-20.5 in
utero exposure to vehicle (Control) and either el3.5-20.5 (DBP 500 L) or el9.5-20.5 (DBP 500 S)
in utero exposure to 500mgDBP/kg/day. Values are litter means ± S.E.M. (n values are shown in
parentheses). ANOVA was highly significant (PO.OOQl). The DBP 500 L regime, induced a
significant decrease (***P<0.001) in the level of testosterone produced compared to the vehicle
control, with a significant but smaller difference induced by the DBP 500 S regime (**P<0.01).
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An additional experiment compared the expression pattern of P450scc in the Leydig cells with that
of another steroidogenic enzyme, namely 3p-HSD. This investigated whether P450scc expression
levels did vary across the testis or whether any variations were localised. This experiment was
facilitated by the use of fluorescent co-localisation of immunostaining of P450scc and 3p-HSD
protein expression in Bouin's fixed testis sections, as described previously (Section 3.3.1.3). The
distribution of co-localisation was compared between the treatments against the vehicle control
testis (Figure 6.14). Expression levels were not quantified but qualitative assessment suggested
that there was no obvious treatment related change in the distribution of the two proteins between
the testes of either of the DBP-exposure regimes and/or the vehicle control. The reduction in
P450scc expression seen with the Western blot analysis (Figure 6.12) could not be reproduced
using this technique.
Figure 6.14: Examination of e21.5 fetal rat testes after el3.5-20.5 in utero exposure to
vehicle (Control) and either el3.5-20.5 (DBP 500 L) or el9.5-20.5 (DBP 500 S) in utero exposure
to 500mgDBP/kg/day. Sections were immunostained for 3P-HSD (red) and P450scc (green) to see
whether the pattern of co-localisation (yellow) was affected by treatment. Blue = nuclear
counterstain. An enlarged image of the region in the white box can be seen below the
corresponding image, taken at x40 magnification.
Additional Western blot analyses were performed, using samples from one animal but in
duplicate. These trial studies quantified blots of: 3P-HSD, Inhibin-a expression in testes and
P450scc expression in adrenals of the same animals. The relative levels of expression were
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determined, compared to testicular SMA as previously, though small groups sizes (n=l, in
duplicate) prohibited any statistical analyses (Figures 6.15 to 6.17). These preliminary
experiments revealed that there was no obvious effect of the treatment regimes on the level of
P450scc expression in the adrenal glands, unlike in the testes (Figure 6.12) and that 3p-HSD
expression in the tests was not obviously affected by the treatments (Figure 6.15), unlike testicular
P450scc. Finally, a "quick look" at testicular inhibin-a hinted that its two isoforms detected by the
antibody used might be differentially affected by in utero exposure to 500mgDBP/kg/day over
both exposure regimes (Figures 6.16 and 6.17). Fetal testis inhibin-a has been shown previously
to produce two bands under reducing conditions, reported as measuring approximately 47 and
50kDa (Noguchi et al., 1997).
These data support the idea that the effect ofDBP is specific to the testis and that not all the
proteins associated with steroid biosynthesis are affected. Any relevance of the possible effect on
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Figure 6.15: Relative protein expression in e21.5 fetal rat testes or adrenals after el3.5-20.5
in utero exposure to vehicle (Control) and either el3.5-20.5 (DBP 500 L) or el9.5-20.5 (DBP 500
S) in utero exposure to 500mgDBP/kg/day. Values are sample means ± SD's (n =2). No statistical
analyses were performed. The data suggest there was no obvious effect of either treatment regime
on adrenal levels of P450scc or on testis levels of 3|3-HSD.
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Ladder Control DBP 500 L DBP 500 S
Figure 6.16: Comparison of protein expression in e21.5 fetal rat testes after el3.5-20.5 in
utero exposure to vehicle (Control) and either el3.5-20.5 (DBP 500 L) or el9.5-20.5 (DBP 500 S)
in utero exposure to 500mgDBP/kg/day. An example of a Western blot, showing the levels of
expression of two inhibin-a related proteins of differing molecular mass is illustrated. This was
quantified using computer assisted image analysis and expressed relative to SMA expression.
irihibin A (larger isoform) inhibin A (smaller isoform)
Figure 6.17: Relative protein expression in e21.5 fetal rat testes after el3.5-20.5 in utero
exposure to vehicle (Control) and either el3.5-20.5 (DBP 500 L) or el9.5-20.5 (DBP 500 S) in
utero exposure to 500mgDBP/kg/day. Values are sample means ± SD's (n =2). No statistical
analyses were performed. The data suggest there might be an effect of both treatment regimes on
testis levels of two inhibin-a related proteins, though it is unclear why there may be a greater
effect with the shorted treatment regime.
Overall, regarding Leydig cell effects, the DBP 500 S exposure regime showed a similar level of
adverse effects on testis development as the DBP 500 L regime, with reduced testosterone levels
and P450scc enzyme expression. Further studies would be needed to confirm the lack of effect on
adrenal P450scc or testicular 3(1-HSD as well as to investigate the possible significance of an effect
on the expression of inhibin-a.
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6.4 Discussion
The primary objective of these studies was to determine if in utero exposure to 500mgDBP/kg/day
on el9.5 and e20.5 affected normal testis morphology and growth by e21.5. Any changes were
compared with those seen in testes exposed for a longer time (el3-e20.5, Chapter 3) or withthose
seen in testis explants exposed in vitro to 1()3M MBP over a similar duration (48h, Chapter 4).
The longer-term studies (el3-e20.5, DBP 500 L), induced an array of changes in the cellular
architecture and protein expression of the fetal testis as reported in Chapter 3, These are compared
to the changes induced by the reduced exposure studies (el9+e20.5, DBP 500 S) reported in this
Chapter.
Both regimes induced a decrease in testis weight at e21.5, though this was not significant for the
DBP 500 S litters. Given that the weight of a testis is affected by the number of cells it contains,
the level of proliferation was measured for the Sertoli cells (Orth, 1984). Neither regime was able
to induce a significant effect on the proliferation index of Sertoli cells. This endpoint had been
unaffected in the in vitro studies also.
Both in utero regimes induced a change in testis architecture with areas between cords containing
cells that were immunopositive for the Sertoli cell nuclear protein WT-1. This change could not be
assessed in the in vitro exposed explants due to the consistent appearance of necrotic regions in
the centre of the explants, regardless of any added chemical treatment.
The number of cords per testis cross-section was quantified for the in vivo experiments and
indicated that both DBP-dosing procedures induced a significant reduction in the number of cords
per cross section, with a more significant reduction associated with the longer-term exposure
method. This endpoint was not assessed in the in vitro experiments.
Within the cords, the gonocytes were dramatically affected by both of the in vivo DBP treatment
routines. Both procedures induced the appearance of abnormal multinucleated gonocytes (MNGs).
However, there was a greater incidence of cords containing MNGs in the DBP 500 S (mean =
36%) testes than in the DBP 500 L (mean = 23%) testes examined, compared to the control testes
(1%). Why the reduced exposure scheme should have had a more severe effect, is unclear. This
endpoint was assessed also in the in vitro-exposed explants but there was such a high incidence of
MNGs in the untreated explants (>15%) that there was no significant effect seen following
phthalate exposure (>20%).
Examination of the Leydig cells saw a significant change in their distribution pattern following
DBP 500 L exposure, with a shift away from small clusters that each accounted for <5% of the
total area of Leydig cells per testis, towards clusters that measured >5% (either 5-15% or >15%).
This pattern was also seen in DBP 500 S exposed testes though the shift was less pronounced and
was not statistically significant. A similar pattern was revealed in the in vitro exposed explants
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though this was not significant either. The number of Leydig cells was unaffected by the DBP 500
L regimen, so was not quantified following either the DBP 500 S or in vitro exposure routines.
The level of testicular testosterone was significantly affected by both in utero DBP treatment
regimes, though there was a greater reduction in animals treated according to the DBP 500 S
scheme (33% of control) than the DBP 500 L regime (59% of control). However, the in vitro
system had been unable to demonstrate any adverse effect of 10"3M MBP on basal testosterone
production.
The level of expression of the steroidogenic enzyme P450scc was quantified in testes exposed to
DBP in vivo. When compared against the relative expression in control testes, both DBP treatment
regimens significantly reduced the levels of P450scc, with the greatest reduction associated with
the DBP 500 L treatment. This endpoint was not assessed for the in vitro exposed explants, as
there was no effect of phthalate exposure on basal testosterone production.
Overall, the DBP 500 S regime induced the same adverse effects as did the DBP 500 L dosing
routine, and to a similar degree. These results confirm that is possible to induce adverse effects on
fetal rat testis development with just 48h of phthalate exposure. Of the eight endpoints that were
compared, the two in utero treatments showed similar effects in all of them, with the DBP 500 S
regime having a more significant effect on the number of cords with MNGs and reducing
testicular testosterone to a greater extent than did the DBP 500 L regime. The in vitro system was
only able to show a shift towards the DBP-associated profile of Leydig cell distribution, with no
significant effect on any other parameter measured.
Taken together, these data do not support the case for the use of the in vitro system, as utilised in
Chapter 4, to make a significant contribution to exploring the cellular and molecular mechanisms
behind the developmental toxicity induced by in utero DBP- exposure. This conclusion also
mitigates against the in vitro system being used to compare the effects ofphthalate exposure on
explants of the fetal rat and human testis. This is unfortunate as this approach had the potential to
enable the direct exposure of human tissue to controlled levels of phthalates and accurately track
any changes induced, thus making an invaluable contribution to the assessment of risk from these
chemicals to human health.
These data support the use of the shorter in utero DBP- exposure regime to help pinpoint the
stages of development most vulnerable to DBP toxicity and to further our understanding of the
normal development of the male reproductive tract. This in turn furthers our understanding of the
risk that endocrine disrupting chemicals pose to human reproductive health. It should be noted
that though there are broad similarities in the basic mechanisms of reproductive tract development
in rodents and primates, there are differences. For this reason, it is critical to determine the details
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of a chemical's mechanism of action before extrapolating effects observed in studies using rats to
potential effects in man (Gray et al., 1989).
To this end, the DBP 500 S studies reinforced the dramatic effect that DBP 500 L exposure had on
fetal testosterone production as shown in Chapter 3. Considering the profile of effects induced by
the in vivo administration ofDBP, various hypotheses have been tested that examine possible
mechanisms behind DBP stimulated toxicity, hence possibly associated with the human condition
TDS.
Lesions in the male reproductive tract have been noted from as early as el7.5, in the Leydig cells,
when following the DBP 500 L dosing regime (Mahood et ah, 2005). By determining the
sequence of the lesion formation from el6.5 to adulthood and comparing how lesions change with
age, it has been proposed that this would indicate the primary sites of DBP-induced pathological
changes and indicate possible mechanisms behind the cellular and molecular pathogenesis
(Barlow and Foster, 2003).
In the fetal testis, Barlow et al (2003) reported an increase in the incidence of three particular
pathological lesions over el7.5 to e21.5 following in utero DBP-exposure, all of which were
reproduced in the present studies, those reported in Chapter 3 and published by this laboratory
(Mahood et al., 2005). The reported lesions are:
• larger but fewer Leydig cell clusters
• abnormally nucleated gonocytes with >2 nucleii
• larger but fewer seminiferous cords
Though the effects of the DBP 500 S regime on adult fertility has yet to be determined, by taking
into consideration those effects associated with the DBP 500 L studies and published data, the
postnatal DBP toxicity profde can be outlined. Following DBP-exposed animals through their
postnatal development, Barlow et al (2003) reported all three of the fetal testis lesions present on
postnatal d3 and d7. By dl6, the abnormal gonocytes were gone but, a decreased number of
spermatocytes was observed in DBP-exposed testes compared to untreated testes. By d21, the
Leydig cell aggregates were no longer evident (Barlow and Foster, 2003). Mahood et al (2005)
propose that the inter-tubular "Leydig cell" aggregates are not exclusively Leydig cells but are
areas of intermingled cells including ectopic Sertoli cells and by d4 even show presumptive
peritubular myoid cells and misshapen cord formation.
Curiously, at postnatal d3, 100% of the animals examined by Barlow et al (2003) had at least one
testis lesion but by d7 this had fallen to 96% and by d21 this had reduced to just 85%. By d70,
only 38% of the young adult DBP -exposed males had Leydig cell hyperplasia, but 100% of
DBP-exposed litters had given rise to testes in which >75% of the tubules showed adversely
affected spermatogenesis, as well as obvious lesions in their accessory sex glands and other
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androgen-dependent tissues, such as hypospadias (Barlow and Foster, 2003). Additionally, this
paper reported the effects ofDBP exposure on the epididymides but concluded that these effects
were likely to be secondary to the direct effect ofDBP on the testes such as the decreased levels
of testicular testosterone.
These studies were followed up in 2004 with a detailed look at the testis lesions in adult rats
following in utero exposure to DBP (Barlow et al., 2004). Between 6-18 months old, the incidence
of unilateral testicular lesions had risen from 36-75%, with little change for bilateral lesions
increasing from 82-88% of DBP-exposed litters affected. Together with the present studies, these
data reinforce the ability ofDBP to instil irreversible changes in the adult testis following in utero
exposure, akin to the TDS hypothesis (Skakkebaek et al., 2001).
However, the diverse cell populations and the dramatic levels of change in gene expression that
are associated with normal fetal testicular development and the divergent phthalate metabolic
pathways in primates and rodents, mean there is still uncertainty about the specific target of this
chemical and its class (Akingbemi et al., 2004; Shultz et al., 2001).
Recent studies of the profile of changes resulting from in utero phthalate exposure, suggest the
toxic effects are consistent with multiple endocrine disturbances (Barlow et al., 2003; Mahood et
al., 2005; Thompson et al., 2004). DBP has been hypothesised to instigate its primary effect as a
general reduction in the expression of testicular steroid biosynthesis related proteins and this is
likely to be via LH independent mechanisms. This has been deduced as initiation of fetal rat testis
testosterone biosynthesis, from el6.5, precedes the detection of LH in serum at el9.5 to stimulate
the Leydig cells (El-Gehani et al., 1998). Work in this laboratory with DBP exposed testes has
shown that Leydig cells are affected by DBP from el7.5, prior to LH stimulation (Mahood et al.,
2005). However, it may be that DBP toxicity also manifests itself via LH dependent mechanisms,
as LH-receptor levels have been shown to be down regulated by e21.5 (Shultz et al., 2001).
Additionally the data presented in this Chapter, show that testicular testosterone levels are
significantly reduced after exposure to DBP over just el9.5- e21.5 when serum LH is predicted to
be influencing testicular testosterone production.
Mahood et al (2005) went on to point out that the testis specific effects ofDBP are perhaps Leydig
cell mediated. Yet even here, the effects within the Leydig cells are not general as the expression
of certain enzymes (e.g. 3(1-USD) are unaffected by either DBP treatment regime (Mahood et al.,
2005). This conclusion is consistent with the preliminary data reported in this Chapter where
expression of the P450scc protein in DBP-exposed adrenal glands was not obviously reduced and
neither was testicular 3(3-HSD following either DBP exposure regime, compared to the
significantly reduced level of testicular P450scc protein expression seen with both treatments. The
lack of effect of these DBP-exposure regimes on the expression level of 3|3-HSD protein seen in
Chapter 6 Short term in vivo phthalate exposure 195
these studies contrasts with significant decreases in 3|3-HSD mRNA levels reported by other
laboratories (Barlow et al., 2003; Shultz et al., 2001). However, Barlow et al (2003) also reported
a disparity between their quantified, reduced mRNA and protein expression revealed by
immunostaining (e.g. SCF data) and failed to support their significant reduction in 3|3-HSD gene
expression (P<0.05) with any data regarding 3(3-HSD protein expression. Therefore, their
conclusion that 3|3-IISD protein expression must also be reduced in el9.5 testes following in utero
DBP-exposure must be considered carefully. Additionally, Thompson et al (2003) showed that
when DBP-exposed fetal testes were incubated with the steroidogenic intermediates normally
catalysed by 3(3-HSD (e.g. pregnenolone), then testosterone levels increased. Admittedly, control
levels of the 3|3-HSD catalysis products were not fully restored, but this data suggests that the
expression level of 3|3-HSD protein was high enough to support steroidogenesis despite reduced
gene expression (Barlow et al., 2003).
However, none of these studies reported any change in the level of the gene or protein expression
for inhibin-a as hinted at in the final experiments reported in this Chapter. Micro-array analysis of
mRNA from el9.5 rat testes, after exposure to 500mgDBP/kg/day or vehicle from el3.5, showed
a highly significant (P<0.01) decrease (-1.63 fold change) in inhibin-a. This data was generated
through collaboration between this laboratory and CXR Biosciences1, where the micro-arrays
were performed and analysed. Data was only generated for el5.5, el7.5 and el9.5 testes treated
according to this laboratory's DBP 500 L regime from el3.5.
Inhibins are heterodimeric glycopoteins involved in the regulation of a number of diverse
physiological functions, including regulation of endocrine hormone production (e.g. FSH) and
possibly germ cell development (Majdic et al., 1997). The a-subunit dimerises with any of the (3-
subunits (A, B or C in the human, plus E in the mouse, plus D in Xenopus), though in mammals,
only the (3B subunit is associated with male reproductive function (Illingworth et al., 1996). It
might be considered that any treatment might be expected to affect both dimers equally (a and
Pb). However, in Chapter 3 there was no significant difference in the levels of intra-testicular
inhibin Pb measured by ELISA in e21.5 testes treated with 500mgDBP/kg/day or vehicle from
el3.5, while preliminary western blot analysis data presented in this Chapter, suggest the
possibility of a change in expression of inhibin-a protein in e21.5 testes following the same
exposure regimen. It has been reported that fetal testes express inactive forms of inhibin-a related
proteins (molecular weights >40kDa) whereas the dimeric bioactive form (<30kDa) is not present
until birth (Meachem et al., 2001; Noguchi et al., 1997). This is consistent with the immunoblots
presented here, which showed the presence of two proteins ofbetween 40-60kDa but no staining
1 CXR Biosciences Ltd., James Lindsay Place, Dundee DDI 5JJ.
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at 30kDa (not shown). It should be noted that small numbers of samples were assessed in all
studies and that this effect of phthalates on inhibin-a has not been supported in the literature, but
given the wide range of influence that both DBP and inhibins have on male reproductive health,
the possibility that DBP may affect the maturation of inhibin-a from larger precursor molecules,
may warrant further investigation.
Overall, these studies have extended our knowledge of the susceptibility of the fetal rat testis to
developmental disruption by acute exposure to high doses ofDBP. Exposure of
500mgDBP/kg/day is an unlikely exposure level for humans but the purpose of this model was to
produce a high incidence of the adverse DBP-induced phenotype, without inducing maternal
toxicity, thereby allowing changes in protein expression associated with the morphological
changes to be detected (Barlow et al., 2003). Much further work is still needed to explore the
cellular and molecular mechanisms behind the developmental toxicity induced by in utero DBP-
exposure. The current ideas regarding the mechanisms behind phthalate induced toxicity and the
recent assessment of the risk phthalates pose to the reproductive health ofman and our
environment are discussed in the final Chapter.
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7 Final Discussion
In 2001 Skakkebaek et al hypothesised that four disorders ofmale reproductive health, comprising
a "Testicular Dysgenesis Syndrome" (TDS), were all consequences of altered development of the
testis and reproductive tract during fetal life. The disorders that encompass this syndrome are
described in Chapter 1. Skakkebaek et al went on to suggest that the increase in the incidence of
these clinical conditions during recent times might be associated with the ubiquitous
contamination of our environment by chemicals with the potential to disrupt normal endocrine
dependent development, as seen in wildlife (Skakkebaek et al., 2001). When the present studies
were conceived, the causal factors behind TDS were unknown. It was considered that exposure of
the pregnant mother was a route of exposure to synthetic chemicals that have become ubiquitous
in the modern environment (eg DBP) that warranted further investigation.
The consequences of in utero exposure of fetal rats to DBP (a known endocrine disrupting
chemical) during testis development, has been explored and the observations made are presented
in experimental Chapters 3 and 6 of this thesis. Studies ofDBP and its metabolite MBP on rat and
human fetal testis development in vitro were carried out and are reported in experimental Chapters
4 and 5, respectively. A detailed introduction to these studies is presented in Chapter 1 with a
description of the scientific approaches, materials and methods used listed in Chapter 2. This final
chapter aims to bring together the achievements of the present studies in the context of relevant
publications ofwork by other research groups.
The toxic effect ofphthalates on the adult testis has been known since the 1980's but more
recently effects of phthalate exposure on the developing testis have been reported. Toxicity was
thought to result from disruption of the complex interactions between Sertoli, Leydig, and germ
cells associated with decreased fetal androgen production (Mylchreest et al., 2002). It was logical
to presume that these effects were mediated by alteration of signal molecules in the local testis
environment (Li and Kim, 2003). Other evidence suggested that the balance between androgen
and oestrogen action may be important in the induction of reproductive tract abnormalities that
manifest as the symptoms of human TDS (Sharpe, 2003).
The present studies demonstrate that late gestational exposure to high levels of the endocrine
disrupting chemical DBP significantly reduces fetal testis testosterone production and
permanently alters aspects of testis pathology. The precise mechanism through which DBP
induces these changes is not clear but the major finding of the present research is the
demonstration that short-term (el9.5-e20.5) in utero exposure to 500mgDBP/kg/day can induce
the same range of changes in the development of rat testes at e21.5, as seen with longer-term
(el3.5-e20.5) gestational exposure, changes reported to occur in human TDS. Additionally, it has
been demonstrated that the exploitation of an in vitro system to investigate the effects of the DBP
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metabolite MBP on the development and steroidogenic regulation of rat fetal testis explants, could
not mimic the effects of the DBP in vivo so this approach was concluded to be an ineffective
means through which to explore the mechanisms behind the DBP-induced changes in testis
development. This also meant that using the in vitro approach to investigate any effect ofDBP/
MBP on human fetal testis explants resulted in limited scope for comparison of effects of
phthalate exposure between the two species.
The DBP-exposure regime described in Chapter 3 was first reported as a potential animal model
for human TDS in Fisher et al (2003). This paper highlighted the important role that animal
models can play to enable characterisation of the normal and abnormal mechanisms of fetal testis
development. The DBP-exposure regime provides a useful tool to examine the altered
mechanism(s) that underlie human TDS because the testicular and other changes in DBP-exposed
rats have all been reported to occur in human TDS (Fisher et al., 2003). This work became the
starting point for the rest of the experiments presented in this thesis.
It was initially thought that Sertoli cell disorders (e.g. failure to mature during fetal/ adolescent
development) that do not present until adulthood, may be an underlying cause of human TDS
(Sharpe et al., 2003). This hypothesis was supported by the critical role Sertoli cells have in the
orchestration of fetal testis development. Fisher et al (2003) demonstrated that immature Sertoli
cells are present in the seminiferous tubules of adult male rats following in utero DBP exposure, at
an age when these cells should have undergone terminal differentiation into their adult form
(Fisher et al., 2003). Flowever, the present data and other sources prompted a revised hypothesis
in which any Sertoli cell effect observed in the DBP model is considered to be secondary to an
earlier effect on Leydig cells (Chapter 3). This Leydig cell effect presents as reduced fetal
testosterone production, from at least el9.5 (Chapter 3 and Mahood et al., 2005). In the present
studies, the level of expression of the protein (P450scc) that performs the rate limiting enzymatic
step of the steroidogenic pathway is reduced following both long-term and short-term in utero
DBP-exposure regimes. Other groups have shown significant dose-dependent reductions in
mRNA and protein concentration of the cholesterol transport proteins SR-B1 and StAR, as well as
the steroidogenic protein P450sccat el9.5 following daily exposure to DBP from el2.5, at doses of
50-500mgDBP/kg/day (Lehmann et al., 2004). Together these data demonstrate a coordinated,
dose-dependent reduction in the expression of key genes and proteins involved in cholesterol
transport and steroidogenesis and a corresponding reduction in testosterone in fetal testes
following maternal exposure to DBP.
The effect ofDBP on steroidogenesis appears to be unique to the testis in the fetal rat as there was
no change in P450scc expression observed in adrenal glands taken from DBP exposed rat fetuses as
reported in Chapter 6. Thompson et al (2005) reported no statistically significant change in the
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level of adrenal corticosterone production nor any statistically significant change in the expression
of genes required for steroidogenesis in the adrenal at el 9.5 following daily DBP exposure from
el2.5 (Thompson et ah, 2005).
The in vitro models presented in Chapters 4 and 5 were unable to demonstrate any reduction in
testosterone production when the cultured fetal testis explants were treated with high doses of
MBP or DBP. Despite the potential of the in vitro system to enable manipulation of the effects of
phthalates on fetal testis explants and to explore any parallels in sensitivity to phthalates between
the rat and the human, this approach was unable to mimic the rat in vivo model. It may be this
approach can make a useful contribution to other studies. It might be that MBP undergoes further
metabolism outside the testis in vivo and it is this alternative metabolite that induces toxicity
hence the testis explants were not affected by the high doses ofMBP in vitro. Evaluation of the
metabolism of a single dose of DBP in female rats confirmed the identities of DBP metabolites
(MBP, monohydroxybutylphthalate and butanoic acid phthalate) in free and glucuronidated forms,
in urine and in maternal and fetal plasma (Fennell et al., 2004). MBP was the major metabolite in
maternal and fetal plasma and in amniotic fluid initially, but by 24h after dosing, the major
metabolite in amniotic fluid was MBP-glucuronide (Fennell et al., 2004). It is possible to measure
a wide range of phthalate metabolites in human urine (Silva et al., 2003). Recent improvements
have enabled the separation and quantification ofMBP from its structural isomer mono-iso-butyl
phthalate (MiBP) (Silva et al., 2004). Further in vivo/ in vitro studies are required to reveal
whether the metabolites ofDBP, other than free MBP e.g. MiBP contribute to DBP induced
testicular toxicity in vivo.
The levels of some phthalate metabolites in the urine of pregnant women in the USA were
recently reported by Swan et al (2005). The urinary levels of four phthalate metabolites (MEP,
MBP, MBzP and MiBP) were inversely related to the AnoGenital Index (AGI=AnoGenital
Distance (mm)/weight at examination (kg)) of their male offspring, indicative of
undermasculinisation. AGD growth is sexually dimorphic and androgen dependent. The AGI was
significantly correlated with the proportion of boys that presented with incomplete testicular
descent and AGD was also significantly correlated with penile volume (Swan, 2005). AGD in
male rats is normally about twice that in females, and a similar sex difference is evident in
humans. AGD was not assessed for the fetal rats in the present studies but has been reported to be
reduced in male rats after in utero exposure with phthalates at concentrations >250mg/kg/day
(Ema and Miyawaki, 2001; Foster, 2005; Zhang et al., 2004). However, this AGD must be
affected by lower levels of phthalate exposure in humans because according to the Swan et al
(2005) data, reduced AGI was measured in boys born to mothers with phthalate levels similar to
those found in about 25% of the adult female U.S. population.
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The Swan data suggests that phthalates could have similar adverse effects on fetal testosterone
production in humans as they do in rats. If this interpretation is correct, it provides a strong link
between phthalate exposure in humans as one potential cause of TDS disorders, a conclusion that
has widespread public health implications (Sharpe, 2005). These novel human data support the
hypothesis that prenatal phthalate exposure at environmental levels could adversely affect male
reproductive development in humans and challenges the previous view of regulatory authorities
that exposure to phthalates at levels well below effect levels in animals, poses no risk to human
health (McKee et al., 2004). However, it must be noted that these correlations do not rule out
other lifestyle factors that may contribute to the changes observed but were not quantified. It must
be noted that there was no significant effect ofMBP on the level of basal testosterone production
by human fetal testis explants incubated with 10"3M MBP for 48h, compared to untreated
explants, as reported in Chapter 5. This suggests that 48h may not be sufficient time for the low
levels of environmental phthalates to exert sufficient influence on the developing testis to induce a
significant reduction in testosterone production.
As well as changes in testosterone production it is apparent that DBP has no direct effect on
sexual determination but it does affect testis differentiation, as shown by the regions of focal
testicular dysgenesis presented in Chapters 3 and 6. The formation of these dysgenetic areas can
be illustrated schematically (Figure 7.1). The precise mechanism initiated by in utero DBP-
exposure that disrupts the completion ofnormal testis cord formation is still unclear. The present
studies have advanced our understanding of the critical window in fetal testis cord formation that
DBP-exposure can induce focal dysgenesis. The long-term DBP-exposure regime (el3-20.5)
produced a shift in the distribution of Leydig cells from small and dispersed clusters to larger
more centralised aggregates. This pattern was also induced by the short-term DBP-exposure
regime (el9-20.5) reported in Chapter 6, though to a lesser degree, corresponding to the reduced
exposure duration. The relevance of this shift in distribution of the steroidogenic cells throughout
the fetal testis is unclear, especially as the short-term DBP-exposure regime reported in Chapter 6
induced a more significant reduction in testicular testosterone production than did the long-term
DBP-exposure regime. The differences in the impact of these treatment regimes on the physiology
of the fetal rat testis warrant further investigation. The ontogeny of the effects induced by the
short-term DBP-exposure regime should be followed up and compared against those described in
Chapter 3 for the long-term treatment regime. Experiments reported by Carruthers and Foster
(2005) were designed to identify the critical days of gestation that DBP exposure induced
abnormal development of the testis. Testicular malformations were most significantly increased in
DBP-exposed males only on GD 16 and 17. Together with the data presented in Chapter 6, it can
be concluded that 2-day DBP exposure is highly detrimental to the developing reproductive tract
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of the male fetus with the most severe abnormal development induced following exposure
between el6-18.5 (Carruthers and Foster, 2005).
Normal differentiation of the testis
• = Sertoli cell nuclei J = Peritubular cells
#= Gonocyte nuclei •' = Leydig cells
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genital ridge
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Figure 7.1 Schematic representation of normal (top panel) vs. dysgenetic (lower panel)
testicular development, as hypothetically induced by in utero DBP-exposure. Reproduced from
RM Sharpe, 2005.
The short-term DBP-exposure regime induced abnormal formation of gonocytes into multinuclear
cells located in the centre of the testicular cords at a significantly higher incidence than the long-
term regime did. The appearance ofmultinuclear gonocytes (MNGs) following in utero DBP
exposure has been investigated and reported by Kleymenova et al (2005). Consistent with the
findings of the present studies, Kleymenova et al reported that histological examination showed a
low incidence of MNGs in the normal fetal rat testis whereas the in utero DBP-exposure regime
significantly increased the number of these abnormal germ cells. As seen in the present studies,
these abnormal cells were not apoptotic in the fetal testes, nor reported in the postnatal testis. The
paper went on to assess the interactions between Sertoli and the MNGs and noted that Sertoli cells
in DBP-exposed fetal testes had retracted apical processes, altered organization of the vimentin
cytoskeleton, and abnormal cell-cell contacts with gonocytes (Kleymenova, 2005). This data was
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considered to indicate that abnormal interactions between Sertoli and germ cells during fetal life
play a role in the development ofMNGs and is consistent with the abnormal gonocyte positioning
and seminiferous cord distension reported in Chapters 3 and 6.
In vitro manipulation with DBP treatment of fetal testis explants would lend itself to investigating
a possible association between the appearance ofmultinucleated gonocytes and the deficiency in
INSL3 (see McKinnell et al, 2005), but these abnormal fetal germ cells were observed in the cords
of fetal rat testis explants following 48h incubation under control conditions as well as when
treated with MBP (Chapter 4). This suggests that the appearance ofMNGs may be indicative of a
stress response by the developing testis. MNGs have been reported as frequent in perinatal rat
testes following in utero DBP-exposure from el9.5 to postnatal d4, but by dlO, no more MNGs
are detected (Fisher et al., 2003).
The exact details of the mechanism through which DBP exerts its effects are not yet understood.
Various candidates have been considered and mostly found to fall short of inducing the wide
repertoire of changes in testis development that DBP and related compounds cause. The wide
repertoire of effects on testis development and testosterone production that manifest as a result of
disrupted retinoid exposure has many similarities with the changes reported for testes exposed in
utero to high doses of DBP (Chapter 3). Retinoic acid is the biologically active derivative of
vitamin A (retinol), which has a fundamental role in vision as well as in the growth and
differentiation of numerous types of cell, including the regulation of testicular functions in
rodents. Retinoids appear to exert an action on the three main testicular types of cell (Sertoli, germ
and Leydig cells), as all three cell types express retinoid receptors (RARs and RXRs) (Boulogne
et al., 1999). Other studies have reported a possible interplay between retinoids, androgen and
inhibin signalling systems in adult Sertoli cells as part of the regulation of spermatogenesis
(Zhuang et al., 1997). More relevant to these studies with fetal testes was the report that retinoids
play a negative role on steroidogenic activity during the differentiation of rat fetal Leydig cells
(Livera et al., 2004). Studies demonstrated that endogenous retinol inhibits normal differentiation
and/or function of fetal Leydig cells and may be required for the normal regression of fetal Leydig
cell function that occurs after el8.5 (Livera et al., 2004).
Alternatively, peroxisome proliferators such as phthalates, are thought to act through peroxisome
proliferator-activated receptors (PPAR), members of the steroid/thyroid hormone receptor
superfamily. PPARs form heterodimers with RXRs and regulate the transcription of genes that
contain peroxisome proliferator-responsive elements (PPREs) (Dufour et al., 2003). How
phthalates might interact with PPARs is not yet known but it is proposed that any regulatory
mechanism that is able to explain the testicular damage by phthalates in vivo should include
PPARs as key players. Lapinskas et al (2005) determined that there are marked species-specific
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differences in the response to peroxisome proliferators, with rodents highly susceptible and
humans reportedly resistant to their short-term effects, perhaps due to lower levels of constitutive
PPAR expression in the human compared to rodents (Lapinskas et al., 2005). Combined with the
low levels of environmental phthalate exposure, it might be concluded that the risk ofphthalate-
related toxicity in humans was unlikely to be great. However, the phthalate-syndrome of effects
on male reproductive tract development in the rat has parallels with the reported human testicular
dysgenesis syndrome (Fisher et al., 2003). As well as disrupting the cellular level of testicular
formation, the long-term in utero DBP-exposure regime reported in Chapter 3 revealed changes in
testis descent and penis formation that did not manifest until later in life. These symptoms
together with the testicular events of abnormal germ development (as an indicator of
predisposition to testicular cancer) and reduced Sertoli cell proliferation (resulting in a restricted
capacity for sperm production) are consistent with the four manifestations that comprise human
TDS (Skakkebaek et al., 2001).
The present studies have contributed to our understanding ofDBP (a ubiquitous contaminant of
the modern environment) as an endocrine disruptor that also specifically targets the fetal testis.
These experiments have helped to rule out the use of an in vitro system with fetal testis explants to
elucidate the still unknown mechanism behind phthalate toxicity. The in vivo data presented is in
agreement with data published by other groups. In these and other studies, DBP has been shown to
effect a marked reduction in fetal testicular testosterone production during the critical window for
androgen dependent development of the male reproductive tract (Mahood et al., 2005). A second
Leydig cell product, Insl3, is also significantly down regulated and together with the decrease in
testosterone is likely to be responsible for the cryptorchidism commonly reported in phthalate-
treated animals (McKinnell et al., 2005). The testosterone decrease is mediated by changes in the
expression levels of a number of enzymes and transport proteins involved in normal testosterone
biosynthesis and transport in the fetal Leydig cell (Foster, 2005).
Since these studies were conceived, the biggest change in the understanding ofDBP-induced
toxicity has been the shift away from the idea that the Sertoli cell was the mediator of DBP
toxicity, towards the view that the Leydig cell is the primary target, due to the adverse effect of
DBP on steroidogenesis and Insl3.
Although no accurate cause and effect relationship has yet been demonstrated to induce TDS after
in utero exposure of humans to phthalate esters, humans are exposed to and produce the critical
phthalate metabolites associated with increased incidence of TDS symptoms in animal models
(Swan, 2005). These metabolites have been detected frequently in the blood of the general
population, with high levels in the urine ofwomen of child bearing age as well as in children and
even in human amniotic fluid (Foster, 2005). To this end, supplementary research is required to
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unravel the mechanisms of phthalate toxicity on the fetal testis further and to clarity the risk these
ubiquitous chemicals pose to human reproductive health.
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